

09/28/00



10-02-00

A/Box/seg

Patent
252/124

To: Box Patent Application
Commissioner for Patents
Washington, D.C. 20231



NEW APPLICATION TRANSMITTAL - UTILITY

Sir:

Transmitted herewith for filing is a **utility** patent application:

Inventor(s): Michael K. Skinner and Jodi L. Patton

Title: A METHOD OF DETERMINING TUMOR CHARACTERISTICS BY DETERMINING ABNORMAL COPY NUMBER OR EXPRESSION LEVEL OF LIPID-ASSOCIATED GENES

I. PAPERS ENCLOSED HEREWITH FOR FILING UNDER 37 CFR § 1.53(b):

- 64 Page(s) of Written Description
- 7 Page(s) Claims
- 1 Page(s) Abstract
- 2 Sheets of Drawings ☒ Informal ☐ Formal

II. ADDITIONAL PAPERS ENCLOSED IN CONNECTION WITH THIS FILING:

- ☒ Declaration
- ☒ Power of Attorney ☒ Separate ☐ Combined with Declaration
- ☒ Assignment to Atairgin Technologies, Inc. and assignment cover sheet
- ☒ Verified Statement establishing "**Small Entity**" under 37 CFR §§ 1.9 and 1.27
- ☐ Priority Document No(s):
- ☐ Information Disclosure Statement w/PTO 1449 ☐ Copy of Citations
- ☒ Sequence Listing and Diskette Containing Sequence Listing
- ☒ Return Postcard

OC-56081.1

CERTIFICATE OF MAILING
(37 C.F.R. §1.10)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as 'Express Mail Post Office To Addressee' in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

EL496952307US
Express Mail Label No.

September 28, 2000
Date of Deposit

Lynne Fulmer
Name of Person Mailing Paper
Lynne Fulmer
Signature of Person Mailing Paper

III. THE FILING FEE HAS BEEN CALCULATED AS SHOWN BELOW:

BASIC FILING FEE:						\$690.00
Total Claims	21	-	20	=	1	x \$18.00 \$18.00
Independent Claims	3	-	3	=	0	x \$78.00 \$0.00
Multiple Dependent Claims	\$260	(if applicable)				<input type="checkbox"/> \$0.00
TOTAL OF ABOVE CALCULATIONS						\$708.00
Reduction by ½ for Filing by Small Entity. Note 37 CFR §§ 1.9, 1.27, 1.28. If applicable, Verified Statement must be attached.						<input checked="" type="checkbox"/> \$354.00
Misc. Filing Fees (Recordation of Assignment -- \$40)						\$40.00
TOTAL FEES DUE HERewith						\$394.00

IV. METHOD OF PAYMENT OF FEES

☒ Charge Lyon & Lyon's Deposit Account No. **12-2475** in the amount of \$394.00.

V. AUTHORIZATION TO CHARGE FEES

The Commissioner is authorized to credit any overpayment and to charge any underpayment to Lyon & Lyon's Deposit Account No. **12-2475** for the following:

- ☐ 37 CFR § 1.16 – (Filing fees and excess claims fees)
- ☐ 37 CFR § 1.17 – (Any application processing fees)
- ☐ 37 CFR § 1.21 – (Assignment recording fees)

VI. CORRESPONDENCE ADDRESS

Please send all correspondence to Customer Number 22249:



22249

PATENT
TRADEMARK
OFFICE

LYON & LYON LLP
Suite 4700
633 W. Fifth Street
Los Angeles, CA 90071

Please direct all inquiries to Kurt T. Mulville, at (949) 567-2300.

Respectfully submitted,

LYON & LYON LLP

Dated: September 28, 2000

By: 

Kurt T. Mulville
Reg. No. 37,194

KTM/lf
633 West Fifth Street, Suite 4700
Los Angeles, California 90071-2066
949/567-2300 X 1124 Telephone
213/955-0440 Facsimile

Applicant or Patentee: Michael K. Skinner and Jodi L. Patton

Serial or Patent No.: Not Yet Assigned

Filed or Issued: Herewith

For: A METHOD OF DETERMINING TUMOR CHARACTERISTICS BY DETERMINING ABNORMAL COPY NUMBER OR EXPRESSION LEVEL OF LIPID-ASSOCIATED GENES

VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS (37 CFR 1.9(f) AND 1.27(c)) – SMALL BUSINESS CONCERN

I hereby declare that I am

- ☐ the owner of the small business concern identified below:
- ☒ an official of the small business concern empowered to act on behalf of the concern identified below:

business concern name and address: Atairgin Technologies, Inc., 4 Jenner, Suite 180, Irvine, California 92618

I hereby declare that the above identified small business concern qualifies as a small business concern as defined in 13 CFR 121.3-18, and reproduced in 37 CFR 1.9(d), for purposes of paying reduced fees under Section 41(a) and (b) of Title 35, United States Code, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third-part or parties controls or has the power to control both.

I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention, entitled

A METHOD OF DETERMINING TUMOR CHARACTERISTICS BY DETERMINING ABNORMAL COPY NUMBER OR EXPRESSION LEVEL OF LIPID-ASSOCIATED GENES

by inventor(s) Michael K. Skinner and Jodi L. Patton

described in

- ☒ the specification filed herewith
- ☐ the application serial no. _____, filed _____.
- ☐ patent no. _____, issued _____.

If the rights held by the above identified small business concern are not exclusive, each individual, concern or organization having rights to the invention is listed below* and no rights to the invention are held by any person, other than the inventor, who could not qualify as an independent inventor under 37 CFR 1.9(c) or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

*NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27).

NAME _____

ADDRESS _____

☐ Individual ☐ Small Business Concern ☐ Nonprofit Organization

NAME _____

ADDRESS _____

☐ Individual ☐ Small Business Concern ☐ Nonprofit Organization

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small business entity is no longer appropriate. (37 CFR 1.28(b)).

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING Patrick D. Walsh

TITLE OF PERSON SIGNING Chief Executive Officer

ADDRESS OF PERSON SIGNING 4 Jenner, Suite 180, Irvine, California 92618

SIGNATURE  DATE 7/5/00

A METHOD OF DETERMINING TUMOR CHARACTERISTICS
BY DETERMINING ABNORMAL COPY NUMBER OR EXPRESSION LEVEL
OF LIPID-ASSOCIATED GENES

FIELD OF THE INVENTION

The present invention relates to a method of determining tumor characteristics in tissue samples taken from a patient by determining the copy number or expression level of genes associated with lipid metabolism, synthesis, or action in the sample. This determination may be made by directly quantifying the gene copy number in the chromosomal material of the tissue sample, or by determining the transcription level of the gene in the tissue sample. The present invention is also drawn to physical platforms which are useful in carrying out the diagnostic method, specifically arrays of nucleic acids useful for determining the copy number or expression level of the lipid associated genes by hybridization techniques.

BACKGROUND OF THE INVENTION

Cancer is the second leading cause of death in the United States, after heart disease: one in every four Americans dies of cancer. As predicted by the SEER program at the National Cancer Institute, there will be over 1.2 million new cases of cancer diagnosed, and over a half-million cancer related deaths in the year 2000 alone. Cancer is characterized by several stages. First, there is an increase in the number of abnormal, or neoplastic, cells which arise from the normal cells in a tissue. Then, these neoplastic cells proliferate to form a tumor mass. Progression of the disease is then characterized by the growth of the tumor and the invasion of adjacent tissues by these neoplastic tumor cells. Finally, the tumor will generate malignant cells which spread via the blood or lymphatic

system to regional lymph nodes and to distant sites. The latter progression to malignancy is referred to as metastasis.

Cancer can be viewed as a breakdown in the cell growth regulatory system, in which proper communication between tumor cells, their normal neighboring cells, and the rest of the body is impaired. Signals, both growth-stimulatory and growth-inhibitory, are routinely exchanged between cells within a tissue. The maintenance of proper organ shape and function is dependant upon cell number stasis at particular positions in an organ. Normally, cells do not divide in the absence of stimulatory signals, and, likewise, will cease dividing in the presence of inhibitory signals. In a cancerous state, a cell bypasses this system of regulatory signals and proliferates under conditions in which normal cells would not.

Tumor cells must acquire a number of distinct aberrant traits to proliferate. Reflecting this requirement is the fact that the genomes of certain well-studied tumors carry several different independently altered genes, including activated oncogenes and inactivated tumor suppressor genes. Each of these genetic changes appears to be responsible for imparting some of the traits that, in aggregate, define a neoplastic cell (Land, H. et al., 1983, Science 222:771; Ruley, H. E., 1983, Nature 304:602; Hunter, T., 1991, Cell 64:249).

In addition to unhindered cell proliferation, cells must acquire several traits for tumor progression to occur. For example, early on in tumor progression, cells must evade the host immune system. Further, as tumor mass increases, the tumor must acquire vasculature to supply nourishment and remove metabolic waste. Additionally, cells must

acquire an ability to invade adjacent tissue, and, ultimately, the capacity to metastasize to distant sites.

An increasing body of evidence implicates genetic mutations as causally important in the induction of human cancers. Advances in recombinant DNA technology have led to the discovery of normal cellular genes (proto-oncogenes and tumor suppressor genes) that control growth, development, and differentiation. Under certain circumstances, the regulation of these genes is altered, causing normal cells to assume neoplastic growth behavior. There are over 40 known proto-oncogenes and suppressor genes to date, which fall into various categories depending on their functional characteristics. These include, (1) growth factors and growth factor receptors, (2) messengers of intracellular signal transduction pathways, for example, between the cytoplasm and the nucleus, and (3) regulatory proteins influencing gene expression and DNA replication. Differential expression of the following suppressor genes has been demonstrated in human cancers: the retinoblastoma gene, RB; the Wilms' tumor gene, WT1 (11p); the gene deleted in colon carcinoma, DCC (18q); the neurofibromatosis type 1 gene, NF1 (17q); and the gene involved in familial adenomatous polyposis coli, APC (5q) (Vogelstein, B. and Kinzler, K. W., 1993, Trends Genet. 9:138-141).

Point mutations have been directly implicated in the causation of many human tumors. Some tumors carry oncogenes of the ras gene family, which differ from their normal cellular counterpart proto-oncogenes by the presence of a point mutation at one of a limited number of sites in these genes. Similarly, point mutations in critical regions of tumor suppressor genes, such as p53, are often detected in tumor cells. Mutation of the p53 suppressor gene is the most common alteration seen in epithelial tumors and, indeed,

in all human tumors (Hollstein, M. et al., Science 253:49-53, 1991). When a tumor suppressor gene, such as p53, becomes mutated, cell proliferation accelerates in the absence of the suppressor. On the other hand, mutations in proto-oncogenes that transform them to active oncogenes, such as a mutant ras oncogene, produces cell proliferation caused by presence of the mutant gene itself.

The mutations that create active oncogenes have been explored with the hopes of providing important diagnostic and prognostic clues for tumor development. For example, a number of mutations have been found to alter the 12th codon of the ras oncogenes, causing replacement of a normally present glycine by any of a number of alternative amino acid residues. Such amino acid substitutions create a potent transforming allele. Thus, the presence of a particular nucleotide substitution may be a strong determinant of the behavior of the tumor cell (e.g., its rate of growth, invasiveness, etc.). As a result, nucleotide hybridization probes of oncogene mutations have been targeted for research as promising diagnostic reagents in clinical oncology.

In addition to point mutations, it has been shown that the amplification of single oncogenes can be linked to malignancy and proliferation of cancerous tumor cells. It is believed that many solid tumors, such as breast cancer, progress from initiation to metastasis through the accumulation of several such genetic aberrations. (Smith et al., Breast Cancer Res. Treat., 18 Suppl. 1: S 514 (1991); van de Vijver and Nusse, Biochim. Biophys. Acta, 1072: 33-50 (1991); Sato et al., Cancer Res., 50: 7184-7189 (1990).) These genetic aberrations, as they accumulate, may confer proliferative advantages, genetic instability and the attendant ability to evolve drug resistance rapidly, and enhanced angiogenesis, proteolysis and metastasis. Deletions and recombination leading to loss of

heterozygosity (LOH) are believed to play a major role in tumor progression by uncovering mutated tumor suppressor alleles.

Gene amplification is a common mechanism leading to upregulation of gene expression. (Stark et al., Cell. 75: 901-908 (1989).) Evidence from cytogenetic studies indicates that significant amplification occurs in over 50% of human breast cancers. (Saint-Ruf et al., supra.) A variety of oncogenes have been found to be amplified in human malignancies. Examples of the amplification of cellular oncogenes in human tumors are shown in Table 1 below.

TABLE 1

Amplified Gene	Tumor	Degree of Amplification
c-myc	Promyelocytic leukemia, cell line, HL60	20x
	Small-cell lung carcinoma cell lines	5-30x
N-myc	Primary neuroblastomas (stages III and IV) and neuroblastoma cell lines,	5-1000x
	Retinoblastoma cell line and primary tumors,	10-200x
	Small-cell lung carcinoma cell lines and tumors	50x
L-myc	Small-cell lung carcinoma cell lines and tumors	10-20x
c-myb	Acute myeloid leukemia	5-10x
	Colon carcinoma cell lines	10x
c-erbB	Epidermoid carcinoma cell	30x
	Primary gliomas	
c-K-ras-2	Primary carcinomas of lung colon, bladder, and rectum	4-20x
N-ras	Mammary carcinoma cell line	5-10x

For example, as disclosed in U.S. Patent No. 5,846,749, the amplification of the Her-2 gene has been linked to invasive breast cancer phenotypes. In a study of node-negative invasive breast carcinomas, the degree of HER-2/neu gene amplification was determined by Southern blot analysis of EcoRI digested tumor tissue and the relative amount of HER-2/neu mRNA was determined by Northern hybridization of total RNA. The amount of HER-2/neu gene expression was roughly proportional to the number of copies of the gene in tumor cells. In addition, increasing levels of HER-2/neu gene amplification in these carcinomas were also associated with an increased risk of recurrent breast cancer. In human breast carcinomas, other proto-oncogenes, such as MYC, INT2, HST, and ERBB2, are frequently found either amplified or overexpressed. Although other similar correlations have been shown for other single oncogene amplifications or deletions, these approaches have proven to be of relatively limited predictive value for prognoses or treatment determinations.

Chromosomal deletions involving tumor suppressor genes may also play an important role in the development and progression of solid tumors. The retinoblastoma tumor suppressor gene (Rb-1), located in chromosome 13q14, is the most extensively characterized tumor suppressor gene (Friend et al., *Nature*, 323: 643 (1986); Lee et al., *Science*, 235: 1394 (1987); Fung et al., *Science*, 236: 1657 (1987)). The Rb-1 gene product, a 105 kDa nuclear phosphoprotein, apparently plays an important role in cell cycle regulation (Lee et al., *supra* (1987); Howe et al., *PNAS (U.S.A.)*, 87: 5883 (1990)). Altered or lost expression of the Rb protein is caused by inactivation of both gene alleles either through a point mutation or a chromosomal deletion. Rb-1 gene alterations have been found to be present not only in retinoblastomas (Friend et al., *supra* (1986); Lee et

al., supra (1987); Fung et al., supra (1987)) but also in other malignancies such as osteosarcomas (Friend et al., supra (1986)), small cell lung cancer (Hensel et al., Cancer Res., 50: 3067 (1990); Rygaard et al., Cancer Res., 50: 5312 (1990)) and breast cancer (Lee et al., Science, 241: 218 (1988); T'Ang et al., Science, 242: 263 (1988); Varley et al., Oncogene, 4: 725 (1989)).

In addition to single gene centered approaches to studying cancer genetics, changes in chromosomal loci associated with cancer have been studied. Chromosome abnormalities have long been associated with genetic disorders, degenerative diseases, and exposure to agents known to cause degenerative diseases, particularly cancer, German, "Studying Human Chromosomes Today," American Scientist, 58: 182-201 (1970); Yunis; "The Chromosomal Basis of Human Neoplasia," Science, 221: 227-236 (1983); and German, "Clinical Implication of Chromosome Breakage," in Genetic Damage in Man Caused by Environmental Agents, Berg, Ed., pgs. 65-86 (Academic Press, New York, 1979). Chromosomal abnormalities include translocations (transfer of a piece from one chromosome onto another chromosome), dicentrics (chromosomes with two centromeres), inversions (reversal in polarity of a chromosomal segment), insertions, amplifications, and deletions.

In cancer, deletion or multiplication of copies of whole chromosomes or chromosomal segments, and higher level amplifications of specific regions of the genome, are common occurrences. With the advent of cloning and detailed molecular analysis, recurrent translocation sites have been recognized as involved in the formation of chimeric genes such as the BCR-ABL fusion in chronic myelogeneous leukemia.

Deletions have been recognized as frequently indicating the location of tumor suppressor genes; and amplifications have been recognized as indicating overexpressed genes.

Human breast carcinomas are also characterized cytogenetically by various anomalies that may be the chromosomal counterpart of the molecular anomalies: regions of amplification are found in more than one-third of the tumors, and various deletions e.g., 1p, 11p, 11q, 13, and 17p, are found recurrently. Although amplification of genetic material is a frequent and probably important event in breast carcinogenesis, the relevant genes involved in such amplifications remain unknown, and do not seem to correspond to the proto-oncogenes commonly considered important in breast cancer. Since these regions of amplification in tumors are most often not at the site of the amplified genes in normal cells, standard cytogenetics does not yield any information that could assist with identification of the gene. Dutrillaux et al., *Cancer Genet. Cytogenet.*, 49: 203-217 (1990) report (at page 203) that "(a)lthough human breast carcinomas are among the most frequent malignant tumors, cytogenetic data remain scarce, probably because of their great variability and of the frequent difficulty of their analysis." In their study of "30 cases with relatively simple karyotypes to determine which anomalies occur the most frequently and, in particular, early during tumor progression" (p. 203), they concluded that "trisomy 1q and monosomy 16q are early chromosomal changes in breast cancer, whereas other deletions and gain of 8q are clearly secondary events." (Abstract, p. 203.) Dutrillaux et al. further state (at page 216) that deletions within tumor suppressor genes "characterize tumor progression of breast cancer."

Restriction fragment length polymorphism (RFLP) studies have indicated that several tumor types have frequently lost heterozygosity at 13q, suggesting that one of the

Rb-1 gene alleles has been lost due to a gross chromosomal deletion (Bowcock et al., Am. J. Hum. Genet., 46: 12 (1990)). The deletion of the short arm of chromosome 3 has been associated with several cancers, for example, small cell lung cancer, renal and ovarian cancers; it has been postulated that one or more putative tumor suppressor genes is or are located in the p region of chromosome 3 (ch. 3p) (Minna et al., Symposia on Quantitative Biology, Vol. LI: 843-853 (SCH Lab 1986); Cohen et al., N. Eng. J. Med., 301: 592-595 (1979); Bergerham et al., Cancer Res., 49: 13901396 (1989); Whang-Peng et al., Can. Genet. Cytogenet., II: 91-106 (1984; and Trent et al., Can. Genet. Cytogenet., 14: 153-161 (1985)).

The Cancer Genome Anatomy Project, sponsored by the National Cancer Institute, has cataloged changes at particular chromosomal locations and correlated them with disease in the Breakpoint Map of Recurrent Chromosomal Aberrations. Unfortunately, the chromosomal change data consists of thousands of often conflicting anecdotal case studies, and chromosomal changes can only be mapped to large areas covering dozens of genes. Thus, although much data has been collected in this area, it has not yielded any discernable patterns in chromosomal change which are clinically useful for characterizing tumors or predicting the progress of cancers.

A universally accepted classification of cancer stages allows evaluation of treatment management, prognosis and statistical comparison for the various anatomic sites of cancer. Although several organizations dedicated to cancer exist, including the American Joint Committee on Cancer (AJCC), International Union Against Cancer (UICC); World Health Organization (WHO); Federation Internationale de Gynecologie et d'Obstertrique (FIGO), there has been a concerted effort to establish a uniform standard

accepted world-wide for classification of cancer. In 1988, the AJCC in cooperation with the TNM Committee of the UICC accepted the TNM (Tumor, Node, and Metastasis) description to indicate the classification and stage of growth for the various anatomical sites of human cancer known . The AJCC Cancer Staging Manual (1997) is now in its 5th edition, and corresponds with the Fifth Edition of the UICC TNM Classification of Malignant Tumors.

The TNM system is based on three significant events in the anatomical history of a cancer: the size of the untreated primary cancer (T), its spread to regional lymph nodes (N) and finally, distant metastasis beyond the regional lymph nodes (M). Classification of a cancer by TNM, therefore, indicates the extent of disease and progression for any cancer growth. Staging classifications are based on documentation of the anatomic extent of disease, derived from morphologic studies and clinical biopsies.

The AJCC, knowing that new information on diagnosis, treatment and etiology will affect the classification system, assigns task committees to meet periodically and recommend revisions. While now based mainly on anatomical criteria, it is very likely that molecular, genetic and other prognostic indicators will be included into the TNM classification system when recommended by the appropriate AJCC committee.

Clinical classification utilizing the TNM system is based on evidence acquired before primary treatment. Pathologic classification includes the evidence acquired before treatment, as well as evidence acquired from surgery. The three components, T, M and N, are assessed. The use of numerical subsets of the TNM components indicates the progressive extent of the malignant disease. Any of the T, N, or M classifications can be divided into subgroups for testing. The TNM components can then be evaluated to

determine the stage grouping (I-IV) of growth for the patient's cancer. The clinical stage is used as a guide to the selection of primary therapy, usually a form of surgery to remove the cancerous lesions. The pathologic stage can also be used as a guide for adjuvant therapy (chemotherapy), prognosis, and reporting end results.

For example, over 90% of all ovarian cancers are derived from a single layer of surface epithelial cells that surrounds the ovary that are known as the ovarian surface epithelium (OSE). The cancerous epithelial cells initially form tumors on the ovary (stage I), slough off and migrate to the fallopian tubes and the uterus (stage II) and ultimately metastasize throughout the peritoneum and into such organs as the liver, bowel and bladder (stage III and IV). Stage I and II tumors are treatable with conventional management (up to 90% survival after five years for Stage IA and 70% survival for stage II), however, a lack of accurate diagnostics has made detecting early stage disease difficult with only 20% of all cases presenting at stage I or II. Most late stage ovarian cancer patients present with large volumes of ascites in the peritoneum. This accrual is thought to be a consequence of impaired lymphatic drainage as well as an increased rate of lymphatic production potentially due to effects of vascular permeability factor also known as vascular endothelial growth factor, which is present at high levels in ascites.

Treatment of all cancers depends on the tumor stage as determined by clinical evaluation and surgical resection. The standard technique for assessing the spread of a tumor is surgical resection of a primary tumor followed by careful review using light microscopy of surgical margins and other tissue, including lymph nodes. Under existing procedure, the adjacent tissue is stained by standard techniques and assessed under light microscopy for the presence of tumor cells. Using the TNM scale, the tumor can then be

assessed and assigned to a particular stage. Accurate histopathologic assessment is critical since it provides important prognostic indicators that determine the probability of survival for a given patient following surgical resection of the primary tumor.

Despite many years of research and billions of dollars in expenditures, the long term survival of patients with malignancies remains disappointingly low, even where no tumor cells were detected in the tumor margins or more distant tissues. This inability to more accurately stage such patients might be due to the limitation inherent in the standard histopathologic methodology which is based upon visual observation and morphologic assessment under light microscopy of adjacent tissue and regional lymph nodes. Thus, a method which uses a more precise technique capable of determining spread of the disease at an earlier stage might provide a more accurate indication of the extent of tumor metastases into adjacent and regional tissues. Although limited advances have been made in the characterization of tumors and pre-cancerous tissues by studying changes in individual genes or at particular loci of chromosomes, these approaches do not take into consideration the interaction of various gene products which is necessary for the myriad steps of tumor progression. Thus, a need exists for a different approach towards the study of the progression of cancer and the development of better tumor diagnostic tools.

Bioactive lipids have recently been recognized to be an integral and pervasive part of cell regulation and signaling. Lysoglycerolphospholipids and sphingoid-based lipids are two important classes of bioactive lipid mediators that have been extensively studied in recent years and have known effects on ovarian cancer cells. LPA and lysophosphatidylcholine (LPC), as well as their sphingoid relatives, S1P and SPC along with the closely related platelet activating factor (PAF) can induce numerous cellular

responses including cell proliferation, smooth muscle contraction, platelet aggregation, angiogenesis and tumor cell invasion. These mediators are produced by numerous cell lineages and are normal constituents of sera. Thus they can be viewed in terms of being a necessary part of physiological responses to specific cellular stresses. Furthermore, these lysophospholipids elicit their effects through classical signal transduction pathways including the regulation of heterotrimeric G-proteins, kinase signaling cascades, calcium mobilization, transcriptional regulation, focal adhesion kinase (p125 FAK) and the actin cytoskeleton. Over the past few years, considerable progress has been made in defining the molecular and cellular effects of LPA on cells, not the least of which is the cloning and characterization of several LPA receptors. These receptors are members of the seven-transmembrane-domain G-protein coupled receptor class and fall into two subfamilies: PSP24 and the Edg-family (endothelial cell differentiation gene) of receptors. The Edg-family is comprised of eight members of which Edg1, Edg2, Edg4 and Edg7 have been demonstrated to bind LPA and to activate a variety of signal transduction pathways in response to exogenous LPA. Edg1, Edg3, Edg5 and Edg6 have demonstrated to be receptors for S1P.

Phosphatidyl choline (PC), also named lecithin, is one of the major sources of polyunsaturated fatty acids such as arachidonic and linoleic acids. The former is a precursor of eicosanoids which have numerous biological activities. Hydrolysis of PC yields lysophosphatidyl choline (LPC) and constituent fatty acids, which have been implicated in signal transduction. An increasing body of evidence indicates that LPC, which is present in high concentrations in oxidized low density lipoproteins may play a significant role in atherogenesis and other inflammatory disorders. LPC has been

reported to increase the transcription of genes encoding platelet derived growth factor A and B chains, and heparin-binding epidermal growth factor-like protein (HB-EGF) in cultured endothelial cells, and to increase mRNA encoding HB-EGF in human monocytes. These gene products are mitogens for smooth muscle cells and fibroblasts. LPC has also been shown to activate protein kinase C in vitro, to potentiate the activation of human T lymphocytes and to potentiate the differentiation of HL-60 cells to macrophages induced by either membrane-permeable diacylglycerols or phorbol esters.

LPC may also provide a source of bioactive lysophosphatidic acid (1-acyl-sn-glycero-3-phosphate, LPA) through hydrolysis by lysophospholipase D. LPA is a naturally occurring phospholipid with a wide range of growth factor-like biological activities. It is well established that LPA can act as a precursor of phospholipid biosynthesis in both eukaryotic and prokaryotic cells. The ability of LPA to act as an intercellular lipid mediator has been noted (Vogt, Arch. Pathol. Pharmacol. 240:124-139 (1960); Xu et al., J. Cell. Physiol. 163:441-450 (1995); Xu et al., Biochemistry 309:933-940 (1995); Tigyi et al., Cell Biol. 91:1908-1912 (1994); Panetti et al., J. Lab. Clin. Med. 129(2):208-216 (1997)). LPA is rapidly generated by activated platelets and can stimulate platelet aggregation and wound repair.

Ascites from ovarian cancer patients contain an activity or activities that are very effective at supporting the growth of ovarian cancer cell lines and of freshly isolated ovarian cancer cells but not of ovarian surface epithelial cells (OSE) or SV-40 large T-antigen-immortalized surface epithelial cells (IOSE). This growth factor-like activity in ascites (originally termed OCAF for Ovarian Cancer Activating Factor) was identified as lysophosphatidic acid (LPA) based on chemical and physical characteristics as well as the

ability of synthetic LPA (but not other growth factors such as platelet-derived growth factor, also present in ascites) to completely desensitize the calcium mobilization response of ovarian cancer cells to ascites fluid and on the ability of phospholipases to destroy OCAF activity in ascites. (Mills et al., Cancer Res. 48:1066 (1988); Mills et al. J. Clin. Invest. 86:851 (1990) and U.S. Patent Nos. 5,326,690 and 5,277,917)

LPA at concentrations present in ascites has multiple effects on ovarian cancer cells including increased cell proliferation, increased cell survival by decreasing apoptosis and anoikis, decreased sensitivity to cisplatin, increased invasiveness, increased production of vascular endothelial growth factor, increased production and activity of urokinase-type plasminogen activator (uPA) as well as the activity of the metalloproteinases MMP2 and MMP9 and finally, increased production of LPA itself. LPA does not produce similar responses in freshly isolated OSE and IOSE.

Other lysophospholipids associated with various conditions include lysophosphatidyl serine (LPS), lysophosphatidyl ethanolamine (LPE), lysophosphatidyl glycerol (LPG) and lysophosphatidyl inositol (LPI). Activated platelets secrete two kinds of phospholipase: sPLA2 and PS-PLA1. sPLA2 is reported to be elevated in inflammatory reactions and inhibition of this enzyme reduced inflammation. PS-PLA1 hydrolyzes phosphatidylserine or lysophosphatidyl serine (LPS) specifically to produce GPS or Glycerol-3-P serine. LPS strongly enhances degranulation of rat mast cells induced by concanavalin A and potentiates histamine release, and can stimulate sPLA2-elicited histamine release from rat serosal mast cells. LPS is an inflammatory lipid mediator and Spla2 has been implicated in inflammation processes. LPI has been shown

to stimulate yeast adenylyl cyclase activity with implications for modulating the activity of downstream effector molecules and their interaction with RAS proteins.

Little is known about the mechanisms regulating LPA levels in vivo; however, the low LPA levels in plasma indicate that production, metabolism or clearance is tightly controlled. LPA is a normal phospholipid constituent of all cells and functions as a metabolic intermediate in de novo synthesis of glycerophospholipids and triglycerides. As with other lipid mediators like diacylglycerol and phosphoinositides, the relationship between this "housekeeping" LPA and LPA that exerts its actions through cell surface receptors is unclear. Clearly a growing variety of cells including platelets, adipocytes, leukocytes, fibroblasts, endothelial cells and, ovarian cancer cells, can release LPA into the extracellular space in response to agonist stimulation. Phospholipase A2 (PLA2)-mediated deacylation of phosphatidic acid (PA), produced by the action of phospholipase D (PLD) on membrane phosphatidylcholine (PC) or by the actions of diacylglycerol kinase on diacylglycerol formed by phospholipase C likely contributes to LPA production in response to cellular activation. The pathway for production of extracellular LPA has been most intensely studied in platelets where release of membraneous microvesicles is a critical step.

SUMMARY OF THE INVENTION

Although the role of bioactive lipids in the proper functioning of an organism is not fully understood, their varied biological activities indicate that they are important cell regulation and signaling molecules. As mentioned above, elevated LPA levels have been linked to ovarian cancer, and several sphingolipids and lysophospholipids have been

implicated in cell signaling events. Applicants postulated that these altered lysophospholipid and sphingolipid levels were indicative of a loss of control over proteins involved in lipid metabolism, synthesis, and signaling at a genomic level, and that this loss of control over bioactive lipid signaling functions is an integral event in the progress of cancer development. Using this unique metabolic approach, applicants have developed a novel method of monitoring cancer progression. The added information concerning tumor characteristics that is supplied to the clinical practitioner by this method can be used to choose more appropriate and effective cancer therapies.

The present invention is drawn to a method for identifying tumor characteristics in tissue samples taken from a patient by determining the copy number or expression level of genes associated with lipid metabolism, synthesis, or action in the sample. Although not bound to any particular theory, applicants believe that the alteration of the chromosomal copy number or loss of control over the expression of lipid associated genes is a very significant event in the genesis and progression of cancer. Thus, the relative stage and characteristics of the disease may be monitored by determining the copy number or expression level of lipid associated genes in the cancerous and pre-cancerous cells of a tumor or surrounding tissues. This determination may be made by directly quantifying the gene copy number in the chromosomal material of the tissue sample, or by determining the transcription level of the gene in the tissue sample. The present invention is also drawn to physical platforms which are useful in carrying out the diagnostic method, specifically arrays of nucleic acids useful for determining the copy number or expression level of the lipid associated genes by hybridization techniques.

Thus, one aspect of the present invention is a method for identifying tumor characteristics from a tissue sample obtained from a patient, wherein the method comprises determining whether the cells of the tissue sample have an abnormal copy number or expression level of at least two genes associated with lipid metabolism, synthesis, or action. Preferred genes for monitoring in making the determination are Phosphatidylinositol-3-kinase (catalytic, alpha polypeptide), Phospholipase D1 (phosphatidylcholine specific), Dihydroxyacetone phosphate acyltransferase, Phosphate cytidylyltransferase 1 (choline specific, alpha form), Phosphate cytidylyltransferase 2 (ethanolamine specific), Phosphatidic Acid Phosphatase type 2c, Prostate Differentiation Factor PLAB, Phospholipase A2, Phospholipase C beta 3 (phosphatidylinositol specific), Phosphatidylinositol-3-Kinase (class2, gamma polypeptide), Choline/ethanolamine phosphotransferase, Lyosphospholipase, Aldehyde dehydrogenase (5 family, member A1), Phospholipase D1 glycosylphosphatidylinositol specific, 1-acylglycerol-3-phosphate acyltransferase, Phosphatidic Acid Phosphate type 2b, EDG 1, Glycerol-3-phosphate dehydrogenase, Sphingosine-1-phosphate lyase 1, Phosphatase and Tenson Homolog (PTEN), Phosphatidic Acid Phosphatase type 2a, Sphingomyelin phosphodiesterase 1, N-acylsphingosine amidohydrolase, Glycerol Kinase, Diacylglycerol Kinase gamma, Acyl-dihydroxyacetone phosphate reductase, Triacylglycerol lipase, EDG 2, EDG 3, EDG 4, EDG 5, EDG 6, and EDG 7. Particularly preferred genes for monitoring in the method of the invention are Phosphatidylinositol-3-kinase (catalytic, alpha polypeptide), Phospholipase D1 (phosphatidylcholine specific), Prostate Differentiation Factor PLAB, Phospholipase A2, Phospholipase D1 glycosylphosphatidylinositol specific, EDG 1,

Glycerol-3-phosphate dehydrogenase, EDG 2, EDG 3, EDG 4, EDG 5, EDG 6, and EDG 7.

Although useful information concerning tumor characteristics may be gleaned by determining the copy number or expression level of as few as two lipid associated genes, it is preferred that more than two genes be so monitored in the methods of the invention. The copy number or expression level of each gene can usually be used to answer one question about the tumor characteristics of the tissue sample, such as "Is the cell metastatic?" or "Is the tumor at stage 2?" Furthermore, where the source of the tumor is not known with complete certainty, the copy number or expression level of each gene can indicate the source of the tumor and provide important information about the origin or source of the tumor and yield insight into the diagnosis or treatment thereof. If more lipid associated genes are monitored, more information will be available to the clinician. In addition, the correlation between tumor stages and the amplification or deletion of any particular gene is usually not 100%. Thus, certainty as to the tumor characteristics identified through the method can be increased by monitoring more than one lipid associated gene that has been correlated to a particular characteristic, or "redundant" genes. Thus, methods employing at least three, four, five, six, seven, eight, nine, ten, fifteen, or twenty genes are all more preferred embodiments of the method of the invention. A most preferable embodiment of the method would determine the copy number or expression level of at least ten lipid associated genes, as this will provide several pieces of information concerning the stage and metastatic potential of the cells in the tissue sample with redundant genes to verify that information.

The method of the invention may be applied to a tissue sample from any organ,

including muscle, dermal tissues, lung, liver, pancreas, stomach, colon/rectal tissues, bone, prostate, testicles, or other organs in which cancer is known to occur. However, especially preferred embodiments of the invention utilize tissue samples from gynecological organs, including breast, cervix, uterus, and ovaries. It is also contemplated that connective, muscle, or lymphoid tissues surrounding the organ of interest will also be a source of tissue samples, as it may be advantageous for a clinician to test these tissues for evidence of invading or metastasizing tumor cells.

The determination of whether the cells of the tissue sample have an abnormal copy number or expression level of the genes associated with lipid metabolism, synthesis, or action may be achieved by any of several methods known in the art for determining gene copy number or expression level. For example, in situ fluorescence hybridization techniques can be used to microscopically "count" the number of gene copies in a cell. Preferred methods for determining the copy number or expression level of lipid associated genes are those which use hybridization probes. Such methods generally include the steps of:

- a) isolating sample nucleic acid polymers from the cells of the tissue sample;
- b) hybridizing the sample nucleic acid polymers with nucleic acid polymers specific for the selected genes under conditions wherein the extent of hybridization may be quantified; and
- c) comparing the hybridization data thus obtained with data obtained from the hybridization of reference nucleic acid polymers isolated from a normal cell of the same tissue type as that of the tissue sample from the patient with the nucleic acid polymers specific for the selected genes under the same conditions.

In the methods of the present invention, the sample nucleic acid polymers and the reference nucleic acid polymers may be either genomic DNA or mRNA encoding expressed genes. It is also contemplated to be within the scope of the claimed method to amplify the sample nucleic acid polymer by a polymerase chain reaction (PCR) technique prior to hybridization in order to increase the amount of the sample nucleic acid polymer available for detection.

The nucleic acid polymer probes specific for the selected genes used in the methods or arrays of the invention are preferably derived from the naturally occurring gene sequence of the gene for which the probe is designed. It is preferable that the nucleic acid probe comprise at least about 19 nucleotides which hybridize under the hybridization conditions used in the method to a similarly sized portion of the naturally occurring gene sequence. However, it is more preferable to use nucleic acid probes with at least about 25 nucleic acids which hybridize to the naturally occurring gene, so that allelic variations and point mutations will not significantly interfere with the detection of the lipid associated gene copy number or expression level. The nucleic acid probe may hybridize with a coding region of one of the selected genes, or with a non-coding sequence functionally linked to the coding region of one of the selected genes, wherein the functionally linked sequence is unique to that gene.

It is also preferred in embodiments of the methods of the present invention to immobilize the nucleic acid polymer probes specific for the selected genes on a solid support, so that a nucleic acid polymer specific for each selected gene is located at a different predetermined position on the solid support. When the nucleic acid polymer

probes are so arranged, the copy number or expression level of several lipid associated genes in the sample nucleic acid polymers may be determined at the same time by sandwich hybridization assay techniques.

Thus, another aspect of the present invention is an array of nucleic acid polymers immobilized on a solid support, in which the array comprises:

- a) a solid support;
- b) at least two different nucleic acid polymers which are each specific for a different gene associated with lipid metabolism, synthesis, or action;

wherein a nucleic acid polymer specific for each gene associated with lipid metabolism, synthesis, or action is located at a different predetermined position on the solid support, and wherein the array comprises less than 100 nucleic acid polymers which are specific for genes other than the selected genes. Although the arrays of the present invention may be part of a larger array for testing nucleic acid polymers isolated from a tissue sample, and such embodiments are envisioned as within the scope of the invention, the arrays are nonetheless intended to be used as relatively focused tools for gathering information about tumor characteristics. Thus, arrays which contain nucleic acid polymer probe sequences specific for each and every human gene, or those which consist of probe sequences specific for every gene expressed by a certain cell type (also referred to as "cDNA library arrays), are not considered to be within the scope of the present invention.

It is preferred that at least two of the nucleic acid polymers which are specific for genes associated with lipid metabolism, synthesis, or action be specific for genes selected from the group consisting of: Phosphatidylinositol-3-kinase (catalytic, alpha polypeptide), Phospholipase D1 (phosphatidylcholine specific), Dihydroxyacetone

phosphate acyltransferase, Phosphate cytidylyltransferase 1 (choline specific, alpha form), Phosphate cytidylyltransferase 2 (ethanolamine specific), Phosphatidic Acid Phosphatase type 2c, Prostate Differentiation Factor PLAB, Phospholipase A2, Phospholipase C beta 3 (phosphatidylinositol specific), Phosphatidylinositol-3-Kinase (class2, gamma polypeptide), Choline/ethanolamine phosphotransferase, Lyso-phospholipase, Aldehyde dehydrogenase (5 family, member A1), Phospholipase D1 glycosylphosphatidylinositol specific, 1-acylglycerol-3-phosphate acyltransferase, Phosphatidic Acid Phosphate type 2b, EDG 1, Glycerol-3-phosphate dehydrogenase, Sphingosine-1-phosphate lyase 1, Phosphatase and Tenson Homolog (PTEN), Phosphatidic Acid Phosphatase type 2a, Sphingomyelin phosphodiesterase 1, N-acylsphingosine amidohydrolase, Glycerol Kinase, Diacylglycerol Kinase gamma, Acyl-dihydroxyacetone phosphate reductase, Triacylglycerol lipase, EDG 2, EDG 3, EDG 4, EDG 5, EDG 6, and EDG 7. It is more preferred that at least one of the nucleic acid polymers which is specific for a gene associated with lipid metabolism, synthesis, or action is specific for a gene selected from the group consisting of: Phosphatidylinositol-3-kinase (catalytic, alpha polypeptide), Phospholipase D1 (phosphatidylcholine specific), Prostate Differentiation Factor PLAB, Phospholipase A2, Phospholipase D1 glycosylphosphatidylinositol specific, EDG 1, Glycerol-3-phosphate dehydrogenase, EDG 2, EDG 3, EDG 4, EDG 5, EDG 6, and EDG 7.

DESCRIPTION OF FIGURES AND SEQUENCE ID'S

FIGURE 1: A diagram of the pathways for various metabolism and synthesis of phospholipids.

FIGURE 2: A diagram of the pathways for various metabolism and synthesis of sphingolipids.

SEQ ID NO. 1: The sequence of the cDNA coding for 1-acylglycerol-3-phosphate acyltransferase.

SEQ ID NO. 2: The sequence of the cDNA coding for Aldehyde dehydrogenase (5 family, member A1).

SEQ ID NO. 3: The sequence of the cDNA coding for Choline/ethanolamine phosphotransferase.

SEQ ID NO. 4: The sequence of the cDNA coding for Diacylglycerol kinase, gamma.

SEQ ID NO. 5: The sequence of the cDNA coding for Dihydroxyacetone phosphate acyltransferase.

SEQ ID NO. 6: The sequence of the cDNA coding for EDG 1.

SEQ ID NO. 7: The sequence of the cDNA coding for EDG 2.

SEQ ID NO. 8: The sequence of the cDNA coding for EDG-3.

SEQ ID NO. 9: The sequence of the cDNA coding for EDG-4.

SEQ ID NO. 10: The sequence of the cDNA coding for EDG-5.

SEQ ID NO. 11: The sequence of the cDNA coding for EDG-6.

SEQ ID NO. 12: The sequence of the cDNA coding for EDG-7.

SEQ ID NO. 13: The sequence of the cDNA coding for Glycerol-3-phosphate dehydrogenase.

SEQ ID NO. 14: The sequence of the cDNA coding for Lyosphospholipase I.

SEQ ID NO. 15: The sequence of the cDNA coding for Human Lysophospholipase Homolog.

SEQ ID NO. 16: The sequence of the cDNA coding for N-acylsphingosine amidohydrolase.

SEQ ID NO. 17: The sequence of the cDNA coding for Phospholipase A2.

SEQ ID NO. 18: The sequence of the cDNA coding for Phospholipase D1 (phosphatidylcholine specific).

SEQ ID NO. 19: The sequence of the cDNA coding for Phospholipase D1 glycosylphosphatidylinositol specific.

SEQ ID NO. 20: The sequence of the cDNA coding for Phosphatidic Acid Phosphatase type 2b.

SEQ ID NO. 21: The sequence of the cDNA coding for Phosphatidic Acid Phosphatase type 2a.

SEQ ID NO. 22: The sequence of the cDNA coding for Phosphatidylinositol-3-Kinase (class2, gamma polypeptide).

SEQ ID NO. 23: The sequence of the cDNA coding for Phosphatidylinositol-3-kinase (catalytic, alpha polypeptide).

SEQ ID NO. 24: The sequence of the cDNA coding for Prostate Differentiation Factor PLAB.

SEQ ID NO. 25: The sequence of the cDNA coding for Phosphatidic Acid Phosphatase type 2c.

SEQ ID NO. 26: The sequence of the cDNA coding for Phosphocholine cytidyltransferase.

SEQ ID NO. 27: The sequence of the cDNA coding for Phosphate cytidylyltransferase 2 (ethanolamine specific).

SEQ ID NO. 28: The sequence of the cDNA coding for Phosphatase and Tenson Homolog (PTEN).

SEQ ID NO. 29: The sequence of the cDNA coding for Sphingosine-1-phosphate lyase 1.

SEQ ID NO. 30: The sequence of the cDNA coding for Sphingomyelin phosphodiesterase 1.

SEQ ID NO. 31: The sequence of the cDNA coding for Phospholipase C beta 3 (phosphatidylinositol specific).

All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.

DETAILED DESCRIPTION OF THE INVENTION

The present invention is directed to a method of identifying tumor characteristics by determining the copy number or expression level of genes associated with lipid metabolism, synthesis, or action in the cells of a tissue sample from a patient, and to arrays used as a tool in the claimed methods. Although the examples and guidance given below primarily concern embodiments of the invention which include the use of array-based nucleic acid hybridization techniques, one of ordinary skill in the art will readily recognize that the invention is not limited to this particular type of methodology for determining lipid- associated gene copy number or expression level. Thus, the method of identifying tumor characteristics taught by the present invention can be readily modified

by those of skill in the art to utilize any other acceptable methods of determining gene copy number or expression level in the cells of a sample, and such modifications are considered to be within the scope of the present invention.

DEFINITIONS

As used herein, "tumor characteristic" means any morphological characteristic associated with tumors or the development and progression of cancers, such as tumor stage and serous, mucinous, metastatic, or endometrioid character. Especially, The metastatic nature and potential of the tumor cells, or the degree of their invasive and migratory nature, may be determined by particular lipid-associated gene copy number or expression level profiles. Tumor stage, defined according to traditional pathological criterion, is of particular interest as a tumor characteristic. Although the traditional methods of describing tumor stages (size, degree of invasion into regional tissues, and the presence of distant metastasis (or colonies of cells from the original tumor)) are not directly determined by the present method, the underlying biochemical changes which allow the tumor cells to drastically increase in size, to live detached from the tumor surface, and to infiltrate the cell layers of surrounding tissues are often linked to changes in the copy number or expression level of lipid-associated genes. In addition, resistance to particular chemotherapies or radiation may be determined from the lipid-associated gene copy number or expression level profile, as the success of particular therapies often depends upon the cell characteristics of the tumor.

“Tissue sample” means any tissue obtained from a patient which is suspected of comprising cancer or tumor cells, including tissues from the tumor body, tissues surrounding the tumor, or tissues obtained from vicinal lymph nodes.

“Patient,” as used herein, is not limited exclusively to human patients. However, the exemplary methods described herein are intended for use with human patients. Modification of the methods described herein, particularly with respect to the particular genes assayed for copy number or expression level, are probably necessary for application of these methods to non-human patients. Several genes associated with lipid metabolism, synthesis, or action are known for a number of non-human mammalian species, and the modification of the present methods for use with these species would be well within the skill of the ordinary practitioner in the biochemical arts.

“Abnormal copy number,” as used herein, denotes a higher or lower number of copies of a gene in a cell’s genome, as compared to the normal number of gene copies in a cell of a particular type in a particular organism. Although ordinarily two copies of most genes are contained in most diploid cells, greater or fewer copies may be considered “normal” for the cell. For instance, only one copy of some genes on the X chromosome is present in a normal diploid cell from a male organism (XY heterozygous).

“Expression level,” as used herein, denotes the level of transcription of a gene in a cell, as determined by the number of mRNA’s encoding a particular protein gene product present in the cell. The number of mRNA copies of most genes will vary by cell tissue type. Thus, an abnormal expression level would be one in which a significantly higher or lower number of mRNA’s for a particular protein exist in the cell as compared to a normal cell of the same tissue type under approximately the same conditions.

“Genes associated with lipid metabolism, synthesis, or action,” include genes whose proteins modify, oxidize, reduce, cleave, bind, or otherwise utilize bioactive lipids as substrates or ligands. Such bioactive lipids include sphingosine-1-phosphate (S1P), sphingophosphatidylcholine (SPC), sphingophosphatidylinositol (SPI), sphingophosphatidylserine (SPS), sphingophosphatidylglycerol (SPG), sphingophosphatidylethanolamine (SPE), lysophosphatidic acid (LPA), lysophosphatidylcholine (LPC), lysophosphatidylserine (LPS), lysophosphatidylinositol (LPI), lysophosphatidyl ethanolamine (LPE), and lysophosphatidyl glycerol (LPG), as well as metabolites of these lipids such as glycerol-3-phosphate (G3P). A non-exhaustive list of such genes include those encoding Phosphatidylinositol-3-kinase (catalytic, alpha polypeptide), Phospholipase D1 (phosphatidylcholine specific), Dihydroxyacetone phosphate acyltransferase, Phosphate cytidylyltransferase 1 (choline specific, alpha form), Phosphate cytidylyltransferase 2 (ethanolamine specific), Sphingosine kinase, Phosphatidic Acid Phosphatase type 2c, Prostate Differentiation Factor PLAB, Phospholipase A2, Phospholipase C beta 3 (phosphatidylinositol specific), Phosphatidylinositol-3-Kinase (class2, gamma polypeptide), Choline/ethanolamine phosphotransferase, Lyosphospholipase, Aldehyde dehydrogenase (5 family, member A1), Phospholipase D1 glycosylphosphatidylinositol specific, 1-acylglycerol-3-phosphate acyltransferase, Phosphatidic Acid Phosphate type 2b, EDG 1, Glycerol-3-phosphate dehydrogenase, Sphingosine-1-phosphate lyase 1, Phosphatase and Tenson Homolog (PTEN), Phosphatidic Acid Phosphatase type 2a, Sphingomyelin phosphodiesterase 1, N-acylsphingosine amidohydrolase, Glycerol Kinase, Diacylglycerol Kinase gamma, Acyl-dihydroxyacetone phosphate reductase, Glycerol-3-phosphate Acyltransferase,

Diacylglycerol Lipase, Phosphatidylethanolamine methyltransferase, Ceramide cholinephosphotransferase, N-acylsphingosine glucosyltransferase, Sphingosine N-acyltransferase, Triacylglycerol lipase, Phosphatidylserine decarboxylase, CDP Diacylglycerol inositol-3-phosphatidyltransferase, EDG 2, EDG 3, EDG 4, EDG 5, EDG 6, and EDG 7.

The term "isolating nucleic acid polymers" means any acceptable method of extracting nucleic acid polymers (such as deoxyribonucleic acids or ribonucleic acids) from the cells of a sample. Normally, such methods will include steps such as lysing the cells in a sample and purifying the nucleic acids from the lysed cells. Traditional methods of purification include solvent partition of cell components or absorption of nucleic acids onto a matrix which has a high affinity for nucleic acids, such as silica. However, "isolation" of the nucleic acid in a sample, as the term is used in this application, can also be accomplished by fixing the nucleic acid within the cell at a known or knowable location, such as in paraffin fixed tissues whose chromosomal DNA can be examined microscopically by microkeratotomy and histopathology techniques. These methods are well known to those of ordinary skill in the art.

The term "hybridizing" denotes a procedure in which complementary, or nearly complementary, nucleic acid polymers are allowed to associate in solution. Usually, if a sample nucleic acid polymer is double stranded chromosomal DNA, the hybridization procedure will include a denaturation or "melting" step. It is preferred that buffers and temperature conditions in the hybridization procedure be such that minimal non-specific interactions between the associating nucleic acid polymers occur. These are usually referred to as "stringent" conditions by those of skill in the art. This will prevent non-

specific binding of the probe nucleic acid polymer to the sample nucleic acid polymers. However, a slight tolerance for mismatched base pair association is also preferable in a hybridization procedure for use in the present invention. This will account for minor allelic variations in the human genetic make-up and for small numbers of substitution mutations (a not uncommon occurrence in tumor cell genomes.) Thus, the conditions used in the hybridization procedure will preferably allow approximately one mismatched base pair association per 15-20 associated based pairs. Hybridization conditions and methods are well known in the art, and it is within the capabilities of one of ordinary skill in the art to adjust such methods to allow for the preferred level of stringency.

The term "conditions wherein the extent of hybridization may be quantified" means any accepted method for quantifying the amount of nucleic acid polymers derived from a sample tissue which associate specifically with the nucleic acid polymer probe used to measure the copy number of the gene of interest. Many methods have been disclosed in the art for making such a quantitative determination. They range from in situ fluorescence hybridization using fluorescently labeled nucleic acid polymer probes to visualize gene copy number on interphase chromosomes (such a system specific for the HER2 gene is offered by Vysis, Downers Grove, IL, USA), to electrically enhanced hybridization systems with fluorescently labeled probes (such as that described in U.S. Patent No. 6,017,696.) Preferred methods for use in the present invention are those which utilize arrays of nucleic acid probed in which different populations of nucleic acid probes are affixed to predetermined locations in the array. Such arrays allow for the hybridization of the sample nucleic acid polymers with several different probes specific for different genes at the same time.

The term "a normal cell of the same tissue type" means a non-cancerous, non-tumor cell of the same tissue type of the tumor's originating cells, or of the surrounding tissue from which the tissue sample is taken. For instance, a normal cell for comparison with a ovarian tumor tissue sample would be obtained from a healthy ovary.

The term "amplified" in the context of sample nucleic acid polymers means that the nucleic acid polymer is replicated in order to obtain a detectable amount of the nucleic acid polymer. Usually, such amplification is effected by self-replicating the nucleic acid polymer through the polymerase chain reaction. Methods of utilizing DNA and RNA polymerases to amplify sample nucleic acid polymers are well known to those of ordinary skill in the biological arts. When amplifying nucleic acids for use in the methods of the present invention, it is preferable that care be taken to normalize the data obtained from the amplified samples in order to obtain quantifiable results. Such a normalization may be achieved by subjecting a substantially similar amount of the reference nucleic acid polymers to the same or similar amplification procedure and obtaining hybridization data to compare to the hybridization data obtained with the amplified sample nucleic acid polymers.

The term "coding region" means a region of the gene which is translated into the amino acid sequence of the gene product, including signal peptides or portions of a pro-peptide which are cleaved from the gene product in order to form a mature protein. Generally, such regions are termed expressed sequences, or "exons."

The term "non-coding sequence functionally linked to the coding regions of the gene" means nucleic acid sequences which are normally not translated into the amino acid sequence of the gene product, but nevertheless form a part of the functional gene.

Such sequences include introns, promoters, enhancers, and nucleic acid sequences which fill in between these elements of the gene and the coding regions of the gene.

The term “immobilized on a solid support” means that the nucleic acid polymer is bound, covalently or through an affinity reaction, to a relatively contiguous surface. The solid support may consist of any appropriate material for binding nucleic acids, including glass, silicas, hydrogels (such as agarose or polyacrylamide), polymers (such as polystyrene or polypropylene), and cellulose derivatives (such as nitrocellulose). The solid support may be in any convenient form for quantifying the amount of hybridization, including beads, resins, microtiter wells, flat surfaces, rods, and the like. For use in the arrays of the present invention, flat silicate surfaces, such as used in U.S. Patent No. 5,744,305, are preferred. Immobilization formats adapted to these surfaces have been developed which can be easily loaded with the lipid associated gene probe sequences described in the invention, and which can be easily read with automated equipment.

The term “predetermined position” means that the location of immobilization on the solid support is known, and can be determined by reference to a detectable orientation point on or attached to the solid support. It is preferred that the surface of the solid support be divided into a grid-like arrangement of positions, in which a different population of nucleic acid polymers specific for a different gene resides at each position, or an “array”. Although it is preferred that this array be arranged in a symmetrical and orderly fashion, such an arrangement is not necessary. The only requirement is that the position of the particular populations of nucleic acid polymers specific for each gene be identifiable. In this way, the hybridization of the sample nucleic polymers to a particular population of nucleic acid polymers in the array may be determined by the physical

location of that hybridization, as visualized by fluorescence or detected by some other means.

The term "specific," as applied to nucleic acid polymers, means that the nucleic acid polymer probe contains a sequence substantially complementary to the lipid associated gene of interest, and not to other genes. Normally, a nucleic acid polymer will be specific for a gene if the probe sequence comprises at least about 19 contiguous nucleotides which are identical or complementary to 19 contiguous nucleotides of the lipid associated gene of interest. It is preferred that the nucleic acid polymer probe contain at least 1-5 additional contiguous identical or complementary nucleic acids: this will ensure hybridization under stringent conditions if a substitution mutation or allelic variation in the sample nucleic acid polymers is present. Those of ordinary skill in the art will recognize that the nucleic acid polymer probes may contain further nucleic acids in order to provide an anchor for immobilizing the nucleic acid polymer on a solid support or for attaching a detectable label to the nucleic acid polymer probe.

CHOICE OF LIPID-ASSOCIATED GENES FOR COPY NUMBER OR EXPRESSION LEVEL DETERMINATION

The first step in carrying out the methods of the invention is choosing which lipid-associated genes to monitor in the tissue samples. Genes associated with lipid metabolism, synthesis, or action suitable for monitoring in the present invention include genes whose proteins modify, oxidize, reduce, cleave, bind, or otherwise utilize bioactive lipids as substrates or ligands. Such bioactive lipids include sphingosine-1-phosphate (S1P), sphingophosphatidylcholine (SPC), sphingophosphatidylinositol (SPI),

sphingophosphatidylserine (SPS), sphingophosphatidylglycerol (SPG), sphingophosphatidylethanolamine (SPE), lysophosphatidic acid (LPA), lysophosphatidylcholine (LPC), lysophosphatidylserine (LPS), lysophosphatidylinositol (LPI), lysophosphatidyl ethanolamine (LPE), and lysophosphatidyl glycerol (LPG), as well as metabolites of these lipids such as glycerol-3-phosphate (G3P). Several of the biological metabolic pathways involving these bioactive lipids and the enzymes involved are illustrated in Figures 2 and 3. A non-exhaustive list of genes associated with lipid metabolism, synthesis, or action suitable for monitoring in the present invention include those encoding Phosphatidylinositol-3-kinase (catalytic, alpha polypeptide), Phospholipase D1 (phosphatidylcholine specific), Dihydroxyacetone phosphate acyltransferase, Phosphate cytidylyltransferase 1 (choline specific, alpha form), Phosphate cytidylyltransferase 2 (ethanolamine specific), Sphingosine kinase, Phosphatidic Acid Phosphatase type 2c, Prostate Differentiation Factor PLAB, Phospholipase A2, Phospholipase C beta 3 (phosphatidylinositol specific), Phosphatidylinositol-3-Kinase (class2, gamma polypeptide), Choline/ethanolamine phosphotransferase, Lyosphospholipase, Aldehyde dehydrogenase (5 family, member A1), Phospholipase D1 glycosylphosphatidylinositol specific, 1-acylglycerol-3-phosphate acyltransferase, Phosphatidic Acid Phosphate type 2b, EDG 1, Glycerol-3-phosphate dehydrogenase, Sphingosine-1-phosphate lyase 1, Phosphatase and Tenson Homolog (PTEN), Phosphatidic Acid Phosphatase type 2a, Sphingomyelin phosphodiesterase 1, N-acylsphingosine amidohydrolase, Glycerol Kinase, Diacylglycerol Kinase gamma, Acyl-dihydroxyacetone phosphate reductase, Glycerol-3-phosphate Acyltransferase, Diacylglycerol Lipase, Phosphatidylethanolamine methyltransferase, Ceramide

cholinephosphotransferase, N-acylsphingosine glucosyltransferase, Sphingosine N-acyltransferase, Triacylglycerol lipase, Phosphatidylserine decarboxylase, CDP Diacylglycerol inositol-3-phosphatidyltransferase, EDG 2, EDG 3, EDG 4, EDG 5, EDG 6, and EDG 7. The copy number or expression level of at least two lipid-associated genes is monitored in the methods of the present invention. Most preferably, at least one of the genes monitored is chosen from the group consisting of Phosphatidylinositol-3-kinase (catalytic, alpha polypeptide), Phospholipase D1 (phosphatidylcholine specific), Prostate Differentiation Factor PLAB, Phospholipase A2, Phospholipase D1 glycosylphosphatidylinositol specific, EDG 1, Glycerol-3-phosphate dehydrogenase, EDG 2, EDG 3, EDG 4, EDG 5, EDG 6, and EDG 7.

Usually, by monitoring the copy number or expression level of a particular gene one will be able to answer at most one question about the tumor characteristics of the tissue sample, such as "Is the cell metastatic?" or "Is the tumor at stage 2?". If more lipid associated genes are monitored, more information will be available to the clinician. Thus, although useful information concerning tumor characteristics may be gleaned by determining the copy number or expression level of as few as two lipid associated genes, it is preferred that more than two genes be so monitored in the methods of the invention. Preferably, a sufficient number of genes to fully characterize the tumor are monitored in the methods of the invention. Thus, complex profiles of increased and decreased lipid-associated gene copy number or expression level for all known lipid-associated genes may be established for various tumor stages and characteristics. However, simplified versions of the present method may be useful in some instances. For example, where a particularly strong correlation exists between metastasis and an increase in gene copy

number or expression level, for instance in the Phosphatidylinositol-3-kinase (alpha polypeptide) and Phospholipase D1 (phosphatidylcholine specific) genes (See data in Table 2), a clinician may choose to only assay the copy number of those particular genes in order to gather information about the metastatic potential of the cells. This situation could arise when a breast tumor biopsy specimen is being evaluated histologically, and an in-situ hybridization format for gene copy number counting is preferred. Even this limited amount of information can be very useful in assisting a physician in counseling a patient as to whether a breast-conserving lumpectomy or mastectomy is indicated.

As illustrated in Tables 2 and 3, several lipid-associated genes are present in altered copy numbers in significant numbers of ovarian cancer tumors. % loss and gain was determined by chromosomal genomic hybridization. These data indicate that the genes associated with lipid metabolism, synthesis, and action play an important role in tumor development and cancer progression. Altered numbers of these genes in tumor cells allow drastically increased (or decreased) production of these critical gene products, and thereby profoundly influence the morphology and physiology of the tumor cell.

As discussed previously, it is usually better to monitor several genes which have been correlated to the same tumor characteristic (metastatic, serous, mucinous, stage 3, etc.) at the same time. As indicated in the illustrative data collected in Tables 2 and 3, the correlation between the altered copy number or expression level of a particular gene and particular tumor characteristics is usually not 100%. Although not bound by any particular theory, applicants believe that this is due to the fact that several alternative pathways exist for the synthesis and metabolism of bioactive lipid products, as is illustrated in Figures 2 and 3. Thus, loss of control over bioactive lipid synthesis at any

one of a number of points can lead to particular tumor characteristics such as vascularization or the ability to grow detached from the tumor surface (a necessary condition for metastasis). Thus, several alternative genetic changes exist which will lead to the same phenotypic characteristic. Therefore, in order to more accurately determine the characteristics of a particular tumor for diagnostic and case management purposes, it is preferable to monitor several lipid-associated genes simultaneously in order to gather "redundant" information about a particular tumor characteristic. Thus, methods employing at least three, four, five, six, seven, eight, nine, ten, fifteen, or twenty genes are all more preferred embodiments of the method of the invention. A most preferable embodiment of the method would determine the copy number or expression level of at least ten lipid associated genes, as this will provide several pieces of information concerning the stage and metastatic potential of the cells in the tissue sample with redundant genes to verify that information.

CONSTRUCTION OF NUCLEIC ACID POLYMER PROBES AND PRIMERS SPECIFIC FOR THE CHOSEN LIPID ASSOCIATED GENES

Once the lipid-associated genes to be monitored have been chosen, probes may be designed to assay the copy number or expression level of those genes in a tissue sample according to any number of conventional methods, including hybridization to immobilized arrays, dot-blot hybridizations, southern blot techniques, or even chromosomal counting through fluorescent in-situ hybridization. The choice of probe and probe production technique will depend on the method used.

For instance, solid-support based synthesis techniques are favored for the production of short probes for immobilization or to use as labeled in-situ hybridization probes. Techniques for synthesizing short oligonucleotides include conventional phosphotriester and phosphodiester methods or automated derivatives thereof. In one such automated method, diethylphosphoramidites are used as starting materials and may be synthesized as described by Beaucage, et al. (Tetrahedron Letters, 22:1-1862, 1981). Another method for synthesizing oligonucleotides on a modified solid support is described in U.S. Pat. No. 4,458,066. DNA solid support synthesis is a routine matter for one of skill in the biochemical arts, and several commercial services currently exist which will synthesize DNA sequences of up to 500 bp in length, and which may include fluorescent, biotin, or hapten labeled nucleotides (e.g., Genset of La Jolla, CA). Thus, once designed, labeled or unlabeled short DNA probes may simply be purchased from a vendor.

Shorter (under 500 bp) nucleic acid polymer probes specific for the lipid associated genes may be designed according to general principles familiar to those of ordinary skill in the biochemical arts. Usually, it is preferable to use a probe containing at least 19 contiguous base pairs which are identical or complementary to 19 contiguous base pairs of the naturally occurring sequence in the lipid-associated gene. Thus, any portion of the sequences SEQ ID NO. 1-31 larger than 19 base pairs would be suitable for use as a lipid-associated gene probe in the present invention. This number of bases allows for hybridization under relatively stringent conditions, and also contains enough sequence information to ensure that the sequence is usually unique to that particular lipid-associated gene. Of course, one of ordinary skill in the art would understand that

common enhancer sequences, polyadenylation sequences, and other sequences which tend to be repeated amongst several mammalian genes should not be used as probe sequences for the lipid-associated genes.

In order to ensure that the probe will hybridize to the lipid-associated gene DNA in the sample if some allelic variation or mutation difference exists between the probe sequence and the sample DNA sequence, it is more preferable that the probe sequence include at least 1-5 additional nucleotides which are identical or complementary to the nucleotide sequence of one of the lipid associated genes, or 20-24 contiguous nucleotides which are identical or complementary to the nucleotide sequence of one of the lipid associated genes. This will account for a small amount of mismatching during hybridization. Due to the prominent role of point mutations in oncogenesis, accounting for such slight variations is preferred in order to correctly assess the copy number or expression level of the lipid-associated genes to be assayed.

The maximum length of the probes to be used will be ascertainable by one of ordinary skill in the art based upon such considerations as the propensity for the formation of secondary structures in the probe DNA, the likelihood of interactions between probe strands in an immobilized matrix embodiment, and the difficulties in reproducing DNA of certain lengths through methods such as the polymerase chain reaction. Although full length gene sequences, including all introns, exons, regulatory sequences, and intervening DNA, may be used as lipid-associated gene probes, such sequences are often several dozen kilobases in length. Sequences of this length have a propensity to form secondary structures and are difficult to replicate by polymerase chain reaction techniques (which is often a necessary step in the production of longer sequence

probes). Thus, probe sequences shorter than the full length gene are preferred as lipid-associated gene probes. Suitable longer probes would include whole exons, or multiple exons as found in a cDNA sequence. One of ordinary skill in the art would be able to choose a suitable long portion of any of SEQ ID NO. 1-31 for use as a long lipid-associated gene probe. Such probes are produced in Example 1.

In order to produce a DNA probe sequence longer than 500 bp, it is preferable to amplify and clone the sequence from a cDNA or genomic library according to methods familiar to those of ordinary skill in the molecular biology arts. Briefly, one synthesizes short (~20-25 nucleotide) forward and reverse polynucleotide primers which flank the portion of the lipid-associated gene's sequence to be cloned. Then, one amplifies the sequence from a cDNA library or genomic DNA utilizing the polymerase chain reaction technique, as described below for amplification of sample nucleic acids. Once a sufficient amount of amplified DNA sequence has been produced, it may be ligated into a suitable plasmid vector, and replicated/maintained in a bacterial host. The DNA sequence may then be cut out of the plasmid with suitable restriction enzymes and either labeled or immobilized for use as a lipid-associated gene probe.

Probes which are to be immobilized in an array are not labeled for detection. Rather, they are covalently linked to a predetermined position in the array, and thus identifiable by location. In these embodiments, the sample DNA to be hybridized with the array is usually labeled utilizing labeled primers during PCR amplification, or by other techniques known in the art. If the probe is to be hybridized to immobilized sample DNA (as in, for example, dot-blot hybridization, the reporter probe in a sandwich

hybridization, or in-situ hybridization), then the probe itself is labeled for detection.

Labeling

The particular label or detectable group attached to the probe or primer nucleic acids is not a critical aspect of the invention, so long as it does not significantly interfere with the hybridization of the probe to the lipid-associated gene sequence in the sample DNA. The detectable group can be any material having a detectable physical or chemical property. Such detectable labels have been well-developed in the field of nucleic acid hybridizations and in general most any label useful in such methods can be applied to the present invention. Thus a label is any composition detectable by spectroscopic, photochemical, biochemical, immunochemical, electrical, optical or chemical means. Useful labels in the present invention include fluorescent dyes (e.g., fluorescein isothiocyanate, texas red, rhodamine, and the like) radiolabels (e.g., ^3H , ^{125}I , ^{35}S , ^{14}C , or ^{32}P), and enzymes (e.g., horse radish peroxidase, alkaline phosphatase and others commonly used in an ELISA).

The nucleic acids can be indirectly labeled using ligands for which detectable anti-ligands are available. For example, biotinylated nucleic acids can be detected using labeled avidin or streptavidin according to techniques well known in the art. In addition, antigenic or haptenic molecules can be detected using labeled antisera or monoclonal antibodies. For example, N-acetoxy-N-2-acetylaminofluorene-labelled or digoxigenin-labelled probes can be detected using antibodies specifically immunoreactive with these compounds (e.g., FITC-labeled sheep anti-digoxigenin antibody (Boehringer

Mannheim)). In addition, labeled antibodies to thymidine-thymidine dimers can be used (Nakane et al. ACTA Histochem. Cytochem. 20:229 (1987)).

Generally, labels which are detectable in as low a copy number as possible, thereby maximizing the sensitivity of the assay are preferred. A label is preferably chosen that provides a localized signal, thereby providing spatial resolution of the signal from each probe. The labels may be coupled to the DNA in a variety of means known to those of skill in the art. In a preferred embodiment the probe or sample DNA will be labeled using nick translation or random primer extension (Rigby, et al. J. Mol. Biol., 113:237 (1977) or Sambrook, et al., Molecular Cloning--A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. (1985)).

CONSTRUCTION OF IMMOBILIZED NUCLEIC ACID POLYMER PROBE ARRAYS

In preferred embodiments of the invention, nucleic acid polymer probes specific for the chosen lipid-associated genes are immobilized on a solid surface in order to create an array of lipid-associated-gene probes. As discussed above, the solid surface may be in any desirable shape which facilitates the hybridization reaction and the detection of hybridized sample nucleic acids. The solid support may be in any convenient form for quantifying the amount of hybridization, including beads, resins, microtiter wells, flat surfaces, rods, and the like. Illustrative solid materials for use in the support include nitrocellulose, nylon, glass, diazotized membranes (paper or nylon), silicones, polyformaldehyde, cellulose, and cellulose acetate. In addition, plastics such as polyethylene, polypropylene, polystyrene, and the like can be used. Other materials

which may be employed include paper, ceramics, metals, metalloids, semiconductive materials, cements or the like. In addition substances that form gels can be used. Such materials include proteins (e.g., gelatins), lipopolysaccharides, silicates, agarose and polyacrylamides. Where the solid surface is porous, various pore sizes may be employed depending upon the nature of the system. For use in the arrays of the present invention, flat coated or uncoated silicate surfaces are preferred. Immobilization formats adapted to these surfaces have been developed which can be easily loaded with the lipid associated gene sequences described in the invention, and which can be easily read with automated equipment.

In preparing the solid support for binding the nucleic acid polymer probes to it, several different materials may be employed, particularly as laminates, to obtain various properties. For example, proteins (e.g., bovine serum albumin) or mixtures of macromolecules (e.g., Denhardt's solution) can be employed to avoid non-specific binding, simplify covalent conjugation, enhance signal detection or the like. If covalent bonding between the probe and support is desired, the surface will usually be polyfunctional or be capable of being polyfunctionalized. Functional groups which may be present on the surface and used for linking can include carboxylic acids, aldehydes, amino groups, cyano groups, ethylenic groups, hydroxyl groups, mercapto groups and the like. The manner of linking a wide variety of compounds to various supports is well known and is amply illustrated in the literature. For example, methods for immobilizing nucleic acids by introduction of various functional groups to the molecules is known (see, e.g., Bischoff et al., *Anal. Biochem.* 164:336-344 (1987); Kremsky et al., *Nuc. Acids Res.* 15:2891-2910 (1987)). In order to introduce these functional groups, modified

nucleotides (such as biotin, halogen, or azo-derivatized nucleotides) can be placed on the nucleic acid probe using PCR primers containing the modified nucleotide, or by enzymatic end labeling with modified nucleotides.

Use of membrane supports (e.g., nitrocellulose, nylon, polypropylene) for the nucleic acid arrays of the invention is advantageous because of well developed technology employing manual and robotic methods of arraying nucleic acid probes at relatively high element densities (e.g., up to 30-40/cm²) while maintaining each probe population as a distinct element. In addition, such membranes are generally available and protocols and equipment for hybridization to membranes is well known. Many membrane materials, however, have considerable fluorescence emission, where fluorescent labels are used to detect hybridization. To optimize a given assay format one of skill can determine sensitivity of fluorescence detection for different combinations of membrane type, fluorochrome, excitation and emission bands, spot size and the like. In addition, low fluorescence background membranes have been described (see, e.g., Chu et al., *Electrophoresis* 13:105-114 (1992)).

Arrays on substrates with much lower fluorescence than membranes, such as glass, quartz, or silicon, can achieve much better sensitivity. For example, elements of various sizes, ranging from the ~1 mm diameter down to ~1 μm can be used with these materials. Small array members containing small amounts of concentrated target DNA are conveniently used for the methods of the invention since the total amount of sample DNA available for binding to each probe will be limited. Thus it is advantageous to have small array members that contain a small amount of concentrated probe DNA so that the signal that is obtained is highly localized and bright. Such small array members are

typically used in arrays with densities greater than 10^4 /cm². Relatively simple approaches capable of quantitative fluorescent imaging of 1 cm² areas have been described that permit acquisition of data from a large number of members in a single image (see, e.g., Wittrup et. al. Cytometry 16:206-213 (1994)).

Covalent attachment of the target nucleic acids to glass or synthetic fused silica can be accomplished according to a number of known techniques. Such substrates provide a very low fluorescence substrate, and a highly efficient hybridization environment. There are many possible approaches to coupling nucleic acids to glass that employ commercially available reagents. For instance, materials for preparation of silanized glass with a number of functional groups are commercially available or can be prepared using standard techniques. Alternatively, quartz cover slips, which have at least 10-fold lower auto fluorescence than glass, can be silanized. Recently, several refined techniques have been developed to array nucleic acid polymers on silicon or coated silicon surfaces, such as those disclosed in U.S. Patent Nos. 5,143,854 and 6,017,696. These methods, which utilize photomasking or electrostatic techniques to couple nucleic acid polymers at specific sites on the support, are able to achieve high concentrations of each nucleic acid polymer probe at specific locations on the silicon support. These techniques are preferred for creating the arrays of the present invention, as the resulting arrays can be readily utilized in automated hybridization and fluorescence detection equipment.

The nucleic acid probes can also be immobilized on commercially available coated beads or other supports. For instance, biotin end-labeled nucleic acids can be bound to commercially available avidin-coated beads or a layer of avidin-permeated

hydrogel. Streptavidin or anti-digoxigenin antibody can also be attached to silanized glass slides by protein-mediated coupling using e.g., protein A following standard protocols (see, e.g., Smith et al. Science, 258:1122-1126 (1992)). Biotin or digoxigenin end-labeled nucleic acids can be prepared according to standard techniques.

Any of these techniques can be utilized by the person of ordinary skill in the art to create an array of probes specific for lipid-associated genes for use in the present invention. An illustrative array, utilizing probes generated from the cDNA sequences of several lipid-associated genes, is constructed on a silanized glass slide in Example 1.

TISSUE SAMPLE PREPARATION AND NUCLEIC ACID ISOLATION

In order to carry out the method of identifying tumor characteristics of the present invention, it is necessary to obtain a tissue sample from the patient. Several standard techniques for biopsy of tissue samples are well known in the prior art. Preferably, the tissue samples are obtained by endoscopic biopsy, or by a biopsy needle gun. When obtaining a tissue sample from a solid tumor in the patient, care should be taken not to allow portions of the tumor to escape from the tumor body into the other tissues of the patient.

The tissue which is isolated can be used directly, frozen, or it can be embedded in, for example, paraffin and stored for future use. Preferably, the tissue is frozen and stored at temperatures of -20° to about -80° C. The term "embedded" refers to a sample that has been infiltrated with a material to provide mechanical support and thereby reduce sample deformation during processes such as sectioning (preparing thin slices for viewing using a microscope). Embedding materials include waxes, such as paraffin wax, epoxies,

gelatin, methacrylate, nitrocellulose, various polymers and the like. The term "non-embedded" refers to a sample that is not embedded, and was not previously embedded. When a tissue sample is embedded in, for example, paraffin, for future use, it will preferably be in sections of about 6 micron thickness. Upon removal from storage, the paraffin-embedded tissue sections will be deparaffinized using a relatively non-polar aprotic organic solvent such as xylene, and then rehydrated using graded alcohols followed by phosphate-buffered saline (PBS). Other suitable solvents for removing the embedding support include aliphatic or aromatic hydrocarbon solvents such as toluene, heptanes, octanes, benzene, acetone and acetonitrile. If a technique such as in situ fluorescent hybridization is used to determine the copy number of the lipid-associated genes, then the preparation of the embedded tissue sample should be carried out according to methods known in the art which maintain the fixed position of the sample nucleic acids in the cell.

If the tissue sample is to be analyzed by an array hybridization technique, or another technique which requires purified isolated nucleic acids, the cells of the tissue sample may be treated to liberate and isolate their nucleic acid polymers. For lysing, chemical lysing will conveniently be employed utilizing detergents or cell membrane degrading enzymes. Several methods of isolating nucleic acids from lysed cells are well known in the art, such phenol extraction followed by ethanol or polyethylene glycol precipitation, or the ketone method disclosed in U.S. Patent No. 5,063,162. Several kits are commercially available to perform genomic DNA or RNA extractions on tissue samples.

Often, the hybridization data obtained from the sample nucleic acid polymers will be compared to that of reference nucleic acid polymers obtained from normal tissues of the same type as the tissue sample. In order to facilitate accurate comparison, the normal tissue sample should be obtained in a similar method as the tissue sample to be tested, and the reference nucleic acids should be isolated from the normal tissue sample in the same manner as the nucleic acids from the patient's sample are isolated. Practitioners of ordinary skill in the art are capable of devising such "controls" for a quantitative comparison based on the specific nucleic acid isolation and hybridization methods which are to be used in any particular embodiment of the method of the invention.

Amplification of Sample Nucleic Acid Polymers

In practicing the methods of the present invention, it is often preferable to amplify the sample nucleic acid polymer sequence before hybridization in order to increase the hybridization signal. The tissue samples obtained from biopsy are often very small in size, and contain a limited amount of sample nucleic acids for detection. In addition to increasing the amount of DNA or RNA available to produce a hybridization signal, amplification reactions may be used to label the sample nucleic acids by utilizing radiolabeled, biotinylated, or fluorescent-moiety substituted nucleic acids or primers. Amplification of the sample nucleic acid polymers can be accomplished using oligonucleotide primers for amplification specifically designed for the lipid-associated gene to be assayed.

These unique oligonucleotide primers are based upon identification of the flanking regions contiguous with the nucleotide sequence of the lipid-associated genes

chosen for copy number or expression level determination. In this manner, it is possible to selectively amplify the specific target nucleic acid sequence containing the nucleic acid of interest. For example, the flanking sequence of the primer may be before the gene in a normal genome, a complementary sequence (opposite strand) after the gene in the normal genome, or within the gene itself. The only requirement of the primer is that it hybridize at a position that will ensure that the portion of the gene for which the nucleic acid probe has been designed will be amplified. As most amplification reactions do not produce nucleic acid products of more than a few hundred base pairs, it is preferred that the primer hybridize about 10 - 100 bases before the probe hybridization site. One of ordinary skill in the art would be capable of designing an appropriate primer for the amplification of any lipid-associated gene monitored, given the information supplied in SEQ ID NO. 1 - 31, and other available genetic information concerning lipid-associated genes.

Experimental conditions conducive to synthesis include the presence of nucleoside triphosphates and an agent for polymerization, such as DNA polymerase, and a suitable temperature and pH. Preferably the reaction mixture will contain labeled nucleotides which can be used to detect the amplified sample nucleic acid polymers when bound to nucleic acid probes in an array. Any of the nucleotide derivatives described in the probe construction section above are suitable for use in the amplification reaction. The use of fluorescent derivatives of nucleic acids to label the sample nucleic acid polymers is particularly preferred in the embodiments of the method of the invention. The primer is preferably single stranded for maximum efficiency in amplification, but may be double stranded. If double stranded, the primer is first treated to separate its strands

before being used to prepare extension products. Preferably, the primer is an oligodeoxyribonucleotide. The primer must be sufficiently long to prime the synthesis of extension products in the presence of the inducing agent for polymerization. The exact length of primer will depend on many factors, including temperature, buffer, and nucleotide composition.

Typically, the amplification process is started by annealing two primers to the sample nucleic acid polymers: one primer is complementary to the negative (-) strand of the nucleotide sequence and the other is complementary to the positive (+) strand. Annealing the primers to denatured nucleic acid followed by extension with an enzyme, such as the large fragment of DNA Polymerase I (Klenow) or Taq DNA polymerase (or an RNA reverse-transcriptase, if the mRNA of a sample is to be amplified) and nucleotides or ligases, results in newly synthesized + and - strands containing the target nucleic acid. Because these newly synthesized nucleic acids are also templates, repeated cycles of denaturing, primer annealing, and extension results in exponential production of the region (i.e., the target mutant nucleotide sequence) defined by the primer. The product of the amplification reaction is a discrete nucleic acid duplex with termini corresponding to the ends of the specific primers employed. Those of skill in the art will know of other amplification methodologies which can also be utilized to increase the amount of the sample nucleic acid polymers and label them for later detection. One method of amplification which can be used according to this invention is the polymerase chain reaction (PCR) described in U.S. Pat. Nos. 4,683,202 and 4,683,195.

HYBRIDIZATION TECHNIQUES .

The particular hybridization technique used will depend on the particular embodiment of the method of the invention. For instance, if the copy number of the lipid-associated genes is to be determined using in-situ gene counting techniques, then hybridization of labeled probes with fixed sample tissues on a slide would be performed according to techniques known in the art. Preferably, the copy number or expression level of the lipid-associated gene sequences in the sample nucleic acids is determined by hybridizing the labeled sample nucleic acids to an array of lipid-associated gene specific probes. The hybridization signal intensity produced by the labeled sample nucleic acids on each lipid-associated gene probe site is determined. Typically, the greater the signal intensity at a particular lipid-associated gene probe site, the greater the copy number or expression level of the lipid-associated gene sequence in the sample nucleic acid. Thus, a determination of the signal intensity at each probe site, as compared to a normal tissue standard, allows a determination of the copy number or expression level of the lipid-associated gene.

Standard hybridization techniques are used to probe the lipid-associated gene probe array. Suitable methods are described in references describing CGH techniques (Kallioniemi et al., Science 258:818-821 (1992) and WO 93/18186). Several guides to general techniques are available, e.g., Tijssen, Hybridization with Nucleic Acid Probes, Parts I and II (Elsevier, Amsterdam 1993). For a descriptions of techniques suitable for in situ hybridizations see, Gall et al. Meth. Enzymol., 21:470-480 (1981) and Angerer et al. in Genetic Engineering: Principles and Methods Setlow and Hollaender, Eds. Vol 7, pgs 43-65 (plenum Press, New York 1985). In addition, several refinements of hybridization techniques relevant to microarray hybridization analysis are discussed in Khan, et al.,

“Expression Profiling in Cancer Using cDNA Microarrays,” Electrophoresis, 20:223-229 (1999); and Cheung, et al., “Making and Reading Microarrays,” Nature Genetics Supp., 21: 15-19 (1999).

Generally, nucleic acid hybridizations comprise the following major steps: (1) immobilization of the probe nucleic acids; (2) prehybridization treatment to increase accessibility of the immobilized DNA, and to reduce nonspecific binding; (3) hybridization of the sample nucleic acids to the probe nucleic acid on the solid support; (4) posthybridization washes to remove sample nucleic acid fragments not bound in the hybridization and (5) detection of the hybridized sample nucleic acid fragments. The reagents used in each of these steps and their conditions for use vary depending on the particular embodiment of the method of the present invention.

Pre-hybridization may be accomplished by incubating the microarray with the hybridization solution at room temperature or at a mildly elevated temperature for a sufficient time to thoroughly wet the array. Usually, incubation at about 35° to 42° C for about 15 minutes to an hour is sufficient to pre-hybridize a microarray on a glass slide.

Various hybridization solutions may be employed, comprising from about 20% to 60% volume, preferably 30%, of an inert polar organic solvent. A common hybridization solution employs about 50% formamide, about 0.5 to 1M sodium chloride, about 0.05 to 0.1M sodium citrate, about 0.05 to 0.2% sodium dodecylsulfate, and minor amounts of Denhardt's solution (EDTA, ficoll (about 300-500 kD), polyvinylpyrrolidone, (about 250-500 kD) and serum albumin.) Optionally, one may include other blocking agents in the hybridization solution, such as about 0.5 to 5 mg/ml of sonicated denatured DNA, e.g., calf thymus or salmon sperm; and optionally from about 0.5 to 2% wt/vol glycine.

Other additives may also be included, such as dextran sulfate of from about 100 to 1,000 kD and in an amount of from about 8 to 15 weight percent of the hybridization solution, or a similarly sized polyethylene glycol.

Various degrees of stringency of hybridization may be employed in the methods of the invention. The more severe the conditions, the greater the complementarity that is required for hybridization between the sample nucleic acids and the lipid-associated gene specific probe for duplex formation. Severity can be controlled by temperature, probe concentration, probe length, ionic strength, time, and the like. Conveniently, the stringency of hybridization is varied by changing the polarity of the reactant solution by manipulating the concentration of formamide in the range of 20% to 50%. Temperatures employed will normally be in the range of about 20.degree. C. to 80.degree. C., usually 30.degree. C. to 75.degree. C. (see, generally, Current Protocols in Molecular Biology, Ausubel, ed., Wiley & Sons, 1989).

After the array has been contacted with a hybridization solution at a moderate temperature for a period of time sufficient to allow hybridization to occur (usually 8-24 hours), the filter is then introduced into a second solution having similar concentrations of sodium chloride, sodium citrate and sodium dodecylsulfate as provided in the hybridization solution. The time the filter is maintained in the second solution may vary from five minutes to three hours or more. The second solution determines the stringency, dissolving cross duplexes and short complementary sequences. After rinsing the filter at room temperature with dilute sodium citrate-sodium chloride solution, the filter may now be assayed for the presence of hybridized sample nucleic acids according to the nature of the label.

ANALYSIS OF DETECTABLE SIGNALS FROM HYBRIDIZATION OF THE SAMPLE NUCLEIC ACIDS WITH THE LIPID-ASSOCIATED GENE PROBES

Standard methods for detection and analysis of signals generated by the hybridization of the sample nucleic acids to the lipid-associated gene specific probes can be used. The particular methods will depend upon the labels used, and the particular embodiment of the method. Generally, fluorescent labels are preferred. Thus, methods suitable in fluorescence in situ hybridization (FISH) are suitable in the present invention. The nucleic acid arrays are imaged in a fluorescence microscope with a polychromatic beam-splitter to avoid color-dependent image shifts. The different color images are acquired with a CCD camera and the digitized images are stored in a computer.

If the preferred microarray embodiments are utilized, such fluorescence data is conveniently gathered with an automated array scanner, such as the Affymetrix 418 Array scanner with epi-fluorescent confocal optics. A computer program is then used to analyze the signals produced by the array in order to determine the hybridization intensity at each lipid-associated gene probe site in the array. This data may then be compared with a standard curve generated from various amounts of DNA or mRNA obtained from normal tissue. This analysis technique is illustrated in Example 2.

The present invention is further described in the following examples. These examples do not, in any way, limit the present invention.

EXAMPLES

The following examples illustrate the preparation of the arrays of lipid-associated genes of the invention for use in the methods of the invention for determining tumor characteristics. The molecular biological techniques utilized in these examples are well-known to those of ordinary skill in the biochemical arts, and could be modified in myriad ways to accomplish the same ends. Thus, the techniques and processes described below serve merely to illustrate an embodiment of the present invention, and should not be interpreted to limit the invention to any particular embodiment. Unless otherwise noted, all kits, reagents, and equipment were used in accordance with the protocols supplied by the producer. More detailed protocols for the techniques described in brief below may be found in a standard molecular biology reference text, such as Maniatis.

Example 1: Preparation of a Lipid-Associated Gene Probe Array

In this example, the preparation of a hybridization microarray of 31 probes for lipid-associated genes on a standard glass slide is prepared for use in the methods of the invention.

1.1 Preparation of DNA probes for use in the Microarray

For each probe to be used in the array, an appropriate pair of unlabeled forward and reverse PCR primers (listed in Table 4), synthesized utilizing solid-support methods, is ordered from Genset (La Jolla, CA). Using these primers, DNA for each probe is amplified by PCR from a human genomic library (available from Invitrogen, Carlsbad, CA, Stratagene, La Jolla, CA, or Promega, Madison, WI) with *Taq* polymerase (obtained

from Promega, Madison, WI) according to supplier's instructions. PCR is carried out in an Eppendorf Scientific Instruments Mastercycler™ thermal cycler for the recommended number of cycles. After PCR, the amplified DNA (which contains single adenine overhangs) is self-ligated into the AccepTor™ plasmid (Novagen, Madison, WI) and transformed into NovaBlue *E. coli* competent cells (Novagen).

Transformed cells are plated onto LB blue/white selection media and grown overnight. White colonies (which contain the amplified DNA insert) are picked, and grown overnight for freezer stocks. After verification of the DNA insert, a 1 liter culture of a clone containing the insert is prepared for each probe, and plasmid DNA is purified from the culture using a Wizard® Plus Megaprep DNA Purification System (Promega). The plasmid DNA is then digested with *EcoR* I (Promega), and the insert-probe DNA separated from the AccepTor™ plasmid DNA by agarose gel electrophoresis. Probe size in the agarose gel is double checked against DNA size standards to ensure that no cleavage with the restriction enzyme occurs. The probe DNA is then purified from the agarose gel slices and resuspended in 2 X SSC (Saline Sodium Citrate) buffer at a concentration of about 1 µg/µl for aminosilane linkage to the glass slide substrate of the array.

1.2 Production of the Microarray

The probes are affixed to a glass slide using the aminosilane linkage chemistry described in Cheung, et al., "Making and Reading Microarrays," Nature Genetics Supp., 21:15-19 (1999). The 31 probes are arrayed in a 6 by 5 plus 1 pattern on a CMT-GAPS™ aminosilane coated slide (Corning, Acton, MA). The assymetrical 6 by 5 plus 1

The arrayed probes are allowed to air-dry on the slide at room temperature. The slides are then briefly moistened in hot water vapor before crosslinking the DNA to the silane surface with about 0.30 J/cm^2 of ultraviolet (254 nm) radiation. After crosslinking, the slides are briefly washed in 0.1% SDS to remove unbound DNA. The probes are then denatured in 95°C water for approximately three minutes.

The resulting microarray of lipid-associated gene probes is then ready for use in sample testing.

In this example, the copy number of several lipid-associated genes is determined simultaneously by hybridization to the probe produced in Example 1.

Genomic DNA is extracted from approximately 300 mg of sample tissue using a Wizard® Genomic DNA Purification Kit (Promega). After purification, the concentration of sample DNA is determined using spectrophotometric techniques. 40 µg of sample is

then amplified by PCR with a mixture of fluorescein labeled primers for all lipid-associated genes monitored by the array (all of those listed in Table 4, obtained from Genset) using *Taq* polymerase (obtained from Promega) according to supplier's instructions. PCR is carried out in an Eppendorf Scientific Instruments Mastercycler™ thermal cycler for the recommended number of cycles. After PCR, the amplified sample DNA is separated from the labeled primers with a Wizard™ PCR Preps DNA Purification System (Promega). Purified sample DNA is then resuspended in 15 µl of hybridization solution (50% formamide, 6 X SSC, 0.5% SDS, 5 X Denhardt's reagent).

2.2 Hybridization of Sample DNA to the Array

The microarray is pre-hybridized with hybridization solution for about 30 minutes. The sample DNAs are denatured for about 4 minutes at 80° C in a hybridization oven. The amplified sample DNA in the hybridization solution is then applied to the microarray in a Corning CMT™ Hybridization Chamber, and then allowed to anneal at 42° C for about 20 hours. After hybridization has been completed, the array slide is washed for five minutes in 0.1% SDS / 0.2 X SSC, and then for about five minutes with 0.2 X SSC. The array is then loaded into an Affymetrix 418 Scanner (Affymetrix), and fluorescence of the hybridized sample DNA on the microarray is detected.

2.3 Data Analysis and Determination of Lipid Associated Gene Copy Number

A standard curve is generated for each probe site in the array utilizing the above procedure with 20µg (haploid), 40µg (normal), 80µg (tetraploid), 160µg (octaploid), and 320µg (hexadecaploid) of genomic DNA purified from normal tissue. By comparison of

detected fluorescent intensity from the hybridization of the sample DNA at each probe site with the standard curve for that probe site, the relative copy number of the lipid-associated genes in the cells of the tissue sample is calculated.

Example 3: Demonstration of the Correlation Between Lipid-Associated Gene Copy
Number and Tumor Characteristics

The correlation between lipid-associated gene copy number and certain tumor characteristics is demonstrated by determining the copy number of lipid-associated genes according to the method described in Example 2, utilizing a lipid-associated gene probe array produced as described in Example 1.

Tumor tissue samples from stage 1, 2, 3, and 4 tumors have been assayed, as well as those characterized as “serous,” “mucinous,” “endometroid,” “low stage,” and “high stage.” Tumors from various types of cancers, including ovarian, breast, cervical, and uterine are analyzed, normal tissues of each type provide a control and a standard curve. This analysis demonstrates that specific tumor stages and characteristics correlate to increases or decreases in the copy number of certain lipid-associated genes.

TABLE 2
Enzymes Involved with Lipid Metabolism
Chromosome Location With Associated Ovarian Tumor Stage and Clinical Outcome

Enzyme	% loss	% gain	Associated Tumor Stage	Associated Clinical Outcome
Phosphatidylinositol-3-Kinase, catalytic, alpha polypeptide	0	50	Low and High Stage	Reduced Survival Duration
Phospholipase D1 phosphatidylcholine specific	0	40	Low and High Stage	Reduced Survival Duration
Sphingosine kinase	-5	20	Low and High Stage	
Aldehyde dehydrogenase 5 family, member A1	-5	15	Borderline tumors	
Phospholipase D1 glycosylphosphatidylinositol specific	-5	15	Borderline tumors	
1-acylglycerol-3-phosphate acyltransferase	-5	15	Borderline tumors	
Sphingosine-1-phosphate lyase 1	0	5	Low Stage - Endometroid	
Phosphatase and tenson homolog (PTEN)	-2.5	5	Low Stage - Endometroid	
Phosphatidic Acid Phosphate type 2a	-2.5	2.5	Borderline tumors	
Sphingomyelin phosphodiesterase 1 (acid sphingomyelinase)	-5	0	High Stage - nonmucinous	Reduced Survival Duration

TABLE 3
Enzymes Involved with Lipid Metabolism
Chromosomal Locations and Associated Genome Copy Number
Changes in Ovarian Tumors

Enzyme	% loss	% gain
Phosphatidylinositol-3-Kinase, catalytic, alpha polypeptide	0	50
Phosphate cytidylyltransferase 1, choline, alpha isoform	0	50
Phospholipase D1 phosphatidylcholine specific	0	40
dihydroxyacetone phosphate acyltransferase	0	22.5
Phosphate cytidylyltransferase 2, ethanolamine	-2.5	20
Sphingosine kinase	-5	20
Phosphatidic Acid Phosphate type 2c	0	20
Prostate differentiation factor PLAB (associated with Edg 3)	0	20
Phospholipase A2	-2.5	17.5
Phospholipase C, beta 3 (phosphatidylinositol specific)	-5	17.5
Phosphatidylinositol-3-Kinase, class 2, gamma polypeptide	0	17.5
Choline/ethanolamine phosphotransferase	-2.5	15
Lysophospholipase	0	15
Aldehyde dehydrogenase 5 family, member A1	-5	15
Phospholipase D1 glycosylphosphatidylinositol specific	-5	15
1-acylglycerol-3-phosphate acyltransferase	-5	15
Phosphatidic Acid Phosphate type 2b	-2.5	7.5
EDG 1	-2.5	7.5
Glycerol-3-phosphate dehydrogenase	0	5
Sphingosine-1-phosphate lyase 1	0	5
Phosphatase and tenson homolog (PTEN)	-2.5	5
Phosphatidic Acid Phosphate type 2a	-2.5	2.5
Sphingomyelin phosphodiesterase 1 (acid sphingomyelinase)	-5	0
N-acylsphingosine amidohydrolase (acid ceramidase)	-15	2.5
EDG 2	-17.5	0

TABLE 4
Lipid-Associate Gene Array Primers and Libraries

Gene	Forward Primer	
Phosphatidylinositol-3-Kinase, catalytic, alpha polypeptide	1213 cgactttgcctttccatttgctc 1235 (SEQ ID NO. 32)	2200 ccttttg (SEQ ID NO. 33)
Phosphocholine cytidyltransferase	792 aaaggagaaagtgaagatgtggagg 817 (SEQ ID NO. 34)	1186 ggaca (SEQ ID NO. 35)
Phospholipase D1 phosphatidylcholine specific	1899 cccacttcaaactctttcacc 1921 (SEQ ID NO. 36)	2878 gccatt (SEQ ID NO. 37)
dihydroxyacetone phosphate acyltransferase	900 gctctgccaaagacattgactcc 921 (SEQ ID NO. 38)	2347 atcatc (SEQ ID NO. 39)
Phosphate cytidyltransferase 2, ethanolamine specific	347 cctacgtcactacactagagacc 370 (SEQ ID NO. 40)	600 gccaaa (SEQ ID NO. 41)
Phosphatidic Acid Phosphatase type 2c	458 aactgctcggctctatgtgcagc 479 (SEQ ID NO. 42)	581 ccaaga (SEQ ID NO. 43)
Prostate differentiation factor PLAB (associated with Edg 3)	881 gctcattcaaaagaccgacaccg 903 (SEQ ID NO. 44)	1154 acaca (SEQ ID NO. 45)
Phospholipase A2	474 cgtctactgcctcaagagaaacc 496 (SEQ ID NO. 46)	740 gtctctat (SEQ ID NO. 47)
Phospholipase C, beta 3 (phosphatidylinositol specific)	1137 aggaagaggaggaacagacagac 1159 (SEQ ID NO. 48)	1276 agcag (SEQ ID NO. 49)
Phosphatidylinositol-3-Kinase, class 2, gamma polypeptide	1713 aacctgtcgtgatagaccacc 1734 (SEQ ID NO. 50)	3101 tctctc (SEQ ID NO. 51)
Choline/ethanolamine phosphotransferase	56 gtaagcaccagccacaaaaacc 77 (SEQ ID NO. 52)	358 ctaacga (SEQ ID NO. 53)
Lysophospholipase 1	119 tggattgggagatactgggcac 140 (SEQ ID NO. 54)	580 ccaaac (SEQ ID NO. 55)
Aldehyde dehydrogenase 5 family, member A1	930 cctgttcttcaacatgggcccag 951 (SEQ ID NO. 56)	1308 cctctc (SEQ ID NO. 57)
Phospholipase D1 glycosylphosphatidylinositol specific	1524 tcttcttcccctaacatcaccatctc 1549 (SEQ ID NO. 58)	2361 tgcatt (SEQ ID NO. 59)
1-acylglycerol-3-phosphate 0-acyltransferase	1043 aaacctcttctctgtctccctc 1066 (SEQ ID NO. 60)	1726 atgtct (SEQ ID NO. 61)
Phosphatidic Acid Phosphatase type 2b	358 tcaacaacaacccgaggaggag 379 (SEQ ID NO. 62)	710 gatggc (SEQ ID NO. 63)
EDG 1	720 acttcgcctcttctgctaate 742 (SEQ ID NO. 64)	2009 cctcca (SEQ ID NO. 65)
EDG 2	153 atttcacagccccagttcacagcc 176 (SEQ ID NO. 66)	633 tgaccac (SEQ ID NO. 67)
EDG 3	59 agcattaccagtacgtggggaag 81 (SEQ ID NO. 68)	356 aacatac (SEQ ID NO. 69)
EDG 4	797 taggctgtgagtcctgcaatgtcc 820 (SEQ ID NO. 70)	902 tcagcat (SEQ ID NO. 71)

EDG 5	28 aaccccaacaaggtccaggaacac 51 (SEQ ID NO. 72)	151 ttccacc (SEQ ID NO. 73)
EDG 6	1177 aagttgcagttctgcgtgtg 1196 (SEQ ID NO. 74)	1382 ggtgg (SEQ ID NO. 75)
EDG 7	378 cttgactgcttcctcaccac 399 (SEQ ID NO. 76)	869 cttttcac (SEQ ID NO. 77)
Sphingosine-1-phosphate lyase 1	797 aggtggatgtgagggcaatgagaag 821 (SEQ ID NO. 78)	1478 cgggc (SEQ ID NO. 79)
Phosphatase and tenson homolog (PTEN)	388 gcctcctcttcgtcttttctaacc 411 (SEQ ID NO. 80)	1631 catcat (SEQ ID NO. 81)
Phosphatidic Acid Phosphatase type 2a	186 tcaaggcataccccctccaac 207 (SEQ ID NO. 82)	796 agtccag (SEQ ID NO. 83)
Sphingomyelin phosphodiesterase 1 (acid sphingomyelinase)	716 tctatgctctttcccatatcccc 738 (SEQ ID NO. 84)	1296 gcgat (SEQ ID NO. 85)
N-acylsphingosine amidohydrolase (acid ceramidase)	279 gtgccaaagtggaaaagtatgcag 302 (SEQ ID NO. 86)	1355 tgtcaa (SEQ ID NO. 87)
Glycerol-3-phosphate dehydrogenase	836 ccccatattatcagctccattgcc 858 (SEQ ID NO. 88)	1562 catccc (SEQ ID NO. 89)
Diacylglycerol kinase, gamma	1360 ccaacctactgcaacttctgcc 1381 (SEQ ID NO. 90)	2446 caacc (SEQ ID NO. 91)
Dihydroxyacetone phosphate acyltransferase	900 gctctgccaaagacattgactcc 921 (SEQ ID NO. 92)	2347 atcatc (SEQ ID NO. 93)
Human Lysophospholipase Homolog	936 gttagccaagagccaggacaag 957 (SEQ ID NO. 94)	1173 gcaag (SEQ ID NO. 95)

WE CLAIM:

1. A method for identifying tumor characteristics comprising:

measuring a copy number of at least two genes associated with lipid metabolism, synthesis, or action in cells of a patient tissue sample and comparing the results with a copy number in a normal cell.

2. The method of claim 1, wherein at least two of the genes associated with lipid metabolism, synthesis, or action are selected from the group consisting of:

Phosphatidylinositol-3-kinase (catalytic, alpha polypeptide), Phospholipase D1 (phosphatidylcholine specific), Dihydroxyacetone phosphate acyltransferase, Phosphate cytidyltransferase 1 (choline specific, alpha form), Phosphate cytidyltransferase 2 (ethanolamine specific), Phosphatidic Acid Phosphatase type 2c, Prostate Differentiation Factor PLAB, Phospholipase A2, Phospholipase C beta 3 (phosphatidylinositol specific), Phosphatidylinositol-3-Kinase (class2, gamma polypeptide), Choline/ethanolamine phosphotransferase, Lyosphospholipase, Aldehyde dehydrogenase (5 family, member A1), Phospholipase D1 glycosylphosphatidylinositol specific, 1-acylglycerol-3-phosphate acyltransferase, Phosphatidic Acid Phosphate type 2b, Edg 1, Glycerol-3-phosphate dehydrogenase, Sphingosine-1-phosphate lyase 1, Phosphatase and Tenson Homolog (PTEN), Phosphatidic Acid Phosphatase type 2a, Sphingomyelin phosphodiesterase 1, N-acylsphingosine amidohydrolase, Glycerol Kinase, Diacylglycerol Kinase gamma, Acyl-dihydroxyacetone phosphate reductase, Triacylglycerol lipase, EDG 2, EDG 3, EDG 4, EDG 5, EDG 6, and EDG 7.

3. The method of claim 1, wherein at least one of the genes associated with lipid metabolism, synthesis, or action is selected from the group consisting of Phosphatidylinositol-3-kinase (catalytic, alpha polypeptide), Phospholipase D1 (phosphatidylcholine specific), Prostate Differentiation Factor PLAB, Phospholipase A2, Phospholipase D1 glycosylphosphatidylinositol specific, Edg 1, Glycerol-3-phosphate dehydrogenase, EDG 2, EDG 3, EDG 4, EDG 5, EDG 6, and EDG 7.
4. The method of claim 1, wherein the determination of the copy number of the genes associated with lipid metabolism, synthesis, or action is made by:
 - isolating sample nucleic acid polymers from cells of the patient tissue sample;
 - hybridizing the sample nucleic acid polymers with nucleic acid polymers specific for the selected genes to quantify the extent of hybridization; and
 - comparing the hybridization data thus obtained with data obtained from the hybridization of reference nucleic acid polymers isolated from a normal cell of the same tissue type as the patient tissue sample.
5. The method of claim 4, wherein the sample nucleic acid polymer in the isolating step is amplified by a polymerase chain reaction (PCR).
6. The method of claim 4, wherein the step of hybridizing the sample nucleic acid polymers uses a nucleic acid polymer comprising at least about 19 nucleotides to hybridize to a coding region of one of the selected genes.

7. The method of claim 4, wherein the step of hybridizing the sample nucleic acid polymers uses a nucleic acid polymer comprising at least about 19 nucleotides to hybridize to a non-coding sequence functionally linked to the coding region of one of the selected genes, and wherein the non-coding functionally linked sequence is unique to that gene.
8. The method of claim 4, wherein the hybridizing step uses nucleic acid polymers specific for the selected genes that are immobilized on a solid support wherein a nucleic acid polymer specific for each selected gene is located at a predetermined position on the solid support.
9. A method for identifying tumor characteristics comprising measuring the expression level of at least two genes associated with lipid metabolism, synthesis, or action in a patient tissue sample and comparing the results with an expression level in normal cells.
10. The method of claim 9, wherein at least two of the genes associated with lipid metabolism, synthesis, or action are selected from the group consisting of:
Phosphatidylinositol-3-kinase (catalytic, alpha polypeptide), Phospholipase D1 (phosphatidylcholine specific), Dihydroxyacetone phosphate acyltransferase, Phosphate cytidylyltransferase 1 (choline specific, alpha form), Phosphate cytidylyltransferase 2 (ethanolamine specific), Phosphatidic Acid Phosphatase type 2c, Prostate Differentiation Factor PLAB, Phospholipase A2, Phospholipase C beta 3 (phosphatidylinositol specific), Phosphatidylinositol-3-Kinase (class2, gamma polypeptide), Choline/ethanolamine phosphotransferase, Lyosphospholipase,

Aldehyde dehydrogenase (5 family, member A1), Phospholipase D1
glycosylphosphatidylinositol specific, 1-acylglycerol-3-phosphate acyltransferase,
Phosphatidic Acid Phosphate type 2b, Edg 1, Glycerol-3-phosphate dehydrogenase,
Sphingosine-1-phosphate lyase 1, Phosphatase and Tenson Homolog (PTEN),
Phosphatidic Acid Phosphatase type 2a, Sphingomyelin phosphodiesterase 1, N-
acylsphingosine amidohydrolase, Glycerol Kinase, Diacylglycerol Kinase gamma,
Acyl-dihydroxyacetone phosphate reductase, Triacylglycerol lipase, EDG 2, EDG 3,
EDG 4, EDG 5, EDG 6, and EDG 7.

11. The method of claim 9, wherein at least one of the genes associated with lipid
metabolism, synthesis, or action is selected from the group consisting of
Phosphatidylinositol-3-kinase (catalytic, alpha polypeptide), Phospholipase D1
(phosphatidylcholine specific), Prostate Differentiation Factor PLAB, Phospholipase
A2, Phospholipase D1 glycosylphosphatidylinositol specific, Edg 1, Glycerol-3-
phosphate dehydrogenase, EDG 2, EDG 3, EDG 4, EDG 5, EDG 6, and EDG 7.

12. The method of claim 9, wherein the determination of the expression level of the genes
associated with lipid metabolism, synthesis, or action is made by:

isolating sample ribonucleic acid polymers from the cells of the patient tissue
sample;

hybridizing the sample ribonucleic acid polymers with nucleic acid polymers
specific for the selected genes to quantify the extent of hybridization; and

comparing the hybridization data thus obtained with data obtained from the hybridization of reference nucleic acid polymers isolated from a normal cell of the same tissue type as the patient tissue sample.

13. The method of claim 12, wherein the sample ribonucleic acid polymer in the isolating step is amplified by a polymerase chain reaction (PCR) technique.
14. The method of claim 12, wherein the step of hybridizing the sample ribonucleic acid polymers uses a nucleic acid polymer comprising at least about 19 nucleotides to hybridize to a coding region of one of the selected genes.
15. The method of claim 12, wherein the step of hybridizing the sample ribonucleic acid polymers uses a nucleic acid polymer comprising at least about 19 nucleotides to hybridize to a non-coding sequence functionally linked to the coding region of one of the selected genes, wherein the functionally linked non-coding sequence is unique to that gene.
16. The method of claim 12, wherein the hybridizing step uses nucleic acid polymers specific for the selected genes that are immobilized on a solid support wherein a nucleic acid polymer specific for each selected gene is located at a predetermined position on the solid support.
17. An array of nucleic acid polymers immobilized on a solid support, comprising:

a solid support;

at least two different nucleic acid polymers which are each specific for a different gene associated with lipid metabolism, synthesis, or action;

wherein each nucleic acid polymer is located at a predetermined position on the solid support, and wherein the array comprises nucleic acid polymers which are specific for less than 100 genes other than the selected genes.

18. The array of claim 17, wherein at least two of the nucleic acid polymers are specific for genes selected from the group consisting of: Phosphatidylinositol-3-kinase (catalytic, alpha polypeptide), Phospholipase D1 (phosphatidylcholine specific), Dihydroxyacetone phosphate acyltransferase, Phosphate cytidyltransferase 1 (choline specific, alpha form), Phosphate cytidyltransferase 2 (ethanolamine specific), Phosphatidic Acid Phosphatase type 2c, Prostate Differentiation Factor PLAB, Phospholipase A2, Phospholipase C beta 3 (phosphatidylinositol specific), Phosphatidylinositol-3-Kinase (class2, gamma polypeptide), Choline/ethanolamine phosphotransferase, Lyosphospholipase, Aldehyde dehydrogenase (5 family, member A1), Phospholipase D1 glycosylphosphatidylinositol specific, 1-acylglycerol-3-phosphate acyltransferase, Phosphatidic Acid Phosphate type 2b, Edg 1, Glycerol-3-phosphate dehydrogenase, Sphingosine-1-phosphate lyase 1, Phosphatase and Tenson Homolog (PTEN), Phosphatidic Acid Phosphatase type 2a, Sphingomyelin phosphodiesterase 1, N-acylsphingosine amidohydrolase, Glycerol Kinase, Diacylglycerol Kinase gamma, Acyl-dihydroxyacetone phosphate reductase, Triacylglycerol lipase, EDG 2, EDG 3, EDG 4, EDG 5, EDG 6, and EDG 7.

19. The array of claim 17, wherein at least one of the nucleic acid polymers is specific for a gene selected from the group consisting of: Phosphatidylinositol-3-kinase (catalytic, alpha polypeptide), Phospholipase D1 (phosphatidylcholine specific), Prostate Differentiation Factor PLAB, Phospholipase A2, Phospholipase D1 glycosylphosphatidylinositol specific, Edg 1, Glycerol-3-phosphate dehydrogenase, EDG 2, EDG 3, EDG 4, EDG 5, EDG 6, and EDG 7.
20. The array of claim 17, wherein at least one of the nucleic acid polymers specific for the selected genes is a nucleic acid polymer comprising at least about 19 nucleotides which hybridize to a coding region of one of the selected genes.
21. The array of claim 17, wherein at least one of the nucleic acid polymers specific for the selected genes is a nucleic acid polymer comprising at least about 19 nucleotides which hybridize under the conditions to a non-coding sequence functionally linked to the coding region of one of the selected genes, wherein the functionally linked sequence is unique to that gene.

ABSTRACT

The present invention relates to a method of determining tumor characteristics in tissue samples taken from a patient by determining the copy number or expression level of genes associated with lipid metabolism, synthesis, or action in the sample. This determination may be made by directly quantifying the gene copy number in the chromosomal material of the tissue sample, or by determining the transcription level of the gene in the tissue sample. The present invention is also drawn to physical platforms which are useful in carrying out the diagnostic method, specifically arrays of nucleic acids useful for determining the copy number of the lipid associated genes by hybridization techniques.

Pathways for Phospholipid Metabolism




FIGURE 1.00000000

Pathways for Sphingolipid Metabolism




FIGURE 2 000000

Lyon & Lyon LLP
Docket Information
252/124**DECLARATION**
Utility Application

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled **A METHOD OF DETERMINING TUMOR CHARACTERISTICS BY DETERMINING ABNORMAL COPY NUMBER OR EXPRESSION LEVEL OF LIPID-ASSOCIATED GENES** the specification of which

(Check One) ☒ is attached hereto OR
☐ was filed on _____ as United States Application Serial No. 09/558,880.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment(s) referred to above.

I acknowledge the duty to disclose information which is material to the patentability of this application in accordance with Title 37, Code of Federal Regulations, § 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Date of Filing	Priority Claimed	
			Yes	No

I hereby claim the benefit under Title 35, United States Code § 119(e) of any United States provisional application(s) listed below.


Application Number(s)	Filing Date

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s), or § 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application

U.S. Parent Application Number	PCT Parent Number	Parent Filing Date	Status-Patented, Pending or Abandoned

Lyon & Lyon LLP
Docket Information
252/124

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Title 18, United States Code, § 1001 and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

201	FULL NAME OF INVENTOR	FIRST Name Michael	MIDDLE Initial K.	LAST Name Skinner	
	RESIDENCE & CITIZENSHIP	City Pullman	State or Foreign Country Washington	Country of Citizenship United States	
	POST OFFICE ADDRESS	770 SW Staley Drive	City Pullman	State or Country Washington	Zip Code 99163
INVENTOR'S SIGNATURE 			DATE <u>6/27/00</u>		

202	FULL NAME OF INVENTOR	FIRST Name Jodi	MIDDLE Initial L.	LAST Name Patton	
	RESIDENCE & CITIZENSHIP	City Pullman	State or Foreign Country Washington	Country of Citizenship United States	
	POST OFFICE ADDRESS	738 NE Campus	City Pullman	State or Country Washington	Zip Code 99163
INVENTOR'S SIGNATURE <u>Jodi L. Patton</u>			DATE <u>6-28-00</u>		

203	FULL NAME OF INVENTOR	FIRST Name	MIDDLE Initial	LAST Name	
	RESIDENCE & CITIZENSHIP	City	State or Foreign Country	Country of Citizenship	
	POST OFFICE ADDRESS		City	State or Country	Zip Code
INVENTOR'S SIGNATURE _____			DATE _____		

204	FULL NAME OF INVENTOR	FIRST Name	MIDDLE Initial	LAST Name	
	RESIDENCE & CITIZENSHIP	City	State or Foreign Country	Country of Citizenship	
	POST OFFICE ADDRESS		City	State or Country	Zip Code
INVENTOR'S SIGNATURE _____			DATE _____		

**POWER OF ATTORNEY
By Assignee**

Atairgin Technologies, Inc., assignee(s) of the application for United States Letters Patent for an improvement in

**A METHOD OF DETERMINING TUMOR CHARACTERISTICS BY DETERMINING ABNORMAL
COPY NUMBER OR EXPRESSION LEVEL OF LIPID-ASSOCIATED GENES**

by Michael K. Skinner and Jodi L. Patton,

the specification of which:

☒ is filed herewith, OR
☐ was filed on _____, having U.S. Patent Application Serial No. _____,

does hereby appoint as my attorneys and/or agents, with full power of substitution and revocation, to prosecute this application and transact all business in the United States Patent and Trademark Office, and in countries other than the United States, and to do all things necessary or appropriate therefor before any competent International Authorities in connection with any international patent application(s) corresponding to the above-identified application, all of the registered practitioners identified by Customer Number 22249:



22249

PATENT TRADEMARK OFFICE


LYON & LYON LLP
Suite 4700
633 W. Fifth Street
Los Angeles, CA 90071
(213) 489-1600

Please send all correspondence to the attention of Patrick S. Eagleman, at the above Customer Number, and direct all telephone calls to **(949) 567-2300**.

I, the undersigned, declare that I have reviewed copies of the documentary evidence establishing chain of title to the patent application identified above from the inventor(s) to the assignee(s), which:

☒ is filed for recordation herewith; or
☐ was recorded at Reel _____, Frame _____; or
☐ has been sent for recordation under separate cover, copy attached herewith.

To the best of the undersigned's knowledge and belief, title is in the assignee(s) identified above. Furthermore, the undersigned is empowered to sign this document on behalf of the assignee(s).

Full Name of Assignee: Atairgin Technologies, Inc.	
Post Office Address: 4 Jenner, Suite 180, Irvine, California 92618	
Signature of Declarant or Assignee: 	Date: 7/5/00
Full Name of Declarant If Other Than Assignee: Patrick D. Walsh	
Title of Declarant: Chief Executive Officer	
Address of Declarant: 4 Jenner, Suite 180, Irvine, California 92618	

[illegible]

Patton, Jodi L.

<130> PATRICK EAGLEMAN: EMBOL-X 252/124

<141>

<170> PatentIn Ver. 2.0

<211> 2045

<213> Homo sapiens

<221> gene

<223> The sequence of the cDNA coding for

1-acylglycerol-3-phosphate acyltransferase

<400> 1

cgacacccccg acagagacag agacacagcc atccgccacc accgctgccg cagcctggct 60
ggggagggggg ccagcccccc aggcccccta cccctctgag gtggccagaa tggatttgtg 120
gccagggggca tggatgctgc tgctgctgct cttcctgctg ctgctcttcc tgctgcccac 180
cctgtgggttc tgcagcccca gtgccaagta cttcttcaag atggccttct acaatggctg 240
gacctcttcc ctggctgtgc tcgccatccc tgtgtgtgcc gtgcgaggac gcaacgtcga 300
gaacatgaag atcttgctgc taatgctgct ccacatcaaa tacctgtacg ggatccgagt 360
ggaggtgcga ggggctcacc acttccctcc ctgcgagccc tatgttgttg tctccaacca 420
ccagagctct ctgatctgc ttgggatgat ggaggtactg ccaggccgct gtgtgcccac 480
tgccaagcgc gagctactgt gggctggctc tgccgggctg gcctgctggc tggcaggagt 540
catcttcacg gaccggaagc gcacggggga tgccatcagt gtcattgtctg aggtcgccca 600
gacctgctc acccaggacg tgagggtctg ggtgtttcct gagggaacga gaaaccacaa 660
tggtccatg ctgcccttca aacgtggcgc cttccatctt gcagtgcagg cccagggttcc 720
cattgtcccc atagtcatgt cctcctacca agacttctac tgcaagaagg agcgctcgctt 780
cacctcggga caatgtcagg tgcgggtgct gccccagtg cccacggaag ggctgacacc 840
agatgacgtc ccagctctgg ctgacagagt ccggcactcc atgctcactg ttttccggga 900
aatctccact gatggccggg gtgggtgtga ctatctgaag aagcctgggg gcggtgggtg 960
aaccctggct ctgagctctc ctcccatctg tcccatctt cctccccaca cctaccacc 1020
cagtgggccc tgaagcaggg ccaaaccctc ttccttgtct cccctctccc cacttattct 1080
cctctttgga atcttcaact tctgaagtga atgtggatac agcgccactc ctgccccctc 1140
ttggcccat ccattggact ttgcctcggg gcagtttcca ctcttgacct ccacctccta 1200
ctgtcttgtc tgtgggacag ttgcctcccc ctcatctcca gtgactcagc ctacacaagg 1260
gaggggaaca ttccatcccc agtggagtct cttcctatgt ggtcttctct acccctctac 1320
cccacattgg ccagtggact catccattct ttggaacaaa tccccccac tccaaagtcc 1380
atggattcaa tggactcatc catttgtgag gaggacttct cgccctctgg ctggaagctg 1440
atacctgaag cactcccagg ctcatcctgg gagctttcct cagcacctc accttccctc 1500
ccagtgtagc ctctgtcag tgggggctgg acccttctaa ttcagaggtc tcatgcctgc 1560

```

ccttgcccag atgcccaggg tcgtgcactc tctgggatac cagttcagtc tccacatttc 1620
tggtttttctg tccccatagt acagttcttc agtggacatg accccaccca gccccctgca 1680
gccctgctgc accatctcac cagacacaag gggaagaagc agacatcagg tgctgcactc 1740
acttctgccc cctggggagt tggggaaagg aacgaaccct ggctggaggg gataggaggg 1800
cttttaattt atttcttttt ctgttgaggc ttccccctct ctgagccagt tttcatttct 1860
tcctggtggc attagccact ccctgcctct cactccagac ctgttcccac aactggggag 1920
gtaggctggg agcaaaagga gaggggtggga ccagttttg cgtggttggg ttttattaat 1980
tatctggata acagcaaaaa aactgaaaat aaagagagag agagaaaaaa aaaaaaaaaa 2040
aaaaa
2045

```

<210> 2

<211> 1554

<212> DNA

<213> Homo sapiens

<220>

<221> gene

<222> (1)..(1554)

<223> The sequence of the cDNA coding for Aldehyde
dehydrogenase (5 family, member A1)

<400> 2

```

atgctgcgct tcctggcacc ccggctgctt agcctccagg gcaggaccgc cctctactcc 60
tcggcagcag ccctcccaag cccattctg aaccagaca tcccctacaa ccagctgttc 120
atcaacaatg aatggcaaga tgcagtcagc aagaagacct tcccgacggt caaccctacc 180
accggggagg tcatcgggca cgtggctgaa ggtgaccggg ctgatgtgga tcgggccgtg 240
aaagcagccc gggaagcctt ccgcctgggg tccccatggc gccgatgga tgcctctgag 300
cggggcoggc tgctgaacct cctggcagac ctagtggagc gggatcgagt ctacttggcc 360

```

tcaactcgaga ccttggacaa tgggaagcct ttccaagagt cttacgcctt ggacttggat 420
 gaggtcatca aggtgtatcg gtactttgct ggctgggctg acaagtggca tggcaagacc 480
 atccccatgc atggccagca tttctgcttc acccggcattg agcccgttgg tgtctgtggc 540
 cagatcatcc cgtggaactt ccccttggtc atgcagggtt ggaaacttgc cccggcactc 600
 gccacaggca aactgtggt tatgaagggtg gcagagcaga ccccccctctc tgccctgtat 660
 ttggcctccc tcatcaagga ggcaggcttt ccccttgggg tggagaacat catcacgggg 720
 tatggcccaa cagcagggtgc ggccatcgcc cagcacatgg atgttgacaa agttgccttc 780
 accggttcca ccgagggtggg ccacctgac cagaaagcag ctggcgattc caacctcaag 840
 agagtcaccc tggagctggg tggtaagagc cccagcatcg tgctggccga tgctgacatg 900
 gagcatgccg tggagcagtg ccacgaagcc ctgttcttca acatgggcca gtgctgctgt 960
 gctggctccc ggaccttcgt ggaagaatcc atctacaatg agtttctcga gagaaccgtg 1020
 gagaaagcaa agcagaggaa agtggggaac ccctttgagc tggacaccca gcaggggcct 1080
 caggtggaca aggagcagtt tgaacgagtc ctaggctaca tccagcttgg ccagaaggag 1140
 ggcgcaaaac tcctctgtgg cggagagcgt ttcggggagc gtggtttctt catcaagcct 1200
 actgtctttg gtggcgtgca ggatgacatg agaattgcca aagaggagat ctttgggcct 1260
 gtgcagcccc tgttcaagtt caagaagatt gaggaggtgg ttgagagggc caacaacacc 1320
 aggtatggcc tggctgcggc tgtgttcacc cgggatctgg acaaggccat gtacttcacc 1380
 caggcactcc aggccgggac cgtgtgggta aacacctaca acatcgtcac ctgccacacg 1440
 ccatttggag ggtttaagga atctggaaac gggagggagc tgggtgagga tgggcttaag 1500
 gcctacacag aggtaaagac ggtcaccatc aaggttcctc agaagaactc gtaa 1554

<210> 3

<211> 2051

<212> DNA

<213> Homo sapiens

<220>

<221> gene

<222> (1)..(2051)

<223> The sequence of the cDNA coding for
Choline/ethanolamine phosphotransferase

<400> 3

ggcagcagct ggagtcggag gcgatatttc taggggtgta cttgttgggg tcagggtaag 60
caccagccac aaaaacctac aaaagaaggg aaattactgt ctttaaatat taacacacac 120
caagatccat gagtgggcat cgatcaacaa ggaaaagatg tggagattct caccgggagt 180
ccccagtggg cttcgggcat atgagtacta caggatgtgt attaaataaa ttgtttcagt 240
taccaacacc accattgtca agacaccaac taaagcggct agaagaacac agatatcaaa 300
gtgctggacg gtccctgctt gagcccttaa tgcaagggtg ttgggaatgg ctcgtagtaa 360
gagttccctc ctggattgcc ccaaattctc tcaccatcat tggactgtca ataaacatct 420
gtacaactat tttattagtc ttctactgcc ctacagctac agagcaggca cctctgtggg 480
catatattgc ttgtgcctgt ggccttttca tttaccagtc tttggatgct attgatggga 540
aacaggcaag aagaaccaat agtagttctc ctctgggaga actttttgat catggctgtg 600
attcactatc aacagttttt gtggttcttg gaacttgatg tgcaagtgcag ctgggggacaa 660
accctgattg gatgtttttt tgttggtttg cggggacatt tatgttctat tgtgcgcact 720
ggcaaacgta tgtttctgga acattgcgat ttggaataat tgatgtgact gaagtgcaaa 780
tcttcataat aatcatgcat ttgctggcag tgattggagg accacctttt tggcaatcta 840
tgattccagt gctgaatatt caaatgaaaa tttttcctgc actttgtact gtagcagggg 900
ccatattttc ctgtacaaat tacttccgtg taatcttcac aggtggtgtt ggcaaaaatg 960
gatcaacaat agcaggaaca agtgcctttt ctccttttct ccatattgga tcagtgatta 1020
cattagctgc aatgatctac aagaaatctg cagttcagct ttttgaaaag catccctgtc 1080
tttatatact gacatttggg tttgtgtctg ctaaaatcac taataagctt gtggttgcac 1140
acatgacgaa aagtgaaatg catttgcatt acacagcatt cataggtccg gcacttttgt 1200
ttctggacca gtattttaac agctttattg atgaatatat tgtactttgg attgccctgg 1260
ttttctcttt ctttgatttg atccgtactg gtgtcagtgt ttgcaatcag attgcgtctc 1320
acctgcacat acatgtcttc agaatcaagg tctctacagc tcattctaata catcattaat 1380

```

gatgtaattg gtatatagga acatcatggt ttctgcagga aagaaagtaa catattaagg 1440
agaatggggg tggataagaa caaatataat ttataataat caatggtgta taacttttat 1500
tctttattat tggtaacacg ccctaactat cctgtgtgag aatgggaatt tcaagtccca 1560
tcttgtaa at tgtatatggt gtcatgcagg gtttgggcca agaaagcatg cagaaaaaaa 1620
tgccatgtga ttgtaattat cctggattca gaataatact gtgatgggga gccagatccg 1680
cagtgggtga gagttcta at gttgactggt tgcaggccaa aagatgattg ctttataatt 1740
ttaacaaatc attgtctttt agtaacatcc ttgttttagt tcttctcaag ctttctttac 1800
tgaggaattc agcttgtgac acagatacat ccactagct tgtgaggtgg aactagta at 1860
aaagaccttg aatttggatt gaaaagtttc ctatctttac attgttgagg aagtcctttt 1920
tttttttttt ttttaattgct caagaaatga ttctctcaca ggcttgggaa atcctgttag 1980
catgcaga at aatgtggtaa ctttgtcaat ttcccatttt atttttttta ataaatatat 2040
gatctaaacg g 2051

```

<210> 4

<211> 3758

<212> DNA

<213> Homo sapiens

<220>

<221> gene

<222> (1)..(3758)

<223> The sequence of the cDNA coding for Diacylglycerol
kinase, gamma

<400> 4

```

cacggagata gacagctttg gagctgctga actccgagca caggggtgaag accccggcgc 60
taccaaccac agcctggcag cctgggtctcc gcggcacc ca ctggggctgc atccccctcc 120
cccgagaggg ctgcgcaggc gggaagacgc cagaggccag cttcgggtccc ccttctgtct 180

```

ctcgggttcct	ctttcctccc	aagtaaggga	ataaacccgc	aagaaggagc	gccccgggcc	240
accgcgcaac	caagtgttgc	ctggtgagga	agagccagga	cttctgaatt	taccttgaat	300
acagacagga	ggatgttgcc	taaggaatag	cagagatctt	gtctcatctt	ctgagaggtg	360
cctgctgctg	ctgtatacac	ttgagtgttc	ccagaagtct	cctgaaaggc	ttacatcgca	420
aacctgcaat	gagccaggcc	ctgggctggg	cctccacttc	agcctagtga	acaaaactcc	480
atcactgccc	tttagccact	cacataaagt	ttaaaaatgg	gtgaagaacg	gtgggtctcc	540
ctcactccag	aagaatttga	ccaactccag	aaatattcag	aatattcctc	caagaagata	600
aaagatgcct	tgactgaatt	taatgagggt	gggagcctca	aacaatatga	cccacatgag	660
ccgattagct	atgatgtctt	caagctgttc	atgagggcgt	acctggaggt	ggaccttccc	720
cagccactga	gcactcacct	cttcctggcc	ttcagccaga	agcccagaca	cgagacctct	780
gaccacccga	cggagggagc	cagcaacagt	gaggccaaca	gcgagatac	taatatacac	840
aatgcagata	atgccaccaa	agcagacgag	gcctgtgccc	ctgatactga	atcaaatatg	900
gctgagaagc	aagcaccagc	tgaagaccaa	gtggctgcga	ccccctgga	acccccctgc	960
cctcggctctt	caagctcgga	atccccagtg	gtgtacctga	aggatgttgt	gtgctacctg	1020
tccttgcctg	agacggggag	gcctcaggat	aagctggagt	tcatgtttcg	cctctatgat	1080
tcagatgaga	acgggtctct	ggaccaagcg	gagatggatt	gcattgtcaa	ccaaatgctg	1140
catattgccc	agtacctgga	gtgggatccc	acagagctga	ggcctatatt	gaaggagatg	1200
ctgcaaggga	tggactacga	ccgggacggc	tttgtgtctc	tacaggaatg	ggtccatgga	1260
gggatgacca	ccatcccatt	gctgggtgtc	ctggggatgg	atgactctgg	ctccaagggg	1320
gatggggggc	acgcctggac	catgaagcac	ttcaagaaac	caacctactg	caacttctgc	1380
catatcatgc	tcatgggcgt	ccgcaagcaa	ggcctgtgct	gcacttactg	taaatacact	1440
gtccacgaac	gctgtgtgtc	caaaaacatt	cctggtttgt	tcaaaacgta	ctcaaagcc	1500
aaaaggagtg	gtgaggtgat	gcagcacgca	tgggtggaag	ggaactcctc	cgtcaagtgt	1560
gaccggtgcc	acaaaagtat	caagtgttac	cagagtgtca	ccgcgcggca	ctgcgtgtgg	1620
tgccggatga	cgtttcaccg	caaatgtgaa	ttatcaacgt	tgtgtgacgg	tggggaactc	1680
agagaccaca	tcttactgcc	cacctccata	tgcccatca	cccgggacag	gccaggtgag	1740
aagtctgatg	gctgcgtgtc	cgccaagggc	gaacttgtca	tgcagtataa	gatcatcccc	1800
accccggtga	cccaccccct	gctggctctt	gtgaacccca	agagtggagg	gagacaagga	1860

gaaagaattc ttcggaatt ccactatctg ctcaaccca aacaagtttt caacctggac 1920
aatggggggc ctactccagg gttgaacttt ttccgtgata ctccagactt ccgtgttttg 1980
gcctgtggtg gagatgggac agttggctgg attttgatt gcattgataa ggccaacttt 2040
gcaaagcatc caccagtggc tgtcctgcct cttggaacag gaaatgacct tgcccgttgt 2100
ctccgctggg gaggagggtta tgaagggggc agcttgacaa aaatcctgaa agacattgag 2160
cagagccctt tggatgatgct ggaccgctgg catctggaag tcatccccag agaggaagtg 2220
gaaaacgggg accaggtccc atacagcatc atgaacaact atttctccat tgggtgtggac 2280
gcttccattg cacacagatt ccatgtgatg agagagaaac atcctgaaaa attcaacagc 2340
aggatgaaga acaagctgtg gtactttgaa tttggcacct cggagacttt tgcagcgacc 2400
tgcaagaaac tccacgacca cattgagttg gagtgtgatg gggttggggg ggacctgagc 2460
aacatcttcc tggaaggcat tgccattctc aacattccca gcatgtacgg aggcaccaat 2520
ctctggggag aaaacaagaa gaaccgggct gtgatccggg aaagcaggaa ggggtgtcact 2580
gaccccaaag aactgaaatt ctgcgttcaa gacctcagt accagctcct tgaagtgggtg 2640
gggctagaag gagccatgga gatggggcag atctacaccg gcctgaagag tgcaggcagg 2700
aggctggccc agtgcgcctc tgtcaccatc aggacaaaca agctgctgcc aatgcaagtg 2760
gatggagAAC cctggatgca gccatgttgc acgattaaaa ttactcaca gaaccaagcg 2820
cccatgatga tggggcctcc ccagaagagc agcttcttct cgttgagaag gaagagccgt 2880
tcaaaagact aaacagtgtg ccaaacacca gctaaaccaa gagagaaaagc aagaaactat 2940
aatgcacact cacacacaat ttatgtgcac actcacacat gcacacacac acacacatac 3000
acactcttct ctaaccagtg gaagcaaagc cacccttcgg gaagaaaacg tcaccttgcc 3060
atacattctg tttcaacagt gggtagacc ctaacagagc cagtccaac aaaacatttt 3120
gaatggactt agggcccatg aggttgtggc tggcttaggc agcaacctcc acattcccac 3180
aggccttgag cagaattttc tgagactgaa gggaaatccc cttttctttc taccagccct 3240
gcaagtttcc tcatggacgc tcgagaggag caggctgcag gtttcctgcc tatggtgaga 3300
tcagatgtgg ccaaggggaag gagctctggt tccagagaat ttgcacaaag ttccctctgt 3360
acagagacaa aacggcctcc ggctctcaga gcataatcct tggcagggct cagcaggcgc 3420
acgttggttt cttggctcgtc ctttgagtga caacttctcc gtgaacctgc tgaagaggca 3480
gaaaggctgt ggaaagctgt atttccattc ttgggtttct gcgccgtcgg tgggcacttg 3540

ttattttcca ggaaccttct cctggtgtct acatgtttgc ttagaggcgg ctccaagagc 3600
cccagagctg cctgcatagc acaccttaga tgtggtattht attttcttag ttctgtgaac 3660
acctgggagg gagagcggag aaactgggat ttatttttca aattggtgtc ataatttgt 3720
gtaaaaaggg aaggaaaaaa aaaaccaccc ccagcttc 3758

<210> 5

<211> 2470

<212> DNA

<213> Homo sapiens

<220>

<221> gene

<222> (1)..(2470)

<223> The sequence of the cDNA coding for
Dihydroxyacetone phosphate acyltransferase

<400> 5

gaattcggca cgagccggga tcctgtgtag cggctgcaga gggtgccgcc gccctaggcg 60
aagtagggcc gtcctgagcg aaagaaccgc ccccagcagg agcaccacca cggcttagca 120
aagaatccca gaccccgcgc gggaaggcag cgcaccatg gagtcttcca gttcatctaa 180
ctcttatttc tccgttggcc caaccagtcc cagcgtgtc gtgctcctct actcgaagga 240
gctcaaaaag tgggatgagt ttgaagatat tttagaagag aggaggcatg tcagtgaactt 300
gaaatttgca atgaaatgct acacacctct tgtctataag ggaattactc catgtaaacc 360
aattgatatt aaatgtagtg ttctcaattc tgaggagatt cattatgtca ttaaacagct 420
ttccaaggaa tcccttcaat ctgtggatgt cctccgagag gaagtgagt agatcttaga 480
tgaaatgagt cacaaactgc gtcttggagc cattcggtht tgtgccttca ccctgagcaa 540
agtattttaa caaatthtct cgaagggtgtg tgtaaatgaa gaaggtattc agaaactaca 600
aagagccatc caggagcatc ctgttgttct gctgcctagt catcgaagtt acattgactt 660

cctcatgttg tcttttcttc tatacaatta tgatttgcct gtgccagtta tagcagcagg 720
aatggacttc ctgggaatga aaatggttgg tgagctgcta cgaatgtcgg gtgccttttt 780
catgcggcgt acctttggtg gcaataaaact ctactgggct gtattctctg aatatgtaaa 840
aactatgtta cggaatggtt atgctcctgt tgaatttttc ctcgaaggga caagaagccg 900
ctctgccaaag acattgactc ctaaatttgg tcttctgaat attgtgatgg agccattttt 960
taaaagagaa gtttttgata cctaccttgt cccaattagt atcagttatg ataagatctt 1020
ggaagaaact ctttatgtgt atgagcttct aggggttcct aaaccaaaaag agtctacaac 1080
tgggttgctg aaagccagaa agattctctc tgaaaatttt ggaagcatcc atgtgtactt 1140
tggagatcct gtgtcacttc gatctttggc agctgggagg atgagtcgga gctcatataa 1200
cttggttcca agatacattc ctcagaaaca gtctgaggac atgcatgcct ttgtcactga 1260
agttgcctac aaaatggagc ttctgcaaat tgaaaacatg gttttgagcc cctggaccct 1320
aatagttgct gttctgcttc agaaccggcc atccatggac tttgatgctc tgggtggaaaa 1380
gactttatgg ctaaaaggct taaccagggc atttgagggg tttctcattt ggcctgataa 1440
taaacctgct gaagaagttg tcccggccag cattcttctg cattccaaca ttgccagcct 1500
tgtcaaagac caggtgattc tgaaagtgga ctccggagac tcggaagtgg tcgatgggct 1560
tatgtccag cacatcactc tcctcatgtg ctcagcttat aggaaccagc tgctcaacat 1620
ttttgtgcgc ccatccttag tagcagtagc attgcagatg acaccagggt tcaggaaaga 1680
ggatgtctac agttgctttc gcttcctacg tgatgttttt gcagatgagt tcatcttcct 1740
tccaggaaac aactaaagg actttgaaga aggctgttac ctgctttgta aaagtgaagc 1800
catacaagtg actacgaaag acatcctagt tacagagaaa ggaaatactg tgttagaatt 1860
tttagtagga ctctttaaac cttttgtgga aagctatcag ataatttgca agtacctttt 1920
gagtgaagaa gaggaccact tcagtgagga acagtacttg gctgcagtca gaaaattcac 1980
aagtcagctt ctgatcaag gtacctctca atgttatgat gtattatctt ctgatgtgca 2040
gaaaaacgcc ttagcagcct gtgtgaggct cggagtagtg gagaagaaga agataaataa 2100
taactgtata tttaatgtga atgaacctgc cacaacaaa ttagaagaaa tgcttggttg 2160
taagacacca ataggaaaac cagccactgc aaaactttta taatcaacaa atagttatgg 2220
aaaattcggc cacgtaatta ctctcatcga aggactcatt acaacaaaca gggaagtaaa 2280
ggaagagaca catcctctca tactccctga gactctgaga acagtggacg cagaggggaag 2340

agatgatcat tggaagcaat cagtttactc ttccccacca cagtgggttaa aaggcgtttg 2400
tatctgacac tatgtgtgtg ttttaaata aacttttga aacatgaaaa aaaaaaaaaa 2460
aaaactcgag 2470

<210> 6

<211> 2757

<212> DNA

<213> Homo sapiens

<220>

<221> gene

<222> (1)..(2757)

<223> The sequence of the cDNA coding for EDG-1

<400> 6

tctaaaggtc gggggcagca gcaagatgcg aagcgagccg tacagatccc gggctctccg 60
aacgcaactt cgccctgctt gagcgaggct gcggtttccg aggccctctc cagccaagga 120
aaagctacac aaaaagcctg gatcactcat cgaaccaccc ctgaagccag tgaaggctct 180
ctcgctcgc cctctagcgt tcgtctggag tagcgccacc ccggttcctt ggggacacag 240
ggttggcacc atggggccca ccagcgtccc gctgggtcaag gccaccgca gctcgggtctc 300
tgactacgtc aactatgata tcatcgtccg gcattacaac tacacgggaa agctgaatat 360
cagcgcggac aaggagaaca gcattaaact gacctcgtg gtgttcattc tcatctgctg 420
ctttatcatc ctggagaaca tctttgtctt gctgaccatt tggaaaacca agaaattcca 480
ccgacccatg tactatttta ttggcaatct ggccctctca gacctgttgg caggagtagc 540
ctacacagct aacctgctct tgtctggggc caccacctac aagctcactc ccgcccagtg 600
gtttctgcgg gaagggagta tgtttgtggc cctgtcagcc tccgtgttca gtctcctcgc 660
catcgccatt gagcgtata tcacaatgct gaaaatgaaa ctccacaacg ggagcaataa 720
cttcgcctc ttctgctaa tcagcgctg ctgggtcatc tcctcatcc tgggtggcct 780

gcctatcatg ggctggaact gcatcagtgc gctgtccagc tgctccaccg tgctgceget 840
ctaccacaag cactatatcc tcttctgcac cacggtcttc actctgcttc tgctctccat 900
cgtcattctg tactgcagaa tctactcctt ggtcaggact cggagccgcc gcctgacgtt 960
ccgcaagaac atttccaagg ccagccgcag ctctgagaat gtggcgctgc tcaagaccgt 1020
aattatcgto ctgagcgtct tcatcgccctg ctgggcaccg ctcttcatcc tgctcctgct 1080
ggatgtgggc tgcaagggtga agacctgtga catcctcttc agagcggagt acttcctggt 1140
gttagctgtg ctcaactccg gcaccaaccc catcatttac actctgacca acaaggagat 1200
gcgtcggggc ttcattccga tcatgtcctg ctgcaagtgc ccgagcggag actctgctgg 1260
caaattcaag cgacccatca tcgccggcat ggaattcagc cgcagcaaat cggacaattc 1320
ctccccccc cagaaagacg aaggggacaa cccagagacc attatgtctt ctggaaacgt 1380
caactcttct tcctagaact ggaagctgtc caccaccgg aagcgtctt tacttggtcg 1440
ctggccaccc cagtgtttgg aaaaaatct ctgggcttcg actgctgcca gggaggagct 1500
gctgcaagcc agagggagga agggggagaa tacgaacagc ctggtggtgt cgggtgttgg 1560
tggttagagt tagttcctgt gaacaatgca ctgggaaggg tggagatcag gtcccgccct 1620
ggaatatata ttctaccccc ctggagcttt gattttgcac tgagccaaag gtctagcatt 1680
gtcaagctcc taaagggttc atttggcccc tcctcaaaga ctaatgtccc catgtgaaag 1740
cgtctctttg tctggagctt tgaggagatg ttttccttca ctttagtttc aaaccaagt 1800
gagtgtgtgc acttctgctt ctttagggat gccctgtaca tcccacaccc caccctccct 1860
tcccttcata cccctcctca acgttctttt actttatact ttaactacct gagagttatc 1920
agagctgggg ttgtggaatg atcgatcatc tatagcaaat aggctatgtt gagtacgtag 1980
gctgtgggaa gatgaagatg gtttggaggt gtaaaacaat gtccttcgct gaggccaaag 2040
tttccatgta agcgggatcc gttttttgga atttggttga agtcactttg atttctttaa 2100
aaaacatctt ttcaatgaaa tgtgttacca tttcatatcc attgaagccg aaatctgcat 2160
aaggaagccc actttatcta aatgatatta gccaggatcc ttggtgtcct aggagaaaca 2220
gacaagcaaa acaaagtga aaccgaatgg attaactttt gcaaaccaag ggagatttct 2280
tagcaaatga gtctaacaaa tatgacatcc gtctttccca cttttgttga tgtttatctc 2340
agaatcttgt gtgattcatt tcaagcaaca acatgttgta ttttggttg ttaaaagtac 2400
ttttcttgat ttttgaatgt atttgtttca ggaagaagtc attttatgga tttttctaac 2460

ccgtgttaac ttttctagaa tccaccctct tgtgccctta agcattactt taactggtag 2520
ggaacgccag aacttttaag tccagctatt cattagatag taattgaaga tatgtataaa 2580
tattacaaag aataaaaata tattactgtc tctttagtat ggttttcagt gcaattaaac 2640
cgagagatgt cttgtttttt taaaaagaat agtatttaat aggtttctga cttttgtgga 2700
tcattttgca catagcttta tcaactttta aacattaata aactgatttt tttaaag 2757

<210> 7

<211> 1217

<212> DNA

<213> Homo sapiens

<220>

<221> gene

<222> (1)..(1217)

<223> The sequence of the cDNA coding for EDG-2

<400> 7

ctgacaccta cagcatcagg tacacagctt ctcttagcat gacttcgatc tgatcagcaa 60
acaagaaaat ttgtctcccg tagttctggg gcgtgttcac cacctacaac cacagagctg 120
tcatggctgc catctctact tccatccctg taatttcaca gccccagttc acagccatga 180
atgaaccaca gtgcttctac aacgagtcca ttgccttctt ttataaccga agtggaaagc 240
atcttgccac agaatggaac acagtcagca agctggtgat gggacttgga atcactgttt 300
gtatcttcat catgttggcc aacctattgg tcatggtgga aatctatgtc aaccgccgct 360
tccattttcc tatttattac ctaatggcta atctggctgc tgcagacttc tttgctgggt 420
tggcctactt ctatctcatg ttcaacacag gaccaatac tcggagactg actgtcagca 480
catggctcct tcgtcagggc ctcatcgaca ccagcctgac ggcatctgtg gccaaacttac 540
tggctattgc aatcgagagg cacattacgg ttttccgcat gcagctccac acacggatga 600
gcaaccggcg ggtagtggtg gtcattgtgg tcatctggac tatggccatc gttatgggtg 660

ctatacccag tgtgggctgg aactgtatct gtgatattga aaattgttcc aacatggcac 720
 ccctctacag tgactcttac ttagtcttct gggccatttt caacttgggtg acctttgtgg 780
 taatgggtgg tctctatgct cacatctttg gctatgttcg ccagaggact atgagaatgt 840
 ctcggcatag ttctggaccc cggcgggaatc gggataccat gatgagtctt ctgaagactg 900
 tggtcattgt gcttggggcc tttatcatct gctggactcc tggattgggtt ttgttacttc 960
 tagacgtgtg ctgtccacag tgcgacgtgc tggcctatga gaaattcttc cttctccttg 1020
 ctgaattcaa ctctgccatg aaccccatca tttactccta ccgcgacaaa gaaatgagcg 1080
 ccacctttag gcagatcctc tgctgccagc gcagtgagaa cccaccggc cccacagaag 1140
 gctcagaccg ctcggcttcc tccctcaacc acaccatctt ggctggagtt cacagcaatg 1200
 atcactctgt ggtttag 1217

<210> 8

<211> 1137

<212> DNA

<213> Homo sapiens

<220>

<221> gene

<222> (1)..(1137)

<223> The sequence of the cDNA coding for EDG-3

<400> 8

atggcaactg ccctcccgcc gcgtctccag ccggtgcggg ggaacgagac cctgcgggag 60
 cattaccagt acgtggggaa gttggcgggc aggtgaagg aggcctccga gggcagcacg 120
 ctcaccaccg tgcctcttctt ggtcatctgc agcttcatcg tcttggagaa cctgatgggtt 180
 ttgattgcca tctggaaaaa caataaatct cacaaccgca tgtacttttt cattggcaac 240
 ctggctctct gcgacctgct ggccggcatc gcttacaagg tcaacattct gatgtctggc 300
 aagaagacgt tcagcctgtc tcccacggtc tggttcctca gggagggcag tatgttcgtg 360

gcccttgggg cgtccacctg cagcttactg gccatcgcca tcgagcggca cttgacaatg 420
 atcaaaatga ggccttacga cgccaacaag aggcaccgcg tcttcctcct gatcgggatg 480
 tgctgggtca ttgccttcac gctggggcgc ctgcccattc tgggctggaa ctgcctgcac 540
 aatctccctg actgctctac catcctgccc ctctactcca agaagtacat tgccttctgc 600
 atcagcatct tcacggccat cctggtgacc atcgtgatcc tctacgcacg catctacttc 660
 ctggtgaagt ccagcagccg taagggtggc aaccacaaca actcggagcg gtccatggca 720
 ctgctgcgga ccgtggtgat tgtggtgagc gtgttcatcg cctgctggtc cccactcttc 780
 atcctcttcc tcattgatgt ggctgcagg gtgcaggcgt gccccatcct cttcaaggct 840
 cagtggttca tcgtgttggc tgtgctcaac tccgccatga acccggtcat ctacacgctg 900
 gccagcaagg agatgcggcg ggccttcttc cgtctggtct gcaactgcct ggtcagggga 960
 cggggggccc gcgcctcacc catccagcct gcgctcgacc caagcagaag taaatcaagc 1020
 agcagcaaca atagcagcca ctctccgaag gtcaaggaag acctgcccca cacagacccc 1080
 tcctctgca tcattggaaa gaacgcagca cttcagaatg ggatcttctg caactga 1137

<210> 9

<211> 1056

<212> DNA

<213> Homo sapiens

<220>

<221> gene

<222> (1)..(1056)

<223> The sequence of the cDNA coding for EDG-4

<400> 9

atggtcatca tgggccagtg ctactacaac gagaccatcg gcttcttcta taacaacagt 60
 ggcaaagagc tcagctccca ctggcggccc aaggatgtgg tcgtggtggc actggggctg 120
 accgtcagcg tgctggtgct gctgaccaat ctgctggtca tagcagccat cgctccaac 180


```

cgccgcttcc accagcccat ctactacctg ctcggaatc tggccgcggc tgacctcttc 240
gggggcgtgg cctacctctt cctcatgttc cacactgggc cccgcacagc ccgactttca 300
cttgagggct ggttcctgcg gcagggttg ctggacacaa gcctcactgc gtcggtggcc 360
acactgctgg ccatcgccgt ggagcggcac cgcagtgtga tggccgtgca gctgcacagc 420
cgccctgccc gtggccgcgt ggtcatgttc attgtgggcg tgtgggtggc tgccctgggc 480
ctggggctgc tgccctgcca ctctggcac tgccctctgt ccctggaccg ctgctcacgc 540
atggcacccc tgctcagccg ctctatttg gccgtctggg ctctgtcgag cctgcttgct 600
ttcctgctca tgggtggctgt gtacaccgc attttcttct acgtgcggcg gcgagtgcag 660
cgcatggcag agcatgtcag ctgccacccc cgctaccgag agaccacgct cagcctgggc 720
aagactgttg tcatcatcct gggggcggtc gtggtctgct ggacaccagg ccagggtggta 780
ctgctcctgg atggtttagg ctgtgagtc tgcaatgtcc tggctgtaga aaagtacttc 840
ctactgttgg ccgaggccaa ctactgggc aatgctgctg tgtactcttg ccgagatgct 900
gagatgcgcc gcaccttcg ccgccttctc tgctgcgcgt gcctccgcca gtccaccgc 960
gagtctgtcc actatacatc ctctgccag ggaggtgcca gcactcgcat catgcttccc 1020
gagaacggcc acccactgat ggactccacc cttag                                     1056

```

<210> 10

<211> 1062

<212> DNA

<213> Homo sapiens

<220>

<221> gene

<222> (1)..(1062)

<223> The sequence of the cDNA coding for EDG-5

<400> 10

```

atgggcagct tgtactcgga gtacctgaac cccaacaagg tccaggaaca ctataattat 60

```

```

accaaggaga cgctggaaac gcaggagacg acctcccgcc aggtggcctc ggccttcata 120
gtcatectct gttgcgccat tgtggtggaa aaccttctgg tgctcattgc ggtggcccga 180
aacagcaagt tccactcggc aatgtacctg tttctgggca acctggccgc ctccgatcta 240
ctggcaggcg tggccttcgt agccaatacc ttgctctctg gctctgtcac gctgaggctg 300
acgcctgtgc agtgggttgc ccgggagggc tctgcctcca tcacgctctc ggcctctgtc 360
ttcagcctcc tggccatcgc cattgagcgc cacgtggcca ttgccaaggt caagctgtat 420
ggcagcgaca agagctgccg catgcttctg ctcatcgggg cctcgtggct catctcgctg 480
gtcctcggtg gcctgcccat cttgggtggt aactgcctgg gccacctcga ggctgtctcc 540
actgtcctgc ctctctacgc caagcattat gtgctgtgcg tggtgaccat cttctccatc 600
atcctgttgg ccatcgtggc cctgtacgtg cgcactctact gcgtggtccg ctcaagccac 660
gctgacatgg ccgccccgca gacgctagcc ctgctcaaga cggtcaccat cgtgctaggc 720
gtctttatcg tctgctggct gccgccttc agcatcctcc ttctggacta tgctgtccc 780
gtccactcct gcccgatcct ctacaaagcc cactactttt tcgccgtctc caccctgaat 840
tcctctgca acccgcgtcat ctacacgtgg cgcagccggg acctgcggcg ggaggtgctt 900
cggccgctgc agtgctggcg gccgggggtg ggggtgcaag gacggaggcg ggtcggggacc 960
ccggggccacc acctcctgcc actccgcagc tccagctccc tggagagggg catgcacatg 1020
cccacgtcac ccacgtttct ggagggcaac acggtggtct ga 1062

```

<210> 11

<211> 1566

<212> DNA

<213> Homo sapiens

<220> .

<221> gene

<222> (1)..(1566)

<223> The sequence of the cDNA coding for EDG-6

<400> 11

gagtcagccc ccgggggagg ccatgaacgc cacggggacc ccggtggccc ccgagtcctg 60
 ccaacagctg gcgggccggcg ggcacagccg gctcattgtt ctgcactaca accactcggg 120
 ccggctggcc gggcgcgggg ggccggagga tggcggcctg ggggccctgc gggggctgtc 180
 ggtggccgcc agctgcctgg tggtgctgga gaacttgctg gtgctggcgg ccatcaccag 240
 ccacatgcgg tcgcgacgct gggctacta ttgcctgggtg aacatcacgc tgagtgaact 300
 gctcacgggc ggggcctacc tggccaacgt gctgctgtcg ggggcccgca ctttcctgt 360
 gggccccgcc cagtgggttc tacgggaggg cctgctcttc accgccctgg ccgcctccac 420
 cttcagcctg ctcttactg caggggagcg ctttgcacc atggtgcggc cggtggccga 480
 gagcggggcc accaagacca gccgcgtcta cggcttcata ggctctgct ggctgctggc 540
 cgcgctgctg gggatgctgc ctttgctggg ctggaactgc ctgtgcgcct ttgaccgctg 600
 ctccagcctt ctgcccctct actccaagcg ctacatctc ttctgcctgg tgatcttcgc 660
 cggcgtcctg gccaccatca tgggcctcta tggggccatc ttccgcctgg tgcaggccag 720
 cgggcagaag gccccacgcc cagcggcccg ccgcaaggcc cggcgctgc tgaagacggt 780
 gctgatgate ctgctggcct tcctgggtgt ctggggccca ctcttcgggc tgctgctggc 840
 cgacgtcttt ggctccaacc tctgggcccc ggagtacctg cggggcatgg actggatcct 900
 ggccctggcc gtctcaact cggcgggtcaa ccccatcatc tactccttcc gcagcagggg 960
 ggtgtgcaga gccgtgctca gcttctctg ctgcgggtgt ctccggctgg gcatgcgagg 1020
 gcccggggac tgctggccc gggccgtcga ggctcactcc ggagcttcca ccaccgacag 1080
 ctctctgagg ccaagggaca gctttcgcg ctcccgctcg ctcagctttc ggatgcggga 1140
 gcccctgtcc agcatctcca gcgtgcggag catctgaagt tgcagtcttg cgtgtggatg 1200
 gtgcagccac cgggtgcgtg ccaggcaggc cctcctgggg tacaggaagc tgtgtgcacg 1260
 cagcctcgcc tgtatgggga gcagggaacg ggacaggccc ccatggtctt cccggtggcc 1320
 tctcggggct tctgacgcca aatgggcttc ccatggtcac cctggacaag gaggtaacca 1380
 ccccacctcc ccgtaggagc agagagcacc ctggtgtggg ggcgagtggg tccccacaac 1440
 cccgcttctg tgtgattctg gggaagtccc ggcccctctc tgggcctcag tagggctccc 1500
 aggctgcaag ggggtggactg tgggatgcat gccctggcaa cattgaagtt cgatcatggt 1560
 aaaaaa 1566

00360 = 60360

<210> 12

<211> 1148

<212> DNA

<213> Homo sapiens

<220>

<221> gene

<222> (1)..(1148)

<223> The sequence of the cDNA coding for EDG-7

<400> 12

cttcttttaaa tttcttttcta ggatgttcac ttctttctcca caatgaatga gtgtcactat 60
gacaagcaca tggacttttt ttataatagg agcaacactg atactgtcga tgactggaca 120
ggaacaaagc ttgtgattgt tttgtgtgtt gggacgtttt tctgcctggt tatttttttt 180
tctaattctc tggatcatgc ggcagtgatc aaaaacagaa aatttcattt ccccttctac 240
tacctgttgg ctaatttagc tgctgccgat ttcttcgctg gaattgccta tgtattcctg 300
atgtttaaca caggcccagt ttcaaaaact ttgactgtca accgctgggt tctccgtcag 360
gggcttctgg acagtagctt gactgcttcc ctcaccaact tgctggttat cgccgtggag 420
aggcacatgt caatcatgag gatgcgggtc catagcaacc tgaccaaaaa gagggtgaca 480
ctgctcattt tgcttgtctg ggccatcgcc atttttatgg gggcgggtccc cacactgggc 540
tggaattgcc tctgcaacat ctctgcctgc tcttccttgg ccccatatta cagcaggagt 600
taccttgttt tctggacagt gtccaacctc atggccttcc tcatcatggt tgtgggtgtac 660
ctgcggatct acgtgtacgt caagaggaaa accaacgtct tgtctccgca tacaagtggg 720
tccatcagcc gccggaggac acccatgaag ctaatgaaga cggatgatgac tgtcttaggg 780
gcgtttgtgg tatgctggac cccgggcctg gtggttctgc tcctcgacgg cctgaactgc 840
aggcagtgtg gcgtgcagca tgtgaaaagg tggttcctgc tgctggcgct gctcaactcc 900
gtcgtgaacc ccatcatcta ctctacaag gacgaggaca tgtatggcac catgaagaag 960

atgatctgct gcttctctca ggagaaccca gagaggcgtc cctctcgcat cccctccaca 1020
gtcctcagca ggagtgcacac aggcagccag tacatagagg atagtattag ccaaggtgca 1080
gtctgcaata aaagcattc ctaaactctg gatgcctctc ggcccaccca ggtgatgact 1140
gtcttagg 1148

<210> 13

<211> 1606

<212> DNA

<213> Homo sapiens

<220>

<221> gene

<222> (1)..(1606)

<223> The sequence of the cDNA coding for
Glycerol-3-phosphate dehydrogenase

<400> 13

tttttttttt tttttttttt ttgggtggcg ggggggttgca agtgggaagc ctgctgttca 60
gctgccgggg ctctccgcct cccccacct gtatgaggct gggctctggg aacctgtgct 120
cagcattcca cccctggag cttgggcttg gtcttcctg cgggtccctg cgctgacatt 180
caggcgggga gccaggaggc ctggcgcgcc tccagagccc gccgggggag ccgggagagg 240
gttctgggct ctgacggcgg ggtcgcaggg tcgcccgcct cctggacacg tctgtaggcc 300
tagggaagcc tgccggccgg gaggtacaga gtaggagaag ccagatccca gggcggacaa 360
cgagaagtcg tcaggctaag aaatggcatt tcaaaaggca gtgaaaggga cgattcttgt 420
tgaggagggt gctcttgcaa ctgttttagg actttctcag tttgctcatt acagaaggaa 480
acaaatgaac ctggcctatg ttaaagcagc agactgcatt tcagaaccag ttaacaggga 540
gcctccttcc agagaagctc agctactgac tttgcaaaat acatctgaat ttgatattct 600
tgttattgga ggaggagcaa caggaagtgg ctgtgcgcta gatgctgtca ccagaggact 660

```

aaaaacagcc cttgtagaaa gagatgattt ctcatcaggg accagcagca gaagcactaa 720
attgatccat ggtggtgtga gatatctgca gaaggccatc atgaagttgg atattgagca 780
gtataggatg gtaaaagaag cccttcatga gcgtagcaac ctgctagaaa ttgctcccca 840
tttatcagct ccattgccta taatgcttcc agtttacaag tgggtggcagt taccttacta 900
ctgggtagga atcaagctgt atgatttggg tgcaggaagc aattgcctaa aaagcagtta 960
tgtctcagc aaatcaagag cccttgaaca tttccaatg ctccagaagg acaaactggg 1020
aggagcaatt gtctactatg acggacaaca taacgatgca cggatgaacc ttgccattgc 1080
tctgactgct gccaggatg gggctgccac agccaattac atggaggtag tgagcttgct 1140
caagaagaca gacccccaga cagggaagt gcatgtgagc ggcgcacggg gcaaggatgt 1200
cctcacaggg caggaatttg acgtgagagc caaatgtgtt atcaatgccca cgggaccttt 1260
cacggactct gtgcgcaaaa tggatgataa agacgcagca gctatctgcc agccaagtgc 1320
tgggtgtccat attgtgatgc ctggttatta cagcccagag agcatgggac ttcttgacct 1380
agcgaccagt gatgggagcag ttattttctt cttaccctgg caaaagatga cgatcgctgg 1440
cactactgat actccaactg atgttacaca ccatccaatt ccttcagaag aagatatcaa 1500
cttcattttg aatgaagtgc gtaattacct gagtttgat gttgaagtga gaagagggga 1560
tgtctggca gcatggagtg gaatccgtcc tcttggtaca gacccc 1606

```

<210> 14

<211> 2417

<212> DNA

<213> Homo sapiens

<220>

<221> gene

<222> (1)..(2417)

<223> The sequence of the cDNA coding for

Lyosphospholipase I

<400> 14

cttccttccg cttgcgctgt gagctgaggc ggtgtatgtg cggcaataac atgtcaaccc 60
cgctgcccgc catcgtgccc gccgcccga aggccaccgc tgcggtgatt ttcctgcatg 120
gattgggaga tactgggcac ggatgggcag aagcctttgc aggtatcaga agttcacata 180
tcaaatatat ctgcccgcac gcgcctgtta ggctgttac attaaatatg aacgtggcta 240
tgccctcatg gtttgatatt attgggcttt caccagattc acaggaggat gaatctggga 300
ttaaacaggc agcagaaaat ataaaagctt tgattgatca agaagtgaag aatggcattc 360
cttctaacag aattattttg ggagggtttt ctgaggagg agctttatct ttatatactg 420
cccttaccac acagcagaaa ctggcagggtg tcaactgcact cagttgctgg cttccacttc 480
gggcttcctt tccacagggt cctatcgggtg gtgctaata agatatttct attctccagt 540
gccacgggga ttgtgaccct ttgggtcccc tgatgtttgg ttctcttacg gtggaaaaac 600
taaaaacatt ggtgaatcca gccaatgtga cctttaaacc ctatgaagg atgatgcaca 660
gttcgtgtca acaggaaatg atggatgtca agcaattcat tgataaactc ctacctcaa 720
ttgattgacg tactaagag gccttggtga gaagtacacc agcatcattg tagtagagt 780
taaacccttt cccatgccc gtcttcaaat ttctaattgt ttgcagtgtt aaaatgtttt 840
gcaaatacat gccgataaca cagatcaaat aatatctcct catgagaaat ttatgatctt 900
ttaagtttct atacatgtat tcttataaga cgaccaggga tctactatat tagaatagat 960
gaagcaggta gcttcttttt tctcaaatgt aattcagcaa aataatacag tactgccacc 1020
agatttttta ttacatcatt tgaaaattag cagtatgctt aatgaaaatt tgttcaggta 1080
taaagagca gttaagatat aaacaattta tgcagtgtgt gacttagtct atggatttat 1140
tccaaaattg cttagtcacc atgcagtgtc tgtattttta tatatgtgtt catatatata 1200
taatgattat aatacataat aagaatgagg tggattaca ttattcctaa taatagggat 1260
aatgctgttt attgtcaaga aaaagtaaaa tcgttctctt caattaatgg cctttttatt 1320
ttgggaccag gctttttatt tccctgatat ttttctatt taatactctt ttctctcaag 1380
aaaaaaaaa aagtttgttt tttctttatt gtccttcata gcaggccaag tattgcctct 1440
ctgcaataga cagctactgt caatacatgc tgtaatttga cattctgggt cacagatata 1500
aggatattta aatctattta tgctttatag agaaaccaga cattaaaact tcatgcacta 1560
cttatttcga attactgtac cttatccaaa ttacaccta gctattagga tcttcaaccc 1620

aggtaacagg aataattctg tggtttcatt tttctgtaaa caactgaaag aataattaga 1680
 tcatattcta gtatgttctg aaatatcttt aagactgatc ttaaaaaacta acttctaaga 1740
 tgatttcac tttcatagat atagagttaa ctttgtaaac gttgaaacca actactgtag 1800
 aagatgagga atctattgta attttttgc tttttttcat ctgccagtgg acttatttga 1860
 attttcactt tagtcaaatt attttttgta ttagtttttg atgcagacat aaaaatagca 1920
 atcattttta attgtcaaaa tttccagatt actggtaaaa attatttgaa aacaaactta 1980
 tgggtaataa aggctagtca gaaccctata ccataaagtg tagttaccat acagattaat 2040
 atgtagcaaa aatgtatgct tgatatttct caactgtgtt aatttttctg ctgtattcca 2100
 gctgaccaa acaatattaa gaatgcatct ttataaatgg gtgctaattg ataatggaaa 2160
 taatttagta atggactata caggatgtta ataatgaagc catatgttta tgtctggatt 2220
 taaaaatttt aaacaatcat ttactatgtc atttttcttt accttgaaga acataaactg 2280
 ttatttcact tctacaaatc agcaagatat tatttatggc aagaaatatt ccattgaaat 2340
 attgtgctgt aacatgggaa agtgtaaagt tttttcatgg tttctatcaa tgtgaaataa 2400
 aatttaattc tgaaaaa 2417

<210> 15

<211> 1192

<212> DNA

<213> Homo sapiens

<220>

<221> gene

<222> (1) .. (1192)

<223> The sequence of the cDNA coding for Human

Lysophospholipase Homolog

<400> 15

ccagcccgaa aggcagggtc tgggtgcggg aagagggctc ggagctgcct tctgctgcc 60

ttggggccgc ccagatgagg gaacagcccc atttgccctgg ttctgattct ccaggctgtc 120
 gtggttgtgg aatgcaaacg ccagcacata atggaaacag gacctgaaga cccttccagc 180
 atgccagagg aaagtcccc caggcggacc ccgcagagca ttccctacca ggacctccct 240
 cacctggtca atgcagacgg acagtacctc ttctgcaggt actggaaacc cacaggcaca 300
 cccaaggccc tcattcttgt gtcccatgga gccggagagc acagtggccg ctatgaagag 360
 ctggctcgga tgctgatggg gctggacctg ctggtgttcg cccacgacca tggtggccac 420
 ggacagagcg aaggggagag gatggtagtgt tctgacttcc acgttttcgt cagggatgtg 480
 ttgcagcatg tggattccat gcagaaagac taccctgggc ttctgtctt ccttctgggc 540
 cactccatgg gaggcgccat cgccatcctc acggccgcag agaggccggg ccacttcgcc 600
 ggcattggtac tcatttcgcc tctggttctt gccaatcctg aatctgcaac aactttcaag 660
 gtccttgtct cgaaagtgt caaccttgtg ctgccaaact tgtccctcgg gcccatcgac 720
 tccagcgtgc tctctcgga taagacagag gtcgacattt ataactcaga cccctgatc 780
 tgccgggcag ggctgaaggt gtgcttcggc atccaactgc tgaatgccgt ctcacgggtg 840
 gagcgcgccc tccccaaagt gactgtgccc ttctgtctgc tccagggtc tgccgatcgc 900
 ctatgtgaca gcaaaggggc ctacctgctc atggagttag ccaagagcca ggacaagact 960
 ctcaagattt atgaaggtgc ctaccatgtt ctccacaagg agcttcctga agtcaccaac 1020
 tccgtcttcc atgaaataaa catgtgggtc tctcaaagga cagccacggc aggaactgcg 1080
 tccccaccct gaatgcattg gccggtgccc ggctcatggt ctgggggatg caggcagggg 1140
 aagggcagag atggcttctc agatatggct tgcaaaaaaa aaaaaaaaaa aa 1192

<210> 16

<211> 2333

<212> DNA

<213> Homo sapiens

<220>

<221> gene

<222> (1) .. (2333)

<223> The sequence of the cDNA coding for
N-acylsphingosine amidohydrolase

<400> 16

ggcacgagggc tagagcgatg ccggggccgga gttgcgtcgc cttagtcctc ctggctgccg 60
ccgtcagctg tgccgtcgcg cagcacgcgc cgccgtggac agaggactgc agaaaatcaa 120
cctatcctcc ttcaggacca acgtacagag gtgcagttcc atggtagacc ataaatcttg 180
acttaccacc ctacaaaaga tggcatgaat tgatgcttga caaggcacca atgctaaagg 240
ttatagtga ttctctgaag aatatgataa atacattcgt gccaaagtga aaagttatgc 300
aggtggtgga tgaaaaattg cctggcctac ttggcaactt tcctggccct tttgaagagg 360
aaatgaaggg tattgccgct gttactgata tacctttagg agagattatt tcattcaata 420
ttttttatga attatttacc atttgtactt caatagtagc agaagacaaa aaaggtcatc 480
taatacatgg gagaaacatg gattttggag tatttcttgg gtggaacata aataatgata 540
cctgggtcat aactgagcaa ctaaacctt taacagtga tttggatttc caaagaaaca 600
acaaaactgt cttcaaggct tcaagctttg ctggctatgt gggcatgtta acaggattca 660
aaccaggact gttcagtcct acactgaatg aacgtttcag tataaatggg gggttatctgg 720
gtattctaga atggattctg ggaaagaaag atgccatgtg gatagggttc ctactagaa 780
cagttctgga aaatagcaca agttatgaag aagccaagaa ttatttgacc aagaccaaga 840
tattggcccc agcctacttt atcctgggag gcaaccagtc tggggaaggt tgtgtgatta 900
cacgagacag aaaggaatca ttggatgtat atgaactcga tgctaagcag ggtagatggg 960
atgtggtaca aacaaattat gaccgttga aacatccctt cttccttgat gatcgcagaa 1020
cgcttcaaaa gatgtgtctg aaccgcacca gccaaagaaa tatctcattt gaaaccatgt 1080
atgatgtcct gtcaacaaaa cctgtcctca acaagctgac cgtatacaca accttgatag 1140
atgttaccac aggtcaattc gaaacttacc tgcgggactg ccctgaccct tgtataggtt 1200
ggtagacaca cgtctggcct acagaatgcg gcctctgaga catgaagaca ccatctccat 1260
gtgaccgaac actgcagctg tctgaccttc caaagactaa gactcgcggc aggttctctt 1320
tgagtcaata gcttgtcttc gtccatctgt tgacaaatga cagatctttt ttttttccc 1380
cctatcagtt gatttttctt atttacagat aacttcttta ggggaagtaa aacagtcac 1440

tagaattcac tgagttttgt ttcactttga catttgggga tctggtgggc agtcgaacca 1500
 tggatgaactc cacctccgtg gaataaatgg agattcagcg tgggtgttga atccagcacg 1560
 tctgtgtgag taacgggaca gtaaacactc cacattcttc agtttttcac ttctacctac 1620
 atatttgtat gtttttctgt ataacagcct tttccttctg gttctaactg ctgttaaaat 1680
 taatatatca ttatctttgc tgttattgac agcgatatta ttttattaca tatcattaga 1740
 gggatgagac agacattcac ctgtatatat cttttaatgg gcacaaaatg ggcccttgcc 1800
 tctaaatagc actttttggg gttcaagaag taatcagtat gcaaagcaat cttttataca 1860
 ataattgaag tgttcctttt ttcataatta ctctacttcc cagtaaccct aaggaagttg 1920
 ctaacttaaa aaactgcac ccacgttctg ttaatttagt aaataaaca gtcaaagact 1980
 tgtggaaaat aggaagtga cccatatttt aaattctcat aagtagcatt gatgtaataa 2040
 acaggttttt agtttgttct tcagattgat agggagtttt aaagaaattt tagtagttac 2100
 taaaattatg ttactgtatt tttcagaaat caaactgctt atgaaaagta ctaatagaac 2160
 ttgttaacct ttctaacctt cagattaac tgtgaaatgt acgtcatttg tgcaagaccg 2220
 tttgtccact tcattttgta taatcacagt tgtgttcctg acactcaata aacagtcact 2280
 ggaaagagtg ccagtcagca gtcatgcacg ctgataaaaa aaaaaaaaaa aaa 2333

<210> 17

<211> 1016

<212> DNA

<213> Homo sapiens

<220>

<221> gene

<222> (1)..(1016)

<223> The sequence of the cDNA coding for Phospholipase

A2

<400> 17

atggatacca atgttccgac tggagacggg gagcccgca gacccgggtc tccagggctc 60
 gccaaggaa gttgctcatg ggagcagacc cctagagcag gatttgaggc caggccaaag 120
 agaaccacag agatgaaagg cctcctccca ctggcttggt tcctggcttg tagtgtgcct 180
 gctgtgcaag gaggcttgct ggacctaaaa tcaatgatcg agaaggtgac aggaagaac 240
 gccctgacaa actacggctt ctacggctgt tactgcggtt ggggcggccg aggaaccccc 300
 aaggatggca ccgattggtg ctgttgggcg catgaccact gctatgggcg gctggaggag 360
 aagggtgca acattcgac acagtcctac aaatacagat tcgcgtgggg cgtggtcacc 420
 tgcgagcccc ggcccttctg ccatgtgaac ctctgtgcct gtgaccgaa gctcgtctac 480
 tgctcaaga gaaacctac gagctacaac ccacagtacc aatactttcc caacatcctc 540
 tgctcctagg cctccccagc gagctcctcc cagaccaaga cttttgttct gttttctac 600
 aacacagagt actgactctg cctggttcct gagagaggct cctaagtcac agacctcagt 660
 ctttctcgaa gcttggcgga ccccagggc cacactgtac cctccagcga gtcccaggag 720
 agtgactctg gtcataggac ttggtagggt ccaggggtcc ctaggcctcc acttctgagg 780
 gcagccccctc tggtgccaag agctctcctc caactcaggg ttggctgtgt ctcttttctt 840
 ctctgaagac agcgtcctgg ctccagttgg aacactttcc tgagatgcac ttacttctca 900
 gcttctgcga tcagattatc atcaccacca cctccagag aattttacgc aagaagagcc 960
 aaattgactc tctaaatctg gtgtatgggt attaaataaa attcattctc aaggct 1016

<210> 18

<211> 3609

<212> DNA

<213> Homo sapiens

<220>

<221> gene

<222> (1)..(3609)

<223> The sequence of the cDNA coding for Phospholipase

D1 (phosphatidylcholine specific)

[illegible]

ggcacgagga	gccctgagag	tccgccgcca	acgcgcaggt	gctagcggcc	ccttcgccct	60
gcagccctt	tgtttttact	ctgtccaaag	ttaacatgtc	actgaaaaac	gagccacggg	120
taaatacctc	tgcactgcag	aaaattgctg	ctgacatgag	taatatcata	gaaaatctgg	180
acacgcggga	actccacttt	gagggagagg	aggtagacta	cgacgtgtct	cccagcgatc	240
ccaagataca	agaagtgtat	atccctttct	ctgctattta	taacactcaa	ggatttaagg	300
agcctaatat	acagacgtat	ctctccggct	gtccaataaa	agcacaagtt	ctggaagtgg	360
aacgcttcac	atctacaaca	agggtagcaa	gtattaatct	ttacactatt	gaattaacac	420
atggggaatt	taaatggcaa	gttaagagga	aattcaagca	ttttcaagaa	tttcacagag	480
agctgctcaa	gtacaaagcc	tttatccgca	tccccattcc	cactagaaga	cacacgttta	540
ggaggcaaaa	cgtcagagag	gagcctcgag	agatgcccgag	tttgccccgt	tcatctgaaa	600
acatgataag	agaagaacaa	ttccttggtg	gaagaaaaca	actggaagat	tacttgacaa	660
agatactaaa	aatgcccatt	tatagaaact	atcatgccac	aacagagttt	cttgatataa	720
gccagctgtc	tttcatccat	gatttggggc	caaagggcat	agaaggatat	ataatgaaaa	780
gatctggagg	acacagaata	ccaggcttga	attgctgtgg	tcagggaaga	gcctgctaca	840
gatggtcaaa	aagatggtta	atagtgaag	attccttttt	attgtatatg	aaaccagaca	900
gcggtgccat	tgccttcgtc	ctgctggtag	acaaagaatt	caaaattaag	gtggggaaga	960
aggagacaga	aacgaaatat	ggaatccgaa	ttgataatct	ttcaaggaca	cttattttta	1020
aatgcaacag	ctatagacat	gctcggtggt	ggggaggggc	tatagaagaa	ttcatccaga	1080
aacatggcac	caactttctc	aaagatcctc	gatttgggtc	atatgctgct	atccaagaga	1140
atgctttagc	taaatggtat	gttaatgcc	aaggatat	tgaagatgtg	gcaaattgcaa	1200
tggaagaggc	aaatgaagag	atTTTTatca	cagactgggtg	gctgagtcca	gaaatcttcc	1260
tgaaacgccc	agtggttgag	ggaaatcggt	ggagggttga	ctgcattctt	aaacgaaaag	1320
cacaacaagg	agtgaggatc	ttcataatgc	tctacaaaga	ggtggaactc	gctcttggca	1380
tcaatagtga	atacaccaag	aggactttga	tgcgtctaca	tcccaacata	aagggtgatga	1440
gacacccgga	tcatgtgtca	tccaccgtct	atttgtgggc	tcaccatgag	aagcttgtca	1500
tcattgacca	atcggttggc	tttgtggggg	ggattgacct	ggcctatgga	aggtggggacg	1560

acaatgagca cagactcaca gacgtgggca gtgtgaagcg ggtcacttca ggaccgtctc 1620
 tgggttccct cccacctgcc gcaatggagt ctatggaatc cttagactc aaagataaaa 1680
 atgagcctgt tcaaaaccta cccatccaga agagtattga tgatgtggat tcaaaactga 1740
 aaggaatagg aaagccaaga aagttctcca aatttagtct ctacaagcag ctccacaggc 1800
 accacctgca cgacgcagat agcatcagca gcattgacag cacctccagt tattttaatc 1860
 actatagaag tcatcacaaat ttaatccatg gtttaaaacc ccacttcaaa ctctttcacc 1920
 cgtccagtga gtctgagcaa ggactcacta gacctcatgc tgataccggg tccatccgta 1980
 gtttacagac aggtgtggga gagctgcatg gggaaaccag attctggcat ggaaaggact 2040
 actgcaattt cgtcttcaaa gactgggttc aacttgataa accttttgct gatttcattg 2100
 acaggtactc cacgccccgg atgccctggc atgacattgc ctctgcagtc cacgggaagg 2160
 cggctcgtga tgtggcacgt cacttcatcc agcgtggaa cttcacaaaa attatgaaat 2220
 caaaatatcg gtccctttct tacccttttc tgcttccaaa gtctcaaaca acagcccatg 2280
 agttgagata tcaagtgcct gggctctgcc atgctaactg acagttgctc cgctctgctg 2340
 ctgattggtc tgctggtata aagtaccatg aagagtccat ccacgccgct tacgtocatg 2400
 tgatagagaa cagcaggcac tatacttata tcgaaaacca gtttttcata agctgtgctg 2460
 atgacaaagt tgtgttcaac aagataggcg atgccattgc ccagaggatc ctgaaagctc 2520
 acagggaaaa ccagaaatac cgggtatatg tcgtgatacc acttctgcca gggttcgaag 2580
 gagacatttc aaccggcgga ggaaatgctc tacaggcaat catgcacttc aactacagaa 2640
 ccatgtgcag aggagaaaat tccatccttg gacagttaaa agcagagctt ggtaatcagt 2700
 ggataaatta catatcattc tgtggtctta gaacacatgc agagctcgaa ggaaacctag 2760
 taactgagct tatctatgtc cacagcaagt tgtaattgc tgatgataac actgttatta 2820
 ttggctctgc caacataaat gaccgcagca tgctgggaaa gcgtgacagt gaaatggctg 2880
 tcattgtgca agatacagag actgttcctt cagtaatgga tggaaaagag taccaagctg 2940
 gccggtttgc ccgaggactt cggctacagt gcttaggggt tgtccttggc tatcttgatg 3000
 acccaagtga ggacattcag gatccagtga gtgacaaatt cttcaaggag gtgtgggttt 3060
 caacagcagc tcgaaatgct acaatttatg acaagggttt cgggtgcctt cccaatgatg 3120
 aagtacacaa ttttaattcag ctgagagact ttataaaca gcccgatta gctaaggag 3180
 atcccattcg agctgaggag gaactgaaga agatccgtgg atttttgggt caattccct 3240

```

tttattttctt gtctgaagaa agcctactgc cttctgttgg gaccaaagag gccatagtgc 3300
ccatggaggt ttggacttaa gagatattca ttggcagctc aaagacttcc accctggaga 3360
ccacactgca cacagtgact tcctggggat gtcatagcca aagccaggcc tgacgcattc 3420
tcgtatccaa cccaaggacc ttttggaatg actggggagg gctgcagtca cattgatgta 3480
aggactgtaa acatcagcaa gactttataa ttccttctgc ctaacttgta aaaagggggc 3540
tgcattcttg ttggtagcat gtactctgtt gagtaaaaca catattcaaa ttccgctcgt 3600
gccgaattc
3609

```

<210> 19

<211> 2893

<212> DNA

<213> Homo sapiens

<220>

<221> gene

<222> (1)..(2893)

<223> The sequence of the cDNA coding for Phospholipase
D1 glycosylphosphatidylinositol specific

<400> 19

```

cgtcattaga ggagccggtg gggaaatgaga gcatgtctgc tttcaggttg tggcccggcc 60
tgctgatgat cgtgatggct tctctctgcc atagaggttc atcgtgtggc ctttcaacgc 120
acatagaaat cggacacaga gctctggagt ttcttcatct tcacaatggg catgttaact 180
acaaagagct gttactagaa caccaggatg catatcaggc tggaaccgtg tttcctgatt 240
gtttttaccc tagcctctgc aaaggaggaa aattccatga tgtgtctgag agcactcact 300
ggactccgtt tcttaacgca agcgttcatt atatccgaga gaactatccc cttccctggg 360
agaaggacac agagaaactg gtagctttct tgtttggaat tacttctcat atggtagcag 420
atgtcagctg gcatagtctg ggcattgaac aaggattcct taggaccatg ggagctattg 480

```

attttcacgg ctctatttct gaggctcatt cagctgggtga ttttggagga gatgtgttga 540
 gccagtttga atttaatttt aattaccttg cacgacgctg gtatgtgcca gtcaaagatc 600
 tgctgggaat ttatgagaaa ctctatggtc gagaagtcac cactgaaaat gtaattgttg 660
 attgttcaca tatccagttc ttagaaatgt atggtgagat gctagctgtt tccaagttat 720
 atccctctta ctctacaaag tccccgtttt tgggtggaaca attccaagag tattttcttg 780
 gaggactgga tgatatggcg ttttgggtcca ctaatattta ccatctaacg agcttcatgt 840
 tggagaatgg gaccagtgac tgcagcctac ctgagaaccc tctgttcatt gcatgtgggtg 900
 gccagcaaaa ccacaccag ggctcgaaaa tgcagaaaaa tgattttcac agaaatttga 960
 cttcatccct aactgaaaac attgacagga atataaacta taccgaaaga ggagtgttct 1020
 tcagtgtaaa ttcctggacc ccggattcca tgtcctttat ctacaaggct ttggaaagga 1080
 acgtaaggac aatgttcata ggtggctctc agttgtcaca gaagcacatc tctagccct 1140
 tagcatctta cttcttgtca tttccttatg caaggcttg ctgggcaatg acctcagctg 1200
 acctcaacca ggatgggtac ggcgacctcg tgggtggcg accaggctac agccgccctg 1260
 gccgatcca catcgggcgc gtgtacctca tctacggcaa tgaactgggt ctgccgcccg 1320
 ttgacctgga cctggacaag gaggcccacg ggatccttga aggtttccag cctcaggctc 1380
 gggttggctc ggccttggct atgttggact ttaacatgga tggcgtgcct gacctggccg 1440
 tgggagctcc ctcggtgggc tctgagcagc tcacctacaa aggtgctgtg tatgtctact 1500
 ttggttccaa acaaggaaga atgtcttctt ccctaacaat caccatctct tgccaggaca 1560
 tctactgtaa cttgggctgg actctcttgg ctgcagatgt gaatggagac agtgagcccg 1620
 atctggctcat tggctcccct tttgcaccag gtggagggaa gcagaaggga attgtggctg 1680
 cgttttattc tggccccagc ctgagcaaca aagagaaact gaacgtggag gcggccaact 1740
 ggacggtgag aggcgaggaa gactttgcct gggttggata ctcccttcac ggtgtcactg 1800
 tggacaacag aaccttgctg ctgggttgga gcccgacctg gaagaatgcc agcaggctgg 1860
 gccgtttgtt acacatccga gatgagaaaa agagccttgg gaggggtgtat ggctacttcc 1920
 caccaaacag ccaaagctgg tttaccattg ttggagacaa ggcaatgggg aaactgggta 1980
 cttccctgtc cagtggccac gtgctgatga atggaactct gaccaggtg ctgctgggtg 2040
 gagccccgac acgtgatgat gtgtctaaga tggcattcct gaccatgacc ctgcaccaag 2100
 gcggagccac tcggatgtac gcgctcacat ccgacctgca gccaccgctg ctcagcacct 2160

tcagcggaga cgcgcgcttc tctcgatttg gtggcgttct gcacttgagt gacctggatg 2220
 atgatggcgt agatgaaatc atcgtggcag cccccctgag gatagcagat gtaacctctg 2280
 ggctgattgg gggagaagat ggccgagttt atgtatataa tggcaaagag accacccttg 2340
 gtgacatgac tggcaaatgc aaatcgtgga tgactccatg tccagaagaa aaggcccaat 2400
 atgtattgat ttctcctgaa gccagctcaa ggtttgggag ctccctgatc accgtgaggt 2460
 ccaaggcaaa gaatcaagtc gtcattgccg ctggaaggag ctctttggga gcccgactct 2520
 ccggggcact tcacgtctat agctttggct cagattgaag atttcactgc gtttccccac 2580
 tctgcccacc tctctcatgc tgaatcacat ccatggtgag cattttgatg gacaaaatgg 2640
 cacatccagt ggagctgtgg cagatcctaa tagatgtggg gtcctggga gtagagacac 2700
 acaccaacag ccaccctttc tggaaatctg ataatgtata tatatgactg caccaggagt 2760
 atgtgaaata tcagacacac tctgctcatt catgtctcct tccacagttt atttcctcgc 2820
 ttcttttgc tctaaacctt tcttctttcc gaactttttg cctatagtca gacctgctgt 2880
 accacctatt tcc 2893

<210> 20

<211> 1362

<212> DNA

<213> Homo sapiens

<220>

<221> gene

<222> (1)..(1362)

<223> The sequence of the cDNA coding for Phosphatidic
 Acid Phosphatase type 2B

<400> 20

ggcgagctc tgcaaaagtt tctgctcggg atctggctct cttccccttg gacttttagaa 60
 cgatttaggg ttgacagagg aaagcagagg cgcgaggag gagcagaaaa caccaccttc 120

tgcagttgga ggcaggcagc cccggctgca ctctagccgc cgcgcccga gccggggccg 180
 acccgccact atccgcagca gcctcggcca ggaggcgacc cgggcgcctg ggtgtgtggc 240
 tgctgttgcg ggacgtcttc gcggggcggg aggctcgcgc cgcagccagc gccatgcaaa 300
 actacaagta cgacaaagcg atcgtcccgg agagcaagaa cggcggcagc ccggcgctca 360
 acaacaaccc gaggaggagc ggcagcaagc ggggtgctgct catctgcctc gacctcttct 420
 gcctcttcat ggcgggcctc cccttctctca tcctcgagac aagcaccatc aagccttacc 480
 accgaggggtt ttactgcaat gatgagagca tcaagtacc actgaaaact ggtgagacaa 540
 taaatgacgc tgtgctctgt gccgtgggga tcgtcattgc catcctcgcg atcatcacgg 600
 gggaattcta ccgatctat tacctgaaga agtcgcggtc gacgattcag aacccttacg 660
 tggcagcact ctataagcaa gtgggctgct tcctctttgg ctgtgccatc agccagtctt 720
 tcacagacat tgccaaagtg tccatagggc gcctgcgtcc tcacttcttg agtgtctgca 780
 accctgattt cagccagatc aactgctctg aaggctacat tcagaactac agatgcagag 840
 gtgatgacag caaagtccag gaagccagga agtccttctt ctctggccat gcctccttct 900
 ccatgtacac tatgctgtat ttgggtgctat acctgcaggc ccgcttctact tggcgaggag 960
 cccgcctgct cgggccctc ctgcagttca ccttgatcat gatggccttc tacacgggac 1020
 tgtctcgcgt atcagaccac aagcaccatc ccagtgatgt tctggcagga tttgctcaag 1080
 gagccctggg ggctgctgc atagttttct tcgtgtctga cctcttcaag actaagacga 1140
 cgctctccct gcctgcccct gctatccgga aggaaatcct ttcacctgtg gacattattg 1200
 acaggaacaa tcaccacaac atgatgtagg tgccaccac ctctgagct gtttttgtaa 1260
 aatgactgct gacagcaagt tcttgctgct ctccaatctc atcagacagt agaatgtagg 1320
 gaaaaacttt tgcccgactg atttttaaaa aaaaaaaaaa aa 1362

<210> 21

<211> 1043

<212> DNA

<213> Homo sapiens

<220>

<221> gene

<222> (1)..(1043)

<223> The sequence of the cDNA coding for Phosphatidic

Acid Phosphatase type 2a

<400> 21

cccgccccgg gctcgagaat caagggcctc ggccgccgtc ccgcagctca gtccatcgcc 60
cttgccggggc agcccgggca gagaccatgt ttgacaagac gcggctgccg tacgtggccc 120
tcgatgtgct ctgctgtgtg ctggctggat tgccttttgc aatttttact tcaaggcata 180
ttacttcaag gcataccccc ttccaacgag gagtattctg taatgatgag tccatcaagt 240
acccttaca aagaacaccc ataccttatg cgttattagg tggaataatc attccattca 300
gtattatcgt tattattctt ggagaaaccc tgtctgttta ctgtaacctt ttgcactcaa 360
attcctttat caggaataac tacatagcca ctatttaca agccattgga acctttttat 420
ttgggtgcagc tgctagtcag tccctgactg acattgccaa gtattcaata ggcagactgc 480
ggcctcactt cttggatggt tgtgatccag attgggtcaaa aatcaactgc agcgatgggt 540
acattgaata ctacatatgt cgaggggaatg cagaaagagt taaggaaggc aggttgtcct 600
tctattcagg ccactcttcg ttttccatgt actgcatgct gtttgtggca ctttatcttc 660
aagccaggat gaagggagac tgggcaagac tcttacgccc cacactgcaa tttggtcttg 720
ttgccgtatc catttatgtg ggcctttctc gagtttctga ttataaacac cactggagcg 780
atgtgttgac tggactcatt caggagctc tgggtgcaat attagttgct gtatatgtat 840
cggatttctt caaagaaaga acttctttta aagaaagaaa agaggaggac tctcatataa 900
ctctgcatga aacaccaaca actgggaatc actatccgag caatcaccag ccttgaaagg 960
cagcaggggtg ccaggtgaa gctggcctgt tttctaaagg aaaatgattg ccacaaggca 1020
agaggatgca tctttcttcc tgg 1043

<210> 22

<211> 5397

<212> DNA

<213> Homo sapiens

<220>

<221> gene

<222> (1)..(5397)

<223> The sequence of the cDNA coding for
Phosphatidylinositol-3-Kinase (class 2, gamma
polypeptide)

<400> 22

gaattcggca cgagcacttc cttctcggct agattatctg aaactgttgt cggttcttga 60
gatgatacta ccaccgaatg tctgtgtttc attgtctagt ccaacctgta ttgtggatat 120
ctacaacggt ccggcaatag ttttgcaggt gcatcacatt tttgtttttg ttttgggagg 180
aaaagggagg gcacggcagc caggcttcat attcctacaa gtgcatgctt caagattact 240
gtacttacag tgtttccaac atcttctcat aaaaggggaa agcttcatag cctcaaccat 300
gaaggaaacc agtcgcatag ggcattggagc tggagaacta taaacagccc gtggtgctga 360
gagaggacaa ctgccgaagg cgccggagga tgaagccgcg cagtgtgtcc agcctgtcct 420
ccatggagct catccccatc gagttcgtgc tgcccaccag ccagcgcaaa tgcaagagcc 480
ccgaaacggc gctgctgcac gtggccggcc acggcaacgt ggagcagatg aaggcccagg 540
tgtgggtgcg agcgctggag accagcgtgg cggcggactt ctaccaccgg ctgggaccgc 600
atcacttcct cctgctctat cagaagaagg ggcagtggta cgagatctac gacaagtacc 660
aggtggtgca gactctggac tgcttgcgt actggaaggc cacgcaccgg agcccgggccc 720
agatccacct ggtgcagcgg caccgcacct ccgaggagtc ccaagccttc cagcggcagc 780
tcacggcgct gattggctat gacgtcactg acgtcagcaa cgtgcacgac gatgagctgg 840
agttcacgcg ccgtggcttg gtgacccgcg gcatggcgga ggtggccagc cgcgacccca 900
agctctacgc catgcacccg tgggtgacgt ccaagcccct cccggagtac ctgtggaaga 960
agattgccaa caactgcata ttcacgtca ttcaccgcag caccaccagc cagaccatta 1020
aggtctcacc cgacgacacc cccggcgcca tcctgcagag cttcttcacc aagatggcca 1080

agaagaaatc tctgatggat attccccgaaa gccaaagcga acaggatttt gtgctgcgcg 1140
tctgtggccg ggatgagtag ctggtgggcg aaacgcccac caaaaacttc cagtgggtga 1200
ggcactgcct caagaacgga gaagagattc acgtggtact ggacacgcct ccagaccccg 1260
ccctagacga ggtgaggaag gaagagtggc cgctggtgga cgactgcacg ggagtcaccg 1320
gctaccatga gcagcttacc atccacggca aggaccacga gagtgtgttc accgtgtccc 1380
tgtgggactg cgaccgcaag ttcaggggtca agatcagagg cattgatatc cccgtcctgc 1440
ctcggaacac cgacctcaca gttttttag aggcacacat ccagcatggg caacaagtcc 1500
tttgccaaag gagaaccagc cccaaaccct tcacagagga ggtgctgtgg aatgtgtggc 1560
ttgagttcag tatcaaaatc aaagacttgc ccaaaggggc tctactgaac ctccagatct 1620
actgcggtaa agctccagca ctgtccagca aggcctctgc agagtcccc agttctgagt 1680
ccaagggcaa agttcggtt ctctattatg tgaacctgct gctgatagac caccgtttcc 1740
tcctgcgccg tggagaatac gtcctccaca tgtggcagat atctgggaag ggagaagacc 1800
aaggaagctt caatgctgac aaactcacgt ctgcaactaa cccagacaag gagaactcaa 1860
tgtccatctc cattcttctg gacaattact gccacccgat agccctgcct aagcatcagc 1920
ccacccctga cccggaaggg gaccgggttc gagcagaaat gcccaaccag cttcgcaagc 1980
aattggaggc gatcatagcc actgatccac ttaaccctct cacagcagag gacaaagaat 2040
tgctctggca ttttagatac gaaagcctta agcaccctaa agcatatcct aagctattta 2100
gttcagtga atggggacag caagaaattg tggccaaaac ataccaattg ttggccagaa 2160
gggaagtctg ggatcaaagt gctttggatg ttgggttaac aatgcagctc ctggactgca 2220
acttctcaga tgaaaatgta agagccattg cagttcagaa actggagagc ttggaggacg 2280
atgatgttct gcattacctt ctacaattgg tccaggctgt gaaatttgaa ccataccatg 2340
atagcgccct tgccagattt ctgctgaagc gtggtttaag aaacaaaaga attggtcact 2400
ttttgttttg gttcttgaga agtgagatag cccagtccag acactatcag cagaggttcg 2460
ctgtgattct ggaagcctat ctgaggggct gtggcacagc catgctgcac gactttaccc 2520
aacaagtcca agtaatcgag atgttacaaa aagtcaccct tgatattaaa tcgctctctg 2580
ctgaaaagta tgacgtcagt tcccaagtta tttcacaact taaacaaaag cttgaaaacc 2640
tgcagaattc tcaactcccc gaaagcttta gagttccata tgatcctgga ctgaaagcag 2700
gagcgctggc aattgaaaaa tgtaaagtaa tggcctccaa gaaaaaacca ctatggcttg 2760

agttttaa	atg	tgccg	atcct	acagcc	cctat	caa	atg	aaac	aattg	gaatt	atcttt	aaac	2820	
atggtg	atga	tctgc	gcaa	gacat	gotta	tttt	acag	at	tctac	gaatc	atgg	agtcta	2880	
tttggg	agac	tgaat	ctttg	gatct	atgcc	tctt	gccata	tggtt	gcatt	tcaact	ggtg		2940	
acaaa	atagg	aatgat	c	gag	attgt	gaaag	acgcc	acgac	aattg	ccaaa	attcag	caaa	3000	
gcacag	tggg	caacac	ggga	gcattt	taaag	atga	agtcct	gaatc	actgg	ctcaa	agaaa		3060	
aatccc	ctac	tgaag	aaaag	tttcag	gcag	cagtg	ggagag	atttg	ttttat	tctt	gtgcag		3120	
gctact	gtgt	ggcaac	cttt	gttctt	ggaa	taggc	gacag	acaca	atgac	aatatt	atga		3180	
tcaccg	agac	aggaa	acct	tttcat	attg	acttc	ggggc	cattc	ttggg	aattac	aaaa		3240	
gtttc	ctggg	catta	aataa	gagag	agtgc	cattt	gtgct	aacct	ctgac	ttcct	ctttg		3300	
tgatgg	gaac	ttctg	gaaag	aagaca	agcc	cacact	ttcca	gaaatt	tcag	gacat	ctgtg		3360	
ttaagg	ctta	tctag	ccctt	cg	catcaca	caa	acctact	gatcat	cctg	ttct	ccatga		3420	
tgctga	t	gac	aggaat	gccc	cag	tta	acaa	gcaa	agaaga	cattg	aatat		3480	
ccctc	acagt	gggg	aaaaa	at	gaggag	gatg	ctaaa	aagta	tttt	cttgat	cagat	cgaag	3540	
tttgc	agaga	caa	aggat	gg	actgt	gcagt	ttaatt	gggtt	tctac	atctt	gttctt	ggca	3600	
tcaa	acaagg	agaga	aacat	tcagc	ccta	at	ctttag	gct	agaat	caaaa	acaag	ttagt	3660	
gttct	atggt	ttaa	attagc	atag	caatca	tcga	acttgg	attt	caaatg	caatag	acat		3720	
tgtg	aaagct	ggcatt	tcag	aagt	atagct	ctttt	cctac	ctga	actctt	ccctg	gagaa		3780	
aagat	gttgg	cattg	ctgat	tgttt	gg	tta	agcaat	gtcc	agt	gctagga	ttattt	gcag	3840	
gtttg	gtttt	ttct	catttg	tctgt	ggcat	tgg	aga	aatat	tctc	gg	ttta	aacag	actaa	3900
tgactt	ccctt	attgt	ccctg	atatt	tttgac	tatctt	tacta	ttgag	tgc	ctg	gaaattc		3960	
tttgg	aataa	ttgat	gacat	ctatt	tttcat	ctggg	tttag	tctc	aat	ttt	ggttat	cttt	4020	
gtgtt	cctca	agct	ctttta	agaaa	aagat	gtaat	cg	ttg	taac	cttt	gt	ctcatt	cctt	4080
aaatg	atgct	tccaa	acatc	tcctt	tagt	gt	ctgcag	ggtg	tagt	gg	gtg	ctaaa	agcaa	4140
ggaaa	gcgag	ttagt	ctttt	cagt	gtcttt	tgca	attcaa	ttct	tttt	gtc	atgt	tata	act	4200
gagac	acaca	aacac	agcag	gagaa	atcta	aacc	gtt	gtg	cctt	gac	ctt	cctct	gctgg	4260
tctt	gttcca	gggt	tatgaa	aaaaa		taga	gatgag	act	tttt	gtg	tcaact	ctgt		4320
ccaca	agagt	gag	ttatcta	gtat	gattag	tatag	ctttc	tccag	catgg	cagcag	gaag		4380	
taact	acagg	gcct	ctttta	tgct	gacat	ttctt	ccctt	cct	tttt	ccc	tgct	ccctt	4440	

tttcatcaat tgcaatgctc ccacaactct ttacagactt gtgaaatctt caagaacacc 4500
 tttactctat aactcaaaaa ttagttgaaa aataattact tctcaaggat tattagaatc 4560
 ttaggtactt atttgtaaag atgttttagtg actttttttt caagtatcta taaaggaggc 4620
 agattctaga aaatatgaat tagtttccaa atgccttaat tttaaacttt ggcctgaaca 4680
 gttttttctt tttcttaatg gaagaagata tttaatatct taaaaatatt ccaagttagg 4740
 aagaacacta cttgccttat ccatttccca tttaaaggac ttttaaactt tgacacagtc 4800
 cttcagattt cctgaaaatc cttgaaatat cttactttta aaatattttc atctctgaaa 4860
 tatctcgta tttattggag gtattgttta accttagata gaccattaaa ttatttataa 4920
 aatattttgt aattactgta gctaatacat tacatagaaa aaactatgtt aacagtgtct 4980
 ctgtttaagt ataatcagat ataaatatat aacttaattt tttaatTTTA aaaaatagat 5040
 acctgtttga ctttgaggta gtccaggcct ttttcttttt tttttttttt aatgtgtgca 5100
 aaagcccaaa ggttcctaag cctggctgca aagaagaatc aacagggaca ctttttataa 5160
 aactcttat cagcctgggg caacacagtg agactccatc tcttaaaaaa aaaattagct 5220
 gggatatgtg gtatgtgcct gtagtcccag gtactcagga ggctgaggca ggaggattgc 5280
 ctgagcccag gaggtggaaa ctgcagagag tcatgatcat gtccttacac tccagcctgg 5340
 ataacagagc gagaccctgt ctcaaaaaaa aaaaaaaaaa aaaaaaaaaa actcgag 5397

<210> 23

<211> 3424

<212> DNA

<213> Homo sapiens

<220>

<221> gene

<222> (1)..(3424)

<223> The sequence of the cDNA coding for

Phosphatidylinositol-3-kinase (catalytic, alpha
 polypeptide)

<400> 23

aggatcagaa caatgcctcc aagaccatca tcaggtgaac tgtggggcat ccacttgatg 60
cccccaagaa tcctagtggga atgtttacta ccaaattggaa tgatagtgcac tttagaatgc 120
ctccgtgagg ctacattagt aactataaag catgaactat tttaaagaagc aagaaaatac 180
cctctccatc aacttcttca agatgaatct tcttacattt tcgtaagtgt taccacaagaa 240
gcagaaaggg aagaattttt tgatgaaaca agacgacttt gtgatcttcg gctttttcaa 300
ccatttttaa aagtaattga accagtaggc aaccgtgaag aaaagatcct caatcgagaa 360
attggttttg ctatcgcat gccagtggtc gaatttgata tggttaaaga tcctgaagta 420
caggacttcc gaagaaatat tcttaatggt tgtaaagaag ctgtggatct tagggatctt 480
aattcacctc atagtagagc aatgtatgtc tatccgccac atgtagaatc ttcaccagag 540
ctgccaaagc acatatataa taaattggat agaggccaaa taatagtggg gatttgggta 600
atagtttctc caaataatga caagcagaag tatactctga aaatcaacca tgactgtgtg 660
ccagaacaag taattgctga agcaatcagg aaaaaaacta gaagtatggt gctatcatct 720
gaacaattaa aactctgtgt tttagaatat cagggcaagt acattttaaa agtgtgtgga 780
tgtgatgaat acttcctaga aaaatatcct ctgagtcagt ataagtatat aagaagctgt 840
ataatgcttg ggaggatgcc caatttgaag atgatggcta aagaaagcct ttattctcaa 900
ctgccaatgg actgttttac aatgccatct tattccagac gcatttccac agctacacca 960
tatatgaatg gagaaacatc taaaaatcc ctttgggtta taaatagagc actcagaata 1020
aaaattcttt gtgcaacctc cgtgaatcta aatattcgag acattgacaa gatttatggt 1080
cgaacaggta tctaccatgg aggagaacc ttatgtgaca atgtgaacac tcaaagagta 1140
ccttggtcca atcccagggt gaatgaatgg ctgaattatg atatatacat tcctgatctt 1200
cctcgtgctg ctgcactttg cctttccatt tgctctgtta aaggccgaaa gggtgctaaa 1260
gaggaacact gtccattggc atggggaaat ataaacttgt ttgattacac agacactcta 1320
gtatctggaa aaatggcttt gaatctttgg ccagtacctc atggattaga agatttgctg 1380
aaccctattg gtgttactgg atcaaatcca aataaagaaa ctccatgctt agagttggag 1440
tttgactggg tcagcagtggt ggtaaagtcc ccagatatgt cagtgattga agagcatgcc 1500
aattggtctg tatcccagaa agcaggattt agctattccc acgcaggact gagtaacaga 1560

bioRxiv preprint doi: <https://doi.org/10.1101/000000>; this version posted January 1, 2014. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

ctagctagag acaatgaatt aagggaaaat gacaaagaac agctcaaagc aatttctaca 1620
cgagatcctc tctctgaaat cactgagcag gagaaagatt ttctatggag tcacagacac 1680
tattgtgtaa ctatccccga aattctaccc aaattgcttc tgtctgttaa atggaattct 1740
agagatgaag tagcccagat gtattgcttg gtaaaagatt ggccccaat caaacctgaa 1800
caggctatgg aacttctgga ctgtaattac ccagatccta tggttcgagg ttttgctggt 1860
cggtgcttgg aaaaatattt aacagatgac aaactttctc agtatattaat tcagctagta 1920
caggctctaa aatatgaaca atatttggat aacttgcttg tgagattttt actgaagaaa 1980
gcattgacta atcaaaggat tgggcacttt ttcttttggc atttaaaatc tgagatgcac 2040
aataaaacag ttagccagag gtttggcctg cttttggagt cctattgtcg tgcattgtggg 2100
atgtatttga agcacctgaa taggcaagtc gaggcaatgg aaaagctcat taacttaact 2160
gacatttctc aacaggagag gaaggatgaa acacaaaagg tacagatgaa gtttttagtt 2220
gagcaaataa ggcgaccaga tttcatggat gccctacagg gcttgctgtc tcctctaaac 2280
cctgctcatc aactaggaaa cctcaggctt aaagagtgtc gaattatgtc ttctgcaaaa 2340
aggccactgt ggttgaattg ggagaacca gacatcatgt cagagtact gtttcagaac 2400
aatgagatca tctttaaaaa tggggatgat ttacggcaag atatgctaac acttcaaatt 2460
attcgtaata tggaaaatat ctggcaaaat caaggctctg atcttcgaat gttaccttat 2520
ggttgtctgt caatcgggtga ctgtgtggga cttattgagg tggcgcaaaa ttctcacact 2580
attatgcaaa ttcagtgcga aggcggcctg aaagggtgcac tgcagttcaa cagccacaca 2640
ctacatcagt ggctcaaaga caagaacaaa ggagaaatat atgatgcagc cattgacctg 2700
tttacacgtt catgtgctgg atactgtgta gctaccttca ttttgggaat tggagatcgt 2760
cacaatagta acatcatggt gaaagacgat ggacaactgt ttcatataga ttttggacac 2820
tttttggatc acaagaagaa aaaatttggg tataaacgag aacgtgtgcc atttgttttg 2880
acacaggatt tcttaatatg gattagtaaa ggagcccaag aatgcacaaa gacaagagaa 2940
tttgagaggt ttcaggagat gtgttacaag gcttatctag ctattcgaca gcatgccaat 3000
ctcttcataa atcttttctc aatgatgctt ggctctggaa tgccagaact acaatctttt 3060
gatgacattg catacattcg aaagacccta gccttagata aaactgagca agaggctttg 3120
gagtatttca tgaaacaaat gaatgatgca catcatggtg gctggacaac aaaaatggat 3180
tggatcttcc acacaattaa acagcatgca ttgaactgaa agataactga gaaaatgaaa 3240

gctcactctg gattccacac tgcactgtta ataactctca gcaggcaaag accgattgca 3300
taggaattgc acaatccatg aacagcatta gatttacagc aagaacagaa ataaaataact 3360
atataattta aataatgtaa acgcaaacag ggtttgatag cacttaaact agttcatttc 3420
aaaa 3424

<210> 24

<211> 1201

<212> DNA

<213> Homo sapiens

<220>

<221> gene

<222> (1)..(1201)

<223> The sequence of the cDNA coding for Prostate

Differentiation Factor PLAB

<400> 24

agtcccagct cagagccgca acctgcacag ccatgcccgg gcaagaactc aggacgctga 60
atggctctca gatgctcctg gtgttgctgg tgctctcgtg gctgccgcat gggggcgccc 120
tgtctctggc cgaggcgagc cgcgcaagtt tcccgggacc ctgagagttg cacaccgaag 180
actccagatt ccgagagttg cggaacgct acgaggacct gctaaccagg ctgcggggcca 240
accagagctg ggaagattcg aacaccgacc tcgtcccggc ccctgcagtc cggataactca 300
cgccagaagt gcggctggga tccggcgggc acctgcacct gcgtatctct cgggccgccc 360
ttcccagggg gctccccgag gcctcccgcc ttcaccgggc tctgttccgg ctgtccccga 420
cggcgtaag gtcgtgggac gtgacacgac ctctgcggcg tcagctcagc cttgcaagac 480
cccaggcgcc cgcgctgcac ctgcgactgt cgcgcggcc gtcgcagtcg gaccaactgc 540
tggcagaatc ttcgtccgca cggccccagc tggagttgca cttgcggccg caagccgcca 600
gggggcgccg cagagcgcggt gcgcgcaacg gggaccactg tccgctcggg cccgggcgtt 660

gctgccgtct gcacacggtc cgcgcgtcgc tggaagacct gggctgggcc gattgggtgc 720
 tgtcgccacg ggaggtgcaa gtgaccatgt gcatcggcgc gtgcccagac cagttccggg 780
 cggcaaacat gcacgcgcag atcaagacga gcctgcaccg cctgaagccc gacacggtgc 840
 cagcgccctg ctgctgtccc gccagctaca atcccatggt gctcattcaa aagaccgaca 900
 ccgggggtgtc gctccagacc tatgatgact tgtagccaa agactgccac tgcatatgag 960
 cagtcctggt ccttcactg tgcacctgcg cgggggagge gacctcagtt gtcttgcct 1020
 gtggaatggg ctcaaggttc ctgagacacc cgattcctgc ccaaacagct gtatttatat 1080
 aagtctgtta ttattatta atttattggg gtgaccttct tggggactcg ggggctggtc 1140
 tgatggaact gtgtatttat ttaaaactct ggtgataaaa ataaagctgt ctgaactgtt 1200
 c 1201

<210> 25

<211> 1269

<212> DNA

<213> Homo sapiens

<220>

<221> gene

<222> (1)..(1269)

<223> The sequence of the cDNA coding for Phosphatidic
 Acid Phosphatase type 2c

<400> 25

gcgacgggac gcgctgggac cggcgtcggg ggtcgcgggg accatgcagc ggaggtgggt 60
 ctctgtgctg ctgcagtgct tgtgcttact ggtcgcctcc ctgcccttcg ctatcctgac 120
 gctggtgaac gccccgtaca agcgaggatt ttactgcggg gatgactcca tccggtaccc 180
 ctaccgtcca gataccatca cccacggggt catggctggg gtcaccatca cggccaccgt 240
 catccttgtc tcggccgggg aagcctacct ggtgtacaca gaccggctct attctcgtc 300

```

ggacttcaac aactacgtgg ctgctgtata caaggtgctg gggaccttcc tgtttggggc 360
tgccgtgagc cagtctctga cagacctggc caagtacatg attgggcgtc tgaggcccaa 420
cttcctagcc gtctgcgacc ccgactggag ccgggtcaac tgctcgggtct atgtgcagct 480
ggagaaggtg tgcaggggaa accctgctga tgtcaccgag gccagggttg ctttctactc 540
gggacactct tcctttggga tgtactgcat ggtgttcttg gcgctgtatg tgcaggcacg 600
actctgttgg aagtgggcac ggctgctgcg acccacagtc cagttcttcc tggtaggcctt 660
tgccctctac gtgggctaca cccgctgtgc tgattacaaa caccactgga gcgatgtcct 720
tgtaggcctc ctgcaggggg cactggtggc tgccctcact gtctgctaca tctcagactt 780
cttcaaagcc cgacccccac agcactgtct gaaggaggag gagctggaac ggaagcccag 840
cctgtcactg acgttgaccc tgggcgaggc tgaccacaac cactatggat acccgcactc 900
ctcctcctga ggccggaccc cgcccaggca gggagctgct gtgagtccag ctgatgcccc 960
cccaggtggt ccctccagcc tggtaggca ctgagggttc tggacgggct ccaggaaccc 1020
tgggctgatg ggagcagtga gcggttccgc tgccccctgc cctgcactgg accaggagtc 1080
tggagatgcc tgggtagccc tcagcatttg gaggggaacc tgttcccgtc ggtccccaaa 1140
tatcccttcc tttttatggg gttaaggaag ggaccgagag atcagatagt tgctgttttg 1200
taaaatgtaa tgtatatgtg gtttttagta aaatagggca cctgtttcac aaaaaaaaaa 1260
aaaaaaaaa 1269

```

<210> 26

<211> 1286

<212> DNA

<213> Homo sapiens

<220>

<221> gene

<222> (1)..(1286)

<223> The sequence of the cDNA coding for Phosphocholine
cytidyltransferase

<400> 26

cgaccggacc gggctcgggg gagcgtgagt tgcagttaaa agaagatgga tgcacagtgt 60
tcagccaagg tcaatgcaag gaagaggaga aaagaggcgc ccggacccaa cggggcaaca 120
gaagaagatg ggggttccttc caaagtgcag cgctgtgcag tgggcttacg gcaaccagct 180
cctttttctg atgaaattga agttgacttt agtaagccct atgtcagggt aactatggaa 240
gaagccagca gaggaactcc ttgtgagcga cctgtgagag tttatgccga tggaatatatt 300
gacttatctc actctgggtca cgcccgagct ctgatgcaag cgaagaacct tttccctaata 360
acgtacctca ttgtgggagt ttgcagtgat gagctcacac acaacttcaa aggcttcacg 420
gtgatgaacg agaatgagcg ctatgacgca gtccagcact gccgctacgt ggatgagggtg 480
gtgaggaatg cgccctggac gctgacaccc gagttcctgg ccgaacaccg gattgatttt 540
gtagcccatg atgatattcc ttattcatct gctggcagtg atgatgttta taagcacatc 600
aaggaggcag gcatgtttgc tccaacacag aggacagaag gtatctccac atcagacatc 660
atcacccgaa ttgtgcgggg ttatgatgtg tatgcgaggc ggaacctgca gaggggctac 720
acagcaaagg agtcaatgt cagctttatc aacgagaaga aataccactt gcaggagagg 780
gttgacaaag taaaggagaa agtgaaagat gtggaggaaa agtcaaaaaga atttgttcag 840
aagggtggagg aaaaaagcat tgacctcatt cagaagtggg aggagaagtc ccgagaattc 900
attggaagtt ttctggaaat gtttgggtccg gaaggagcac tgaaacatat gctgaaagag 960
gggaagggcc ggatgctgca ggccatcagc ccgaagcaga gcccagcag cagccctact 1020
cgcgagcgct cccctcccc ctctttccga tggcccttct ccggcaagac ttccccacct 1080
tgctccccag caaatctctc caggcacaag gctgcagcct atgatatcag tgaggatgaa 1140
gaagactaat gtttcctccc tcctttcctg tcctcccttt ctgtcccatt accttcagaa 1200
gctctctgtt gaattocgaa ttgtgacccc aacactaaac ctaaggacag ctacaaaagga 1260
aagacaactg gggaaagaag acctag 1286

<210> 27

<211> 1856

<212> DNA

<213> Homo sapiens

<220>

<221> gene

<222> (1)..(1856)

<223> The sequence of the cDNA coding for Phosphate
cytidylyltransferase 2 (ethanolamine specific)

<400> 27

attgcgggcg gcggcgttcg gagtcgccgg gagctgccag gctgtccgcg ccgccgctgc 60
ggggccatga tccggaacgg gcgcggggct gcaggcggcg cagagcagcc gggcccgggg 120
ggcaggcgcg ccgtgagggg gtggtgcgat ggctgctatg acatggtgca ttacggccac 180
tccaaccagc tgcgccaggc acgggccatg ggtgactacc tcatcgtagg cgtgcacacc 240
gatgaggaga tcgccaagca caagggggccc ccggtgttca ctcaggagga gagatacaag 300
atggtgcagg ccatcaaata ggtggacgag gtggtgccag cggtcccta cgtcactaca 360
ctagagaccc tggacaaata caactgtgac ttctgtgttc acggcaatga catcacccctg 420
actgtagatg gccgggacac ctatgaggaa gtaaagcagg ctgggaggta cagagaatgc 480
aagcgcacgc aaggggtgtc caccacagac ctcgtgggcc gcatgctgct ggtaacccaaa 540
gcccatacaca gcagccagga gatgtcctct gagtaccggg agtatgcaga cagttttggc 600
aagtgccttg gtgggcggaa cccctggacc ggggtatccc agttcctgca gacatctcag 660
aagatcatcc agtttgcttc tgggaaggag cccagccag gggagacagt catctatgtg 720
gctggtgcct tcgacctgtt ccacatcggg catgtggact tcctggagaa ggtgcacagg 780
ctggcagaga ggccctacat catcgcgggc ttacactttg accaggaggt caatcactac 840
aaggggaaga actaccccat catgaatctg catgaacgga ctctgagcgt gctggcctgc 900
cggtacgtgt cagaagtggg gattggagcc ccgtacgagg tcacagcaga gtcctaagt 960
cacttcaagg tggacctggg gtgtcacggc aagacagaaa ttatccctga cagggatggc 1020
tccgacccat accaggagcc caagagaagg ggcattctcc gtcagattga cagtggcagc 1080
aacctcacca cagacctcat cgtccagcgg atcatcacca acaggttgga gtatgaggcg 1140

cgaaaccaga agaaggaagc caaggagctg gccttcctgg aggtgccag gcagcaggcg 1200
gcacagcccc tgggggagcg cgatggtgac ttctaacctg gcagaggccc tggccggccc 1260
tccccctgct ctgcttctgc gccttctgcg tttggacata ggactctgca gggccgccct 1320
ctctaactgg cctggctctg gaagggtggt tgaggactct gcctccttgc ctgcctacaa 1380
ggtgcctggt ttgcagcagg ctctccgctc tttccagcaa agctgctcag agaggggtgtc 1440
cagcacagtg gagaggccgg aagtgagacg ggcagacggc acctgcagcc tgaaacgcac 1500
cgctcctgcg tgcgccccca cctggtcccc ggatgcccc accacctgga cagaggccac 1560
actgactgcc caccagctg tggcgggagg tgcagagcag ggggcttttag ggagcagtga 1620
ctgcggtcac cccttttagt ctctgggtgt agaccacacc acctccact gggcaccccc 1680
caacacggtg tcctgccacc cagcgcttgg ctccaggaaa acacgcttgc cttccttccc 1740
ggcagcttcg ccactctcct tatggactct gttctgtttg tacatggctg acggaaatct 1800
ctttggtaca accgaataaa gcctggtggc agtgctgcgc ggggctccca gccaat 1856

<210> 28

<211> 3160

<212> DNA

<213> Homo sapiens

<220>

<221> gene

<222> (1)..(3160)

<223> The sequence of the cDNA coding for Phosphatase
and Tenson Homolog (PTEN)

<400> 28

cctccccctcg cccggcgcggt tcccgctcgc ctctcgctcg cctcccgct cccctcggtc 60
ttccgaggcg cccgggctcc cggcgcgggc gcggaggggg cgggcaggcc ggcgggcggt 120
gatgtggcag gactctttat gcgctgcggc aggatacgcg ctcggcgctg ggacgcgact 180

gcgctcagtt ctctcctctc ggaagctgca gccatgatgg aagtttgaga gttgagccgc 240
 tgtgaggcga ggccgggctc aggcgagggg gatgagagac ggcgggggcc gcggcccggg 300
 gcccctctca gcgcctgtga gcagccgcgg gggcagcgcc ctcggggagc cggccggcct 360
 gcggcgggcg cagcgggcgg gtttctcgcc tcctcttcgt cttttctaac cgtgcagcct 420
 cttcctcggc ttctcctgaa aggggaaggtg gaagccgtgg gctcgggcgg gagccggctg 480
 aggcgcggcg gcggcgggcg cggcacctcc cgctcctgga gcggggggga gaagcgggcg 540
 cggcgggcgg cgcgggggct gcagctccag ggaggggggtc tgagtcgcct gtcaccattt 600
 ccagggctgg gaacgcggga gaggttgtct cttcccttct actgcctcca acacggcggc 660
 ggcgggcgcg gcacatccag ggacccgggc cggttttaaa cctcccgctc gccgcccgcg 720
 cccccccgt ggcccgggct ccggaggccg ccggcgagag cagccgttcg gaggattatt 780
 cgtctttctc ccattccgct gccgccgctg ccaggcctct ggctgctgag gagaagcagg 840
 cccagtcgct gcaaccatcc agcagccgcc gcagcagcca ttaccggct gcggtccaga 900
 gccaaagcggc ggcagagcga ggggcatcag ctaccgcaa gtccagagcc atttccatcc 960
 tgcagaagaa gccccgccac cagcagcttc tgccatctct ctctccttt ttcttcagcc 1020
 acaggctccc agacatgaca gccatcatca aagagatcgt tagcagaaac aaaaggagat 1080
 atcaagagga tggattcgac ttagacttga cctatattta tccaaacatt attgctatgg 1140
 gatttcctgc agaaagactt gaaggcgtat acaggaacaa tattgatgat gtagtaagg 1200
 ttttgattc aaagcataaa aaccattaca agatatacaa tctttgtgct gaaagacatt 1260
 atgacaccgc caaatttaat tgcagagttg cacaatatcc ttttgaagac cataaccac 1320
 cacagctaga acttatcaaa cccttttgtg aagatcttga ccaatggcta agtgaagatg 1380
 acaatcatgt tgcagcaatt cactgtaaag ctggaaagg acgaactgg gtaatgatat 1440
 gtgcatattt attacatcgg ggcaaatttt taaaggcaca agaggcccta gatttctatg 1500
 ggaagtaag gaccagagac aaaaaggag taactattcc cagtcagagg cgctatgtgt 1560
 attattatag ctacctgtta aagaatcatc tggattatag accagtggca ctgttgtttc 1620
 acaagatgat gtttgaaact attccaatgt tcagtggcgg aacttgcaat cctcagtttg 1680
 tggctcgcca gctaaagggtg aagatatatt cctccaattc aggaccaca cgacgggaag 1740
 acaagttcat gtactttgag ttccctcagc cgttacctgt gtgtgggtgat atcaaagtag 1800
 agttcttcca caaacagaac aagatgctaa aaaaggacaa aatgtttcac ttttgggtaa 1860

<220>

<221> gene

<222> (1)..(1707)

<223> The sequence of the cDNA coding for

Sphingosine-1-phosphate lyase 1

<400> 29

atgcctagca cagaccttct gatgttgaag gcctttgagc cctacttaga gattttggaa 60
gtatactcca caaaagccaa gaattatgta aatggacatt gcaccaagta tgagccctgg 120
cagctaattg catggagtgt cgtgtggacc ctgctgatag tctggggata tgagtttgtc 180
ttccagccag agagtttatg gtcaaggttt aaaaagaaat gttttaagct caccaggaag 240
atgcccatta ttggtcgtaa gattcaagac aagttgaaca agaccaagga tgatattagc 300
aagaacatgt cattcctgaa agtggacaaa gagtatgtga aagctttacc ctcccagggc 360
ctgagctcat ctgctgtttt ggagaaactt aaggagtaca gctctatgga cgccttctgg 420
caagagggga gagcctctgg aacagtgtac agtggggagg agaagctcac tgagctcctt 480
gtgaaggctt atggagattt tgcattggag aacccctgc atccagatat cttcccagga 540
ctacgcaaga tagaggcaga aattgtgagg atagcttgtt ccctgttcaa tgggggacca 600
gattcgtgtg gatgtgtgac ttctggggga acagaaagca tactcatggc ctgcaaagca 660
tatcgggatc tggcctttga gaaggggatc aaaactccag aaattgtggc tccccaaagt 720
gcccattgctg catttaacaa agcagccagt tactttggga tgaagattgt gcgggtccca 780
ttgacgaaga tgatggaggt ggatgtgagg gcaatgagaa gagctatctc caggaacact 840
gccattgctg tctgttctac cccacagttt cctcatgggtg taatagatcc tgtccctgaa 900
gtggccaagc tggtgtgcaa atacaaaata ccccttcatg tcgacgcttg tctgggaggc 960
ttcctcatcg tctttatgga gaaagcagga taccactgg agcaccatt tgatttccgg 1020
gtgaaagggtg taaccagcat ttcagctgac acccataagt atggctatgc cccaaaaggc 1080
tcatcattgg tgttgtatag tgacaagaag tacaggaact atcagttctt cgtcgataca 1140
gattggcagg gtggcatcta tgcttcccca accatcgcag gctcacggcc tgggtggcatt 1200
agcgcagcct gttgggctgc cttgatgcac ttcggtgaga acggctatgt tgaagctacc 1260

aaacagatca tcaaaactgc tcgcttcctc aagtcagaac tggaaaatat caaaggcatc 1320
 tttgtttttg ggaatcccca attgtcagtc attgctctgg gatcccgatga ttttgacatc 1380
 taccgactat caaacctgat gactgctaag ggggtggaact tgaaccagtt gcagttccca 1440
 cccagtattc atttctgcat cacattacta cacgcccga aacgagtagc tatacaattc 1500
 ctaaaggaca ttcgagaatc tgtcactcaa atcatgaaga atcctaaagc gaagaccaca 1560
 ggaatgggtg ccatctatgg catggcccag acaactgttg acaggaatat ggttgacaga 1620
 ttgtcctcag tcttcttggg cagcttgtac agcaccgaca ctgtcaccca gggcagccag 1680
 atgaatgggt ctccaaaacc ccactga 1707

<210> 30

<211> 1879

<212> DNA

<213> Homo sapiens

<220>

<221> gene

<222> (1)..(1879)

<223> The sequence of the cDNA coding for Sphingomyelin
 phosphodiesterase 1

<400> 30

cctgccgtgt gccaatccat tgtccacctc tttgaggatg acatgggtgga ggtgtggaga 60
 cgctcagtc tgagcccatc tgaggcctgt ggcctgctcc tgggctccac ctgtgggcac 120
 tgggacattt tctcatcttg gaacatctct ttgcctactg tgccgaagcc gcccccaaa 180
 cccctagcc cccagcccc aggtgcccct gtcagccgca tcctcttcct cactgacctg 240
 cactgggatc atgactacct ggagggcacg gaccctgact gtgcagaccc actgtgctgc 300
 cgccgggggt ctggcctgcc gcccgcatcc cggccaggtg ccggatactg gggcgaatac 360
 agcaagtgtg acctgcccct gaggaccctg gagagcctgt tgagtgggct gggcccagcc 420

ggcccttttg atatggtgta ctggacagga gacatccccg cacatgatgt ctggcaccag 480
 actcgtcagg accaactgcg ggccctgacc accgtcacag cacttgtgag gaagttcctg 540
 gggccagtgc cagtgtaccc tgctgtgggt aaccatgaaa gcataacctgt caatagcttc 600
 cctccccctt tcattgaggg caaccactcc tcccgtggc tctatgaagc gatggccaag 660
 gcttgggagc cctggctgcc tgccgaagcc ctgcgcaccc tcagaattgg ggggttctat 720
 gctctttccc cataccccgg tctccgcctc atctctctca atatgaattt ttgttcccgt 780
 gagaacttct ggctcttgat caactccacg gatcccgagc gacagctcca gtggctgggtg 840
 ggggagcttc aggctgctga ggatcgagga gacaaagtgc atataattgg ccacattccc 900
 ccagggcact gtctgaagag ctggagctgg aattattacc gaattgtagc caggtagtag 960
 aacaccctgg ctgctcagtt ctttggccac actcatgtgg atgaatttga ggtcttctat 1020
 gatgaagaga ctctgagccg gccgctggct gtagccttcc tggcaccag tgcaactacc 1080
 tacatcggcc ttaatcctgg ttaccgtgtg taccaaatag atggaaacta ctccaggagc 1140
 tctcacgtgg tcctggacca tgagacctac atcctgaatc tgaccagggc aaacataccg 1200
 ggagccatac cgcactggca gcttctctac agggctcgag aaacctatgg gctgccccaac 1260
 aactgccta ccgcctggca caacctggta tatcgcatgc ggggcgacat gcaacttttc 1320
 cagaccttct ggttttctta ccataagggc caccaccct cggagccctg tggcagccc 1380
 tgccgtctgg ctactctttg tgcccagctc tctgcccgtg ctgacagccc tgctctgtgc 1440
 cgccacctga tgccagatgg gagcctccca gaggccaga gcctgtggcc aaggccactg 1500
 ttttgctagg gccccagggc ccacatttgg gaaagtctt gatgtaggaa agggtgaaaa 1560
 agcccaaata ctgctgtggg tcaaccaggc aagatcatcc ggtgaaagaa ccagtccctg 1620
 ggccccaagg atgccgggga aacaggacct tctcctttcc tggagctggg ttagctggat 1680
 atgggagggg gtttggctgc ctgtgcccag gagctagact gccttgaggc tgctgtcctt 1740
 tcacagccat ggagtagagg cctaagttga cactgccctg ggagacaag acaggagctg 1800
 tcgccccagg cctgtgctgc ccagccagga accctgtact gctgctgcga cctgatgctg 1860
 ccagtctgtt aaaataaag 1879

<210> 31

<211> 3553

<212> DNA

<213> Homo sapiens

<220>

<221> gene

<222> (1)..(3553)

<223> The sequence of the cDNA coding for Phospholipase

C beta 3 (phosphatidylinositol specific)

<400> 31

gaagcgggtg gagactgcgc tggaatcctg tggcctcaaa ttcaaccgga gtgagtccat 60
ccggcctgat gagttttcct tggaaatctt tgagcggttc ctgaacaagc tgtgtctgcg 120
gccggacatt gacaagatcc tgctggagat aggcgccaag ggcaagccat acctgacgct 180
ggagcagctc atggacttca tcaaccagaa gcaacgcgac ccgagactca acgaagtgct 240
gtaccgcgcc ctgcggccct cccaggcccc gctgctcatc gaaaagtatg agcccaacca 300
gcagtttctg gagcgagacc agatgtccat ggagggcttt agccgctacc tgggaggcga 360
ggagaatggc atcctgcccc tggaagccct ggatctgagc acggacatga cccagccact 420
gagtgcctac ttcataact cctcgcataa cacctatctc actgcggggc agctggctgg 480
gacctcgtcg gtggagatgt accgccaggc actactatgg ggctgccgct gcgtggagct 540
ggacgtgtgg aagggaaggc cgctgagga ggaaccctc attaccacg gcttcacat 600
gaccacagag gtgcctctgc gcgacgtgct ggaggccatt gccgagactg ccttcaagac 660
ctcgccctac cccgtcatcc tctccttcga gaaccatgtg gactcggcaa agcaacaggc 720
aaagatggct gagtactgcc gctccatctt tggagacgcg ctactcatcg agcctctgga 780
caagtaccgg ctggccccag gcgttccccct gccagcccc caggacctga tgggccgtat 840
cctggtgaag aacaagaagc ggcaccgacc cagcgcaggt ggcccagaca gcgccgggcy 900
caagcggccc ctggagcaga gcaattctgc cctgagcgag agtccgcgg ccaccgagcc 960
ctcctccccg cagctgggggt ctcccagctc tgacagctgc ccaggcctga gcaatgggga 1020
ggaggtaggg cttgagaagc ccagcctgga gcctcagaag tctctgggtg acgagggcct 1080

gaaccgaggc ccctatgttc ttggacctgc tgaccgtgag gatgaggagg aagatgagga 1140
agaggaggaa cagacagacc ccaaaaagcc aactacagat gagggcacag ccagcagcga 1200
ggtgaatgcc actgaggaga tgtccacgct tgtcaactac atcgaacctg tcaagttcaa 1260
gtcctttgag gctgctcgaa agaggaacaa atgcttcgag atgtcgtcct ttgtggagac 1320
caaggccatg gagcaactga ccaagagccc catggagttt gtggaataca acaagcagca 1380
gctcagccgc atctaccca agggcacccg cgtggactcc tccaactaca tgccccagct 1440
cttctggaac gtaggggtgcc agcttggtgc gctcaacttc cagaccctcg atgtggcgat 1500
gcagctcaac gcgggcggtt ttgagtacaa cgggcgagc gggtagctgc tcaagccgga 1560
gttcatgcgg cgcccgga agtccttcga ccccttact gaggtcatcg tggatggcat 1620
cgtggccaat gccttgccgg tcaaggtgat ctgagggcag ttctgtccg acaggaaggt 1680
gggcatctac gtggaggtgg acatgtttgg cctccctgtt gatacgccgc gcaagtaccg 1740
caccggacc tctcagggga actcgttcaa ccccggtggtg gacgaagagc ccttcgactt 1800
ccccaaggtg gtgctgcca cgctggcttc acttcgcatt gcagcctttg aggagggggg 1860
taaattcgta gggcaccgga tcctgcctgt ctctgccatc cgctccgat accactacgt 1920
ctgcctgcgg aacgaggcca accaaccgct gtgcctgccg gccctgctca tctacaccga 1980
agccttgga tacattctg acgaccacca ggactatgcg gaggccctga tcaaccccat 2040
taagcacgtc agcctgatgg accagagggc ccggcagctg gccgccctca ttggggagag 2100
tgaggctcag gctggccaag agacgtgcca ggacaccag tctcagcagc tggggtctca 2160
gccgtcctca aacccacccc ccagcccact ggatgcctcc ccccgccggc cccctggccc 2220
caccacctcc cctgccagca cctccctcag cagcccaggg cagcgtgatg atctcatcgc 2280
cagcatcctc tcagaggtgg ccccccacccc gctggatgag ctccgaggtc acaaggctct 2340
ggtcaagctc cggagccggc aagagcgaga cctgcgggag ctgcgcaaga agcatcagcg 2400
gaaggcagtc accctcacc gccgcctgct ggatggcctg gctcaggcac aggctgaggg 2460
caggtgccgg ctgcggccag gtgccctagg tggggccgct gatgtggagg acacgaagga 2520
gggggaggac gagggcaaagc ggtatcagga gttccagaac agacaggtgc agagcctgct 2580
ggagctgcgg gagggccagg tggacgcaga ggcccagcgg aggctggaac acctgagaca 2640
ggctctgcag cggtcaggg aggtcgtcct tgatgcaaac acaactcagt tcaagaggct 2700
gaaagagatg aacgagaggg agaagaagga gctgcagaag atcctggaca gaaagcgcca 2760

taacagcatc tcggaggcca agatgagggg caagcataag aaggaggcgg aactgacgga 2820
 gattaaccgt cggcacatca ctgagtcagt caactccatc cgtcggctgg aggaggccca 2880
 gaagcagcgg catgaccgtc ttgtggctgg gcagcagcag gtcctgcaac agctggcaga 2940
 agaggagccc aagctgctgg ccagctggc ccaggagtgt caggagcagc gggcgaggct 3000
 cccccaggag atccgccgga gcctgctggg cgagatgccg gaggggctgg gggacgggcc 3060
 tctggtggcc tgtgccagca acggtcacgc acccgggagc agcgggcacc tgtcgggcgc 3120
 tgactcggag agccaggagg agaacacgca gctctgaact ggctgagcga ggtggccaca 3180
 gggccagggc gggcgctggg tggagggcag gaggcaatga cactaatgct tttttttttt 3240
 ttttttaact ttttatctag aaattttatt tttttaaac ccgggcaagt acctcagcta 3300
 actcccttca tcctcctggg gccctcctt cctgccctca gtcttaggtt agggccttgg 3360
 tcagggcttt gctccctgtg acaccacac cctcgagcta gcagcgtctc ctcccttccc 3420
 cgggagagct ggctggagac ttggagctcc ggggaagtagg agtcacattt ttttctctat 3480
 tctttgggga ttttttttac atgaataaaa gtggatttca gggaaaaaaa aaaaaaaaaa 3540
 aaaaaaaaaa aaa 3553

<210> 32

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Miscellaneous
 forward primer

<400> 32

cgactttgcc ttccatttg etc

23

<210> 33

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Miscellaneous
reverse primer

<400> 33

ccttttgtgt ttcataccttc ctctcc

26

<210> 34

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Miscellaneous
forward primer

<400> 34

aaaggagaaa gtgaaagatg tggagg

26

<210> 35

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Miscellaneous
reverse primer

<400> 35

ggacagaaag ggaggacagg aaag

24

<210> 36

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Miscellaneous
forward primer

<400> 36

ccccacttca aactctttca ccc

23

<210> 37

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Miscellaneous
reverse primer

<400> 37

gccatttcac tgtcacgctt tc

22

<210> 38

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Miscellaneous
forward primer

<400> 38

gctctgccaa gacattgact cc

22

<210> 39

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Miscellaneous
reverse primer

<400> 39

atcatctctt ccctctgcgt cc

22

<210> 40

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Miscellaneous
forward primer

<400> 40

cctacgtcac tacactagag accc

24

<210> 41

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Miscellaneous
reverse primer

<400> 41

gccaaaactg tctgcatact ccc

23

<210> 42

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Miscellaneous
forward primer

<400> 42

aactgctcgg tctatgtgca gc

22

<210> 43

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Miscellaneous
reverse primer

<400> 43

ccaagaacac catgcagtac atcc

24

<210> 44

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Miscellaneous
forward primer

<400> 44

gctcattcaa aagaccgaca ccg

23

<210> 45

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Miscellaneous
reverse primer

<400> 45

acacagttcc atcagaccag cc

22

<210> 46

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Miscellaneous
forward primer

<400> 46

cgtctactgc ctcaagagaa acc

23

<210> 47

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Miscellaneous
reverse primer

<400> 47

gtcctatgac cagagtcact ctcc

24

<210> 48

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Miscellaneous
forward primer

<400> 48

aggaagagga ggaacagaca gac

23

<210> 49

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Miscellaneous
reverse primer

<400> 49

agcagcctca aaggacttga ac

22

<210> 50

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Miscellaneous
forward primer

<400> 50

aacctgctgc tgatagacca cc

22

<210> 51

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Miscellaneous
reverse primer

<400> 51

tctctccact gctgcctgaa ac

22

<210> 52

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Miscellaneous
forward primer

<400> 52

gtaagcacca gccacaaaaa cc

22

<210> 53

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Miscellaneous
reverse primer

<400> 53

ctaacgagcc attcccaata ccc

23

<210> 54

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Miscellaneous
forward primer

<400> 54

tggattggga gatactgggc ac

22

<210> 55

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Miscellaneous
reverse primer

<400> 55

ccaaacatca ggggaaccaa agg

23

<210> 56

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Miscellaneous
forward primer

<400> 56

cctgttcttc aacatgggcc ag

22

<210> 57

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Miscellaneous
reverse primer

<400> 57

cctctcaacc acctcctcaa tcttc

25

<210> 58

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Miscellaneous
forward primer

<400> 58

tcttcttccc ctaacatcac catctc

26

<210> 59

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Miscellaneous
reverse primer

<400> 59

tgcatttgcc agtcatgtca cc

22

<210> 60

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Miscellaneous
forward primer

<400> 60

aaaccctctt ccttgtctcc cctc

24

<210> 61

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Miscellaneous
reverse primer

<400> 61

atgtctgctt cttccccttg tgtc

24

<210> 62

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Miscellaneous
forward primer

<400> 62

tcaacaacaa cccgaggagg ag

22

<210> 63

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Miscellaneous
reverse primer

<400> 63

gatggcacag ccaaagagga ag

22

<210> 64

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Miscellaneous
forward primer

<400> 64

acttccgcct cttcctgcta atc

23

<210> 65

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Miscellaneous
reverse primer

<400> 65

cctccaaacc atcttcatct tccc

24

<210> 66

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Miscellaneous
forward primer

<400> 66

atttcacagc cccagttcac agcc

24

<210> 67

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Miscellaneous
reverse primer

<400> 67

tgaccacaat gaccaccact accc

24

<210> 68

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Miscellaneous
forward primer

<400> 68

agcattacca gtacgtgggg aag

23

<210> 69

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Miscellaneous
reverse primer

<400> 69

aacatactgc cctccctgag gaac

24

<210> 70

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Miscellaneous
forward primer

<400> 70

taggctgtga gtcttgcaat gtcc

24

<210> 71

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Miscellaneous
reverse primer

<400> 71

tcagcatctc ggcaagagta cac

23

<210> 72

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Miscellaneous
forward primer

<400> 72

aacccaaca aggtccagga acac

24

<210> 73

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Miscellaneous
reverse primer

<400> 73

tttccaccac aatggcgcaa cag

23

<210> 74

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Miscellaneous
forward primer

<400> 74

aagttgcagt cttgcgtgtg

20

<210> 75

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Miscellaneous
reverse primer

<400> 75

ggtggttacc tccttgtcca

20

<210> 76

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Miscellaneous
forward primer

<400> 76

cttgactgct tccctcacca ac

22

<210> 77

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Miscellaneous
reverse primer

<400> 77

cttttcacat gctgcacgcc

20

<210> 78

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Miscellaneous
forward primer

<400> 78

aggtggatgt gagggcaatg agaag

25

<210> 79

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Miscellaneous
reverse primer

<400> 79

cgggcgtgta gtaatgtgat gcag

24

<210> 80

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Miscellaneous
forward primer

<400> 80

gcctcctctt cgtcttttct aacc

24

<210> 81

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Miscellaneous
reverse primer

<400> 81

catcatcttg tgaaacaaca gtgcc

25

<210> 82

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Miscellaneous
forward primer

<400> 82

tcaaggcata ccccttcca ac

22

<210> 83

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Miscellaneous
reverse primer

<400> 83

agtccagtca acacatcgct cc

22

<210> 84

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Miscellaneous
forward primer

<400> 84

tctatgctct ttccccatac ccc

23

<210> 85

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Miscellaneous
reverse primer

<400> 85

gcgatatacc aggttggtgcc ag

22

<210> 86

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Miscellaneous
forward primer

<400> 86

gtgccaagtg gaaaagttat gcag

24

<210> 87

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Miscellaneous
reverse primer

<400> 87

tgtcaacaga tggacgaaga caag

24

<210> 88

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Miscellaneous
forward primer

<400> 88

ccccatttat cagctccatt gcc

23

<210> 89

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Miscellaneous
reverse primer

<400> 89

catcccctct tctcacttca acatc

25

<210> 90

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Miscellaneous
forward primer

<400> 90

ccaacctact gcaacttctg cc

22

<210> 91

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Miscellaneous
reverse primer

<400> 91

caaccccatc acactccaac tc

22

<210> 92

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Miscellaneous
forward primer

<400> 92

gctctgccaa gacattgact cc

22

<210> 93

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Miscellaneous
reverse primer

<400> 93

atcatctctt ccctctgcgt cc

22

<210> 94

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Miscellaneous
forward primer

<400> 94

gttagccaag agccaggaca ag

22

<210> 95

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Miscellaneous
reverse primer

<400> 95

gcaagccata tctgagaagc catc

24